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General introduction  
and aims of the thesis
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THe HuMAn MIcRobIoMe
Our human body is colonized by a diversity of microorganisms. These microorganisms 
reside in different niches of the body, including the gut, upper respiratory tract and 
skin (figure 1). Most of them are harmless colonizers, commensals, and it is becoming 
increasingly clear that these microorganisms participate in important physiological pro-
cesses, such as metabolism (particularly gut microbes), immunity and barrier integrity.1-3 
The postnatal microbiome is relatively homogeneous and mainly shaped by maternal 
transmission at birth.4-7 During childhood the microbiome becomes more diverse and 
develops into a microbiome which is unique and relatively stable per individual.4,8,9 
Multiple factors influence the microbial composition. A recent population-based 
metagenomics study found 126 factors of influence on the gut microbiome, together 
explaining around 20% of the variability between individuals. Major contributing 
factors were dietary patterns and exposure to medication, in particular proton pump 
inhibitors and antibiotics.6,7 The skin microbiome is also known to be influenced by the 
use of antimicrobial agents. Additionally, UV-light and skin characteristics (such as lipid 
composition) are of influence.10,11 Washing and use of soap might also have an effect 
on the skin microbiome, but these effects are still poorly explored.12,13 In this thesis we 
will study the role of the microbiome in the pathogenesis of atopic dermatitis (AD), 
with a focus on bacteria. Bacteria can be classified according to taxonomic ranks into 
phyla and further down to genera and species. The most common generum in the 
gut is Bacteroides, followed by Faecalibacterium and Bifidobacterium, while on the skin 
Corynebacterium, Propionibacterium and Staphylococcus are most abundant.14,15 In the 
last years, a rapid development of high throughput sequencing techniques led to more 
comprehensive determination of microbial populations, compared to the older culture 
techniques that focus on single bacteria.16 For identification of bacteria, sequencing of 
the well conserved 16S ribosomal RNA gene is often used. More recently, whole genome 
shotgun metagenomics (WGS) sequencing has been developed, which explores the full 
genomic complement of bacteria, fungi and viruses, reflecting both the composition 
and functional profile of the microbiome.17 These developments led to rapid discoveries 
of changes in the microbiome (microbial dysbiosis) in relation to different diseases, in-
cluding inflammatory bowel disease, diabetes type 1 and AD18,19 However, a lot of basic 
aspects are still to be explored in microbiome research. For example, it is still unclear 
what exactly constitutes a ‘normal’ microbiome (if it exists) and which microbial func-
tions impact human physiology.6,20 Especially in skin microbiome research, a young field 
of microbiome research, there are obstacles to overcome. The unique characteristics 
of the skin, including a site specific microbiota, a distinct immune system and the low 
microbial biomass, require standardization of methods, including techniques for sample 
collection and sample processing.21,22
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AToPIc DeRMATITIs bAckgRounD
Prevalence
AD is one of the most common inflammatory diseases affecting up to 25% of children 
and 1-7% of adults.25,26 Its incidence has been increasing during the past decades and 
is still on the rise, especially in developing countries.27 Although the disease can start at 
any age, symptoms start in infancy in most patients, followed by long continuous peri-
ods of disease or a relapsing-remitting course with symptom-free intervals.28,29 AD has 
been found to negatively impact the quality of life of both patients and their families.30,31
clinical features and comorbidities
The characteristic clinical features in AD are intense itch and recurrent eczematous le-
sions. Infants usually have lesions that show acute inflammation and oozing, while older 
children have more polymorphous lesions. In adolescents and adults chronic lesions 
Figure 1. The skin microbiome (Published with permission. Grice et al. Nature Reviews Microbiology 2011).23
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NOTE: Microorganisms also reside in the deeper layers of the skin, where the microbial composition differs from 
that of the skin surface and interaction can take place with living dermal cells.24 
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with lichenification are part of the clinical presentation. Typically, also the location of 
the lesions changes with the age of the patient. Infants show lesions in the face, at the 
extensor site of the limbs and sometimes the trunk. In older children the lesions are 
particularly located in the flexural folds and in adults the flexures, hands, eyelids, head 
and neck, upper trunk and scalp are sites of predilection.32,33 Particularly more severe AD 
is frequently associated with other atopic diseases, including asthma, allergic rhinitis 
and food allergy.29 Together with epidemiological and genetic data that associate AD 
with other diseases, such as rheumatoid arthritis, ulcerative colitis and diabetes type 1, 
this suggests that AD should be considered as a systemic disease rather than an inflam-
mation limited to the skin.34,35
Risk factors
Both genetic and environmental factors underlie the development of AD and the course 
of the disease. Different environmental risk- and protective factors for AD have been 
identified until now. The main environmental risk factors for AD are a ‘Western’ diet (fast-
food, low fruit) and broad-spectrum antibiotic exposure in early life.36 Some studies have 
shown that air pollution and maternal psychiatric symptoms during pregnancy are as-
sociated with an increased risk of eczema.36,37 The main protective factors that have been 
identified are UV light and factors related to microbial exposure, such as dog ownership 
and rural residence.36
A positive family history for atopic diseases is a strong risk factor for AD and multiple 
genetic defects have been identified that explain genetic susceptibility to AD.38 The best 
known genetic defect is a null mutation in the gene encoding filaggrin, a protein that 
helps maintain skin barrier homeostasis.39 Although a substantial part of the patients 
with AD do not have a mutation in this gene, it is known that patients who do carry the 
mutation have more persistent disease and a higher risk of atopic comorbidities, includ-
ing asthma and allergic rhinitis.40,41 In recent studies it has been shown that other genes 
may also play a role in susceptibility for AD. In a review of genome-wide association 
studies (GWAS) where thousands of AD cases were tested for associations with single 
nucleotide variants against controls it was shown that a total of 34 gene loci were associ-
ated with AD, including genes involved in skin barrier function and innate and adaptive 
immune defense.42 One of the included GWAS found that the identified loci explain 
around 15% of variation of AD in populations due to genetic variation (heritability) in 
a subset of European studies.43 Interaction between genes and environmental factors 
also seems a major modifier of the disease, although large scale studies investigating 
potential interactions between gene- and environmental effects are lacking.42
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AToPIc DeRMATITIs PATHogenesIs – THe Role oF THe MIcRobIoMe
Three major pathophysiologic changes characterize AD, namely: an impaired skin barrier, 
an altered immune response and changes in microbial composition. The skin epithelial 
function and immune responses have been extensively studied in AD. They are consid-
ered the two major biologic pathways responsible for AD etiology, based on genetic 
studies.33,42 The primary event however is continued to be topic of debate.44 There has 
been an increased interest in understanding the relation between the microbiome and 
AD as alterations in the microbiome are associated with AD and its severity. A summary 
of the known evidence on the main pathological pathways is presented below.
skin barrier impairment
The healthy skin forms a strong barrier against harmful stimuli from the environment, 
including irritants, allergens, antigens and microorganisms. The outermost layer of the 
epidermis, the stratum corneum, consists of densely packed corneocytes (terminally 
differentiated keratinocytes) and proteins that together comprise the mechanical bar-
rier. Thereby, the protective function of the skin is dependent on a balanced activity 
of lipids, acids, enzymes and the production of pro-inflammatory and antimicrobial 
molecules by immune cells and keratinocytes lower in the epidermis.33 Multiple skin 
barrier abnormalities have been associated with AD. An increased water loss, also in the 
non-lesional skin, indicates an overall impairment of the barrier function in patients with 
AD.45 Furthermore, changes in skin pH, reduced expression of antimicrobial peptides 
and changes in the composition of lipids that control skin hydration are associated with 
the disease.46-48 A deficiency in filaggrin, described above as an important genetic risk 
factor for AD, affects multiple aspects that are important for a healthy skin barrier, such 
as water retention and lipid composition.46 The impaired barrier function in AD causes 
environmental irritants, antigens and allergens to penetrate into skin, where they can 
provoke an immune reaction.
Immunological characteristics
One of the immune abnormalities in AD is infiltration of inflammatory cells into the skin. 
Non-lesional skin and newly developing lesions already show signs of low-level inflam-
mation with increased numbers of Th2, Th22, Th17 cells and their pro-inflammatory 
cytokines.34 The pro-inflammatory state in non-lesional skin combined with the existing 
impaired skin barrier in AD allows irritants, antigens and allergens to penetrate into the 
skin. This triggers keratinocytes to produce TSLP (Thymic stromal lymphopoietin) and 
cytokines that stimulate Th2 cell production in the lymph nodes.49,50 A downstream ef-
fector molecule of TSLP, TARC (thymus and activation-regulated chemokine), stimulates 
migration of these Th2 cells to the skin, resulting in a positive feedback mechanism and 
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acute inflammation.51 Acute AD lesions are predominated by infiltration of Th2 cells that 
produce multiple pro-inflammatory cytokines, including interleukin (IL)-4, 13 and 31, 
whereas a shift towards Th1 cells promotes chronic inflammation. This shift is thought 
to occur under the influence of IL-12 produced by dendritic cells, possibly stimulated by 
Staphylococcus (S.) aureus.49 The Th1 cells in chronic lesions produce interferon-γ. This 
inhibits keratinocyte differentiation, causing the hyperplastic epidermis seen in these 
lesions (figure 2).49,52
The humoral immune response has also been shown to contribute to the pathogen-
esis of AD. Mainly abnormalities in immunoglobulin E (IgE) production are attributed to 
the disease. The impaired skin barrier in AD that becomes susceptible to the penetration 
of allergens causes production of IgE by B cells which are stimulated by Th2 cytokines. 
Once formed and released into the circulation, IgE binds mast cells, and subsequent re-
exposure to the allergen can cause degranulation. Many patients with AD show high IgE 
concentrations against specific allergens. Up to two-thirds of the infants with moderate 
to severe AD show sensitization against food allergens, but actual symptoms of a food 
allergy occur in a smaller subset.54,55 In older children, additional IgE sensitization to-
wards inhalant allergens is seen.56 In some patients with AD, increased IgE has also been 
found against microbial antigens, indicating that microbes might act as allergens and 
stimulate mast cells in AD.57-62 Although less in forefront, IgG antibodies have also been 
studied in AD. IgG subclasses IgG1, IgG2, IgG3 and possibly also IgG4 are able to activate 
complement.63 The IgG response in AD has mainly been studied in the context of food 
antigens that interact with the intestinal mucosa. Contact between these antigens and 
immune cells in the mucosa leads to production of specific IgG. A next encounter with 
Figure 2. Inflammatory cells in the skin during acute and chronic inflammation (Adapted from Geoghean et al. 
Trends Microbiol. 2017).53
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the food antigen provokes a pro-inflammatory response leading to phagocytosis of the 
antigen, which involves activation of the complement cascade.64 This IgG based immune 
response probably also occurs in reaction to antigens that penetrate the impaired skin 
in AD. Studies in this field are still scarce but Sohn et al. reported significantly higher 
levels of IgG against microbial antigens in patients with AD compared to controls.65 The 
presence of IgG represents a physiological response to repeated contact with a certain 
antigen. It is unclear whether IgG is just an ‘innocent bystander’ and a marker for interac-
tion between antigens and the immune system or if it also contributes to inflammation 
and barrier dysfunction.64 Measuring IgG against microbial antigens might help us to 
understand how microbes interact with the immune system and possibly induce inflam-
mation in the skin.
Microbiome alterations
The microbiome of the skin, but also that of the nose and gut, have gained major interest 
in AD because of a possible role in inflammation and close interaction with the immune 
system.1 The skin is the most well studied niche in AD. Already since the 1970s stud-
ies describe an overgrowth of S.aureus bacteria on the lesional skin, accompanied by 
reduced diversity of commensal bacteria on the skin.66,67 Until now, microbial research 
has mainly focused on S. aureus. Some mechanisms by which the bacterium interacts 
with the skin barrier and immune system have been unraveled, such as the production 
of α-toxin by the bacterium that induces keratinocyte damage.68 S. aureus strain-specific 
differences in eliciting skin inflammation were demonstrated in a cutaneous coloniza-
tion model.69 However, the exact role of the skin microbiome in the pathogenesis of 
AD remains poorly understood. Recently, the first longitudinal studies were published. 
Meylan et al. found in 149 infants that the presence of S. aureus on the skin at the age 
of three months was associated with the development of AD later in life (20% vs. 5.7%; 
p=0.035).70 Another small study (n=20) found that staphylococci were less abundant 
on the skin in infants at the age of two that developed AD at one year of age. Further 
classification of these staphylococci revealed that S. epidermidis and S. cohnii were most 
abundant, while notably no S. aureus was present.71 These findings relate to a mice study 
that found that early colonization with commensal Staphylococcus species might have 
a role in shaping the adaptive immune response and tolerance against these species.72 
A recent systematic review found that dysbiosis in AD does not only involve increased 
S. aureus. Also other staphylococci and other species such as Propionibacterium and 
Malassezia were found to have an altered abundance.19 At the same time, they state 
that current data are not sufficiently robust for good characterization which emphasizes 
further determination of the role of skin microbes in AD.
Studies on the nasal microbiome have mainly focused on carriage of S. aureus. 
Approximately 20% of general population is a persistent carrier of S. aureus and in 
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another 30% the bacterium is intermittently found.73 Persistent carriers have higher S. 
aureus loads, higher risk of S. aureus infection and higher titers of anti-staphylococcal 
antibodies when compared to intermittent and non-carriers.74 It is still unclear why hu-
mans are not equally susceptible to colonization, as we are all exposed to the bacterium 
from birth. Multiple factors probably determine carriage, including the genotype of the 
bacterium, the host immune response and underlying host genetic factors.75 The nose is 
also an important niche for microbes in AD as the anterior nares are considered an im-
portant reservoir for self-contamination and bacterial spread to the skin. A prospective 
study showed an association between AD and colonization of the nares with S. aureus 
at the age of 6 months and frequent colonization during the first year of life.76 However, 
current literature is conflicting as another study did not find an association between 
nasal S. aureus colonization at 1 month of age and AD development.77 The role of the 
nasal microbiome in AD and its interaction with the skin microbiome or vice versa are 
still unclear.78,79
The gut microbiome is thought to play a role in shaping the immune system and it 
is speculated to influence the development of allergic diseases.80 Gut microbes can 
modulate the direction of T-cell differentiation into T regulatory cells or effector T cells 
(Th1, Th2, Th17), which is important for immune tolerance.81 Studies investigating the 
gut microbiome in children showed associations between changes in the gut microbial 
composition and the development atopic diseases, including asthma and allergic rhini-
tis.82,83 The relation between gut microbiome and development of food allergy is less well 
studied. Literature investigating the actual gut microbiome in relation to AD confirmed 
associations but is still inconclusive.84 Some studies found an increase in Escherichia coli 
and Clostridium difficile and a decrease in Bifidobacteria.85,86 Intervention studies have 
also been inconsistent. However, a large study found a deviating microbiota along with 
reduction in AD after a probiotic intervention, which supports an association between 
the gut microbiota and AD.87
cross-talk between skin barrier, immune system and microbiome
The skin barrier and immune system are known to interact in a bidirectional way, rein-
forcing the process of inflammation. For example, pro-inflammatory cytokines (IL-4, IL-13 
and IL-22) are strong suppressors of filaggrin causing skin barrier dysfunction.88 Another 
example is illustrated by the Th2 cytokine IL-31 that evokes itch, resulting in scratching 
and further skin barrier dysfunction.89 Also the microbiome is in constant interaction 
with the skin barrier and immune system. For example S. aureus facilitates colonization 
and induces inflammation via interactions with the immune system and barrier.53,90 Us-
ing MSCRAMMs (microbial surface component recognizing adhesive matrix molecules), 
such as clumping factor, S. aureus binds to the extracellular matrix.91 After establishing 
contact, S. aureus can secrete molecules that damage the cell membrane, such as alpha 
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toxin.68 Via other antigens, including Protein A and staphylococcal enterotoxins, the 
bacterium modulates the immune system. The enterotoxins can act as superantigens 
and allergens which means that they can directly stimulate T cells, causing proliferation 
and the release of pro-inflammatory cytokines.67,92,93 They are also thought to stimulate 
mast cells, both direct and indirect via IgE binding. Thereby, S. aureus enterotoxin B 
can stimulate IL-22 and alfa-toxin can stimulate IL-31.94,95 At last, binding of S. aureus 
lipoteichoic acid to TLR2 on dendritic cells seems to enhance Th1/Th17 cell priming, 
suggesting a role for S. aureus in the transition towards chronic AD which is more Th1 
cell driven.96 Another study found that, next to lipoteichoic acid, also alpha-toxin might 
facilitate chronic AD via induction of a Th1 cytokine response.97 On the other hand, 
innate immune system abnormalities in AD as well as epidermal barrier abnormalities 
contribute to S. aureus colonization. For example, the inflammatory Th2 milieu induces 
fibrinectin synthesis and thereby adherence of S. aureus.98 And Th2 cytokines IL-4 and IL-
13 can decrease sphingomyelinase, which normally protects against alfa-toxin induced 
keratinocyte damage.68,99 Figure 3 illustrates known interactions between microbiome, 
skin barrier and immune-system, supporting that all three components are important to 
study the process of inflammation in the skin.
Figure 3. S. aureus and its interaction with the skin barrier and immune system
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MAnAgeMenT oF AToPIc DeRMATITIs
general management
Current AD treatment is based on a ‘one size fits all’ principle according to the clinical 
severity of the disease. Basic therapy consists of a daily emollient (and bath oils) and 
avoidance of triggers. Mild AD requires reactive therapy with anti-inflammatory topical 
immunosuppressive agents, including corticosteroids. Moderate disease severity needs 
a more proactive treatment with higher potency topical corticosteroids or calcineurin 
inhibitors. In case of severe AD systemic immune suppression might be indicated. 
UVB therapy might be considered in moderate AD and PUVA therapy (only in adults) 
in severe AD before starting systemic medication.100 New targeted therapies are under 
investigation for the treatment of AD, including small molecules and biologics.101 Two 
phase 3 trials showed promising results of a biologic drug in AD for the first time (Dupi-
lumab, a human monoclonal IgG4 anti IL-4 and IL-13 antibody).102 The downside of the 
current treatment options, especially in moderate to severe AD, is the risk of side effects. 
Long term use of more potent topical and systemic corticosteroids might result in local 
and systemic side effects including adrenal suppression.103 Also systemic therapy can 
cause serious side effects, such as liver dysfunction, hematological and gastro-intestinal 
side effects (azathioprine and methotrexate) or kidney failure and high blood pressure 
(cyclosporine A).104
The microbiome as a therapeutic target
Dutch guidelines recommend antimicrobial (anti-staphylococcal) treatment only in cas-
es of fever, high staphylococcal load or clinically infected AD.100 In these cases treatment 
with antibiotics might be beneficial, but only short term use is allowed (maximum to 14 
days). In case of recurrent infected AD Povidon-iodine (Betadine) scrubs or chlorhexidine 
can be used. American Academy of Dermatology guidelines from 2014 also mention that 
in patients with moderate to severe AD and signs of bacterial infection, bleach baths and 
intranasal mupirocin may be recommended.105 Guidelines published in 2012 mention 
that the use of silver-coated antimicrobial textiles can reduce AD severity, but that their 
use is under investigation and safety concerns exist for the use in infants and toddlers.106
According to the Dutch guidelines there is no place for antibiotics in non-clinically 
infected AD.100 Although international guidelines support this, European guidelines 
shortly mention that in severe exacerbations systemic antibiotic treatment may be help-
ful.100,105,106 Current guidelines are based on clinical studies that mainly used short anti-
microbial interventions and did not clearly show the added value of anti-staphylococcal 
therapy in non-infected AD.107 However, recent studies show effectiveness of chloride 
bathing on AD symptoms after two and three months.108,109 Modulation of the skin 
microbiome can still be promising for the treatment of AD, either by finding out how 
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to apply existing antimicrobials in a way that they result in clinical improvement or via 
newly developed treatment strategies. However, the role of the microbiome in AD needs 
to be further identified to guide treatment approaches that target the microbiome. 
Different new (non-antibiotic) treatment strategies for modulation of the microbiome 
are under development or clinically tested. Different strategies include either target-
ing single pathogenic species or providing control over these species using beneficial 
bacteria. Currently, vaccines and mABs (monoclonal antibodies) are under development 
that neutralize one or more S. aureus toxins, such as alfa toxin.67 Also, the interest in 
the use of bacteriophages and bacteriophage lysins has been renewed. Bacteriophages 
are bacteria-specific viruses that use the host’s cellular machinery to reproduce inside 
the host. They produce endolysins that weaken the bacterial cell wall from inside and 
make the bacterial cell burst, forced by internal osmotic pressure. Currently, the use of 
endolysins instead of the whole phage gained particular interest. Lysins typically consist 
of a domain that allows binding to bacteria-specific structures of the cell wall. Thereby, 
one or two other domains cleave specific bonds in the peptidoglycan.110,111 Their ad-
vantage over antibiotic and also whole phage therapy is their targeted mode of action, 
minimal influence on commensal flora and the low risk of bacterial resistance induction 
(figure 4). Staphefekt SA.100 is an engineered endolysin that specifically lyses the cell 
membrane of S.aureus.112
On the other hand, artificial modification of the skin microbiota using microbes that 
provide control over dominant species (probiotica) might be a promising strategy, 
but until now very few studies report on topical probiotic approaches for skin disor-
ders.113 Few research groups are investigating the effect of adding beneficial bacteria 
to moisturizers. Seite et al. describe a reduction of AD flares after treatment with an 
emollient containing non-living extract of a Gram-negative proteobacterium, Vitreoscila 
filiformis.114 An ongoing study of Gallo et al. uses beneficial S. aureus species.115 These 
new strategies mentioned above seem promising. However, we should keep in mind 
Figure 4. The left figure shows lysis of the bacterial host by endolysins, a critical step in replication cycle of 
bacteriophages. The right figure shows lyses the cell from the outside by the endolysin. (Courtesy from Micreos)
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that modification of the microbiome might have unexpected effects. For example by 
eliminating a (single) species from the microbiome, one might create a niche for other 
pathogenic organisms to grow.
AIMs AnD scoPe oF THe THesIs
The impaired skin barrier and altered immune mechanisms in AD are widely studied 
and considered as the two major players in AD inflammation. A third player, the altered 
microbiome, is an established finding in AD but its role in the pathogenesis is still poorly 
understood. Studies have focused mainly on a single species, namely S. aureus, and on 
the cutaneous microbiome. However, other species and other niches might also be 
involved. In this thesis, we first aimed to characterize the microbial composition of the 
skin, nose and gut in pediatric patients with mild to severe AD. Our second aim was 
to estimate the prevalence of S. aureus in patients with AD and to study the humoral 
immune response against S. aureus. Third, we aimed to design a clinical study to test 
the effect of a new endolysin-based therapy that specifically targets S. aureus in AD. The 
results of this research are presented in this thesis. This knowledge will help to better 
understand the role of the microbiome in the pathogenesis of AD. Furthermore, it will 
help to determine if there is a role for therapy that targets the microbiome in the treat-
ment of AD, and to identify possible microbial therapeutic targets of interest.
ouTlIne oF THe THesIs
In the first part of the thesis we examined the microbiome composition of different 
niches of the body in patients with AD. In chapter 2 we characterized the bacterial mi-
crobiota of the skin and nose using 16S rRNA sequencing in a cohort of children with AD. 
We tested associations between the microbial composition and AD severity phenotypes 
and explored the relations between the skin and nasal microbiome. In chapter 3 we 
characterized the gut microbiome in AD and evaluated whether the microbiome can 
discriminate between children with and without a food allergy.
In the second part we focused on S. aureus and the humoral immune response against 
this bacterium. In chapter 4 we estimated the prevalence of S. aureus colonization in 
lesional and non-lesional skin as well as in the nose via a systematic literature search 
and meta-analysis. We additionally studied the colonization for different disease severity 
phenotypes. chapter 5 outlines a systematic review and meta-analysis that summarizes 
the available literature on the human antibody responses towards the different S. aureus 
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virulence factors. In chapter 6 we studied the serum IgG response against 55 S. aureus 
virulence factors in two cohorts of pediatric patients with AD.
In the third part we work towards studying the effect of new therapeutics that target 
the skin microbiome in AD. chapter 7 of this thesis outlines a comparison between skin 
swabs and scrubs to identify the most sensitive method for studying microbial outcomes 
in intervention and cross-sectional studies. Using the results of the chapters described 
above, we finally designed a protocol for a randomized controlled trial that studies the 
effect of a new targeted anti-S. aureus therapy on the symptoms in AD, described in 
chapter 8. Finally, the main findings and recommendations for clinical implication and 
future research were discussed in chapter 9.
sTuDy DesIgn
The research described in this thesis was based on two pediatric patient cohorts, the 
SMA and the DAVOS cohort. SMA included patients with mild to severe AD from 0 to 18, 
between November 2009 and December 2011. DAVOS included children with difficult 
to treat eczema from 8 to 18 years, between January 2011 and June 2015. Microbial 
samples of the skin, nose and gut of the GMA cohort were included to characterize 
microbial composition in these niches in relation to AD severity and food allergy. Se-
rum samples of both studies were used to study the IgG immune response towards S. 
aureus in relation to AD severity. In both studies, AD severity was assessed using the 
Self Administrated-Eczema Area and Severity Index (SA-EASI) and levels of thymus and 
activation-regulated chemokine (TARC), a serum biomarker for AD severity. A third adult 
patient cohort was included to study different collection methods for skin microbiome 
sampling, as part of designing a trial to study the effects of long-term microbial modula-
tion in adult patients with AD.
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AbsTRAcT
background
Changes in the skin microbiome have been associated with atopic dermatitis (AD) and 
its severity. The role of the nasal microbiome in relation to the severity of AD and its 
relation with the skin microbiome, are less well studied.
objective
We aimed to characterize the nasal and skin microbiome in children with AD in relation 
to disease severity. Additionally, we explored differences and correlations between the 
nasal and skin communities.
Methods
We characterized the microbial composition of nasal and lesional skin samples from 90 
and 108 patients with AD, respectively, using 16S-rRNA sequencing. Additional quanti-
tative (q)PCR for Staphylococcus (S.) aureus and S. epidermidis was performed on the skin 
samples. Disease severity was estimated using the self-administered eczema area and 
severity index.
Results
We found an association between the microbial composition and AD severity in both the 
nose and skin samples (R2=2.6%; p=0.017 and R2=7.0%; p=0.004). Staphylococci were 
strong drivers for the associations with severity. However, other species also contrib-
uted, such as Moraxella in the nose. Skin lesions were positive for S. aureus in 50% of the 
children and the presence and load of S. aureus was not associated with disease severity. 
Although the nose and skin harbor distinct microbial communities based on Bray–Curtis 
dissimilarity (n=48 paired samples; p<0.001), we found that correlations exist between 
species in the nose and (other) species on the skin.
conclusion
The results show that both the nasal and skin microbiome are associated with disease 
severity in children with AD. Next to staphylococci, other species contribute to this as-
sociation.
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InTRoDucTIon
Changes in the microbial composition of the skin and nose have been suggested to 
contribute to the complex pathogenesis of atopic dermatitis (AD).1 The microbiome of 
the skin in AD is characterized by an increased abundance of Staphylococcus (S.) au-
reus.2-4 A recent systematic review on the skin microbiome in AD also reports changes 
in other bacterial species.5 For example, S. epidermidis has been found increased on 
the lesional skin, and reductions in Propionibacterium and Streptococcus were reported 
during AD flares.3,5,6 These microbial alterations were reported in small single studies 
and need further validation.5 Prospective studies observed increased skin colonization 
with S. aureus at the age of 3 months in infants who later develop AD.7 Another small 
study also found an association between skin colonization in the antecubital fold with 
commensal staphylococci (S. epidermidis and S. cohnii) at the age of 2 months, and AD 
later in life.8,9 Although data are still limited, these prospective studies suggest that the 
skin microbiome might contribute to both (severity of the) inflammation in AD and the 
development of the disease.
There is also evidence that the nasal microbiome is involved in the pathogenesis of 
AD. For example, it has been shown that patients with AD are almost five times more 
likely to carry S. aureus in the nose compared to healthy controls.2 In a large birth cohort 
study, colonization of the nares with S. aureus at the age of 6 months and frequent colo-
nization during the first year of life were associated with AD and its severity.10 However, 
this was not confirmed in other studies.3,11 Studies into the nasal microbiome in AD are 
often limited to S. aureus and there is very little known about the nasal microbiome in 
children in relation to AD severity.
The identification of species that contribute to the pathogenesis of AD is important for 
the development of new specific treatment strategies that aim to modulate the micro-
biome. Also, knowledge about which microbial niches are involved in AD and how they 
interact is needed to guide these developments. Several studies described the impor-
tance of relations between the nasal and skin microbiome with regard to S. aureus.4,12,13 
The anterior nares could be an important reservoir for self-contamination and bacterial 
spread from the nose to the skin or vice versa. However, the relation between the skin 
and nasal microbiome in AD has barely been studied before.
In this study we aimed to characterize the nasal and skin microbiome composition 
in children with AD and determined its association with AD severity. Additionally, we 
explored differences and correlations between the nasal and skin microbiome.
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study design and patients
This cross sectional study was embedded in a randomized controlled trial that compared 
group consultation with individual consultations in children with AD, treated in the 
outpatient clinic of the Wilhelmina Children’s Hospital of the University Medical Center 
Utrecht (ISRCTN08506572).14 Inclusion criteria were: diagnosis of AD according to UK 
Working Party criteria, age between 0 and 18 years and parental ability to answer Dutch 
questionnaires.15 Microbial swabs of the nose and skin, eczema severity scores and pa-
tient characteristics were all obtained at baseline and analyzed in the current study. The 
medical ethical committee of the University Medical Center Utrecht approved the study 
(08-368/K) and written informed consent was obtained from all participants. Severity 
of the AD was estimated using the self-administered eczema area and severity index 
(SA-EASI) by a research nurse.16 Patients with a SA-EASI from 0 to 17.35 were classified as 
mild eczema, from 17.35 to 46.27 as moderate eczema and higher than 46.27 as severe 
eczema, calculated based on cut-offs of the SCORAD score (Supplementary methods).17
Microbial samples
A total of 90 microbial samples were taken from the mucosal surfaces of the anterior 
nares. Skin microbial samples were taken from the lesional skin (n=108), preferably the 
antecubital fold or popliteal fossa. Samples were collected by a trained research nurse, 
according to a standardized procedure and using a sterile swab (Sterile Dryswab™) 
moistened with sterile NaCl 0.9%. After collection, the samples were aliquoted and 
frozen at -20⁰C until further processing.
DnA isolation and qPcR
For DNA isolation approximately 150 ul of cutaneous or nasal material (retained by rins-
ing the swabs in lysis buffer) was directly transferred to the DNA isolation plate. Then 
0.5 mL phenol pH8.0 (Phenol solution, catalogue P4557, Sigma-Aldrich, St Louis, MO) 
was added and the samples were mechanically disrupted by bead beating 2 times 3 
minutes with a 96-well plate Beadbeater (Biospec Products, Bartlesville). Samples were 
centrifuged at 1880 rcf (4000rpm) for 10 minutes to separate the aqueous and phenolic 
phases. The aqueous phase was transferred to a new 96-well plate and DNA was purified 
with the AGOWA mag Mini DNA Isolation Kit (AGOWA, LGC genomics, Berlin, Germany) 
in accordance with the manufacturer’s recommendations. After elution, total load of S. 
aureus and S. epidermidis was assessed by quantitative (q)PCR using the following prim-
ers and probe: 16S-S.aur-F1 (5’-GCG AAG AAC CTT ACC AAA TCT TG-3’) and 16S-S.aur-R1 
(5’-TGC ACC ACC TGT CAC TTT GTC-3’), 16S-S.aur MGB Taqman® probe (5’-CAT CCT TTG 
ACA ACT CT-3’) with a FAM label, 16S-S.epi-F1(GCG AAG AAC CTT ACC AAA TCT TG) and 
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16S-S.epi-R1 (CAT GCA CCA CCT GTC ACT CTG T) and the 16S-S.epi MGB Taqman probe 
(CCT CTG ACC CCT CTA G) with VIC label.
16s rRnA sequencing
The microbial composition of each sample was characterized by mass sequencing of the 
V4 hypervariable region of the 16S rRNA gene on the Illumina MiSeq sequencer (Illumina, 
San Diego, CA). To prevent over-amplification, barcoded DNA fragments spanning the 
Archaeal and Bacterial V4 hypervariable region were amplified with a standardizing level 
of template DNA (1 ng). These amplicons, generated using adapted primers F515 and 
R806 (using 30 PCR cycli), were bidirectionally sequenced using the MiSeq system.18,19 
After removing samples with less than 1000 sequences, 89 nasal and 60 skin samples 
remained (figure S1). Pre-processing and classification of sequences was performed us-
ing modules implemented in the Mothur V.1.31.1 software platform.20 Sequences were 
trimmed between 243-263nt and chimeric sequences were identified per sample using 
UCHIME in de novo mode and removed.21 Sequences with 97% sequence similarity or 
higher were grouped into operational taxonomic units (OTU) using MOTHUR. Taxonomic 
names were assigned to all sequences using the Ribosomal Database Project (RDP) 
naïve Bayesian classifier with confidence threshold of 60% and 1000 iterations and the 
mothur-formatted version of the RDP training set v.9 (trainset9_032012).22 For each OTU, 
the most common sequence was selected as the most representative sequence. Read 
counts for each OTU were tabulated for downstream analysis. Standardized mock com-
munities were included to check for technical performance of all experimental steps. 
Negative control samples of the lysis buffer did not show signs of contamination. Based 
on preliminary cluster analyses we identified three outlier samples in the skin database 
(data not shown). Two of these samples were dominated by contaminant species (Bifi-
dobacterium, Enterobacter ) likely transferred via the feces as the samples were collected 
from the legs of young children. The third skin sample was dominated by Enhydrobacter. 
The three samples were excluded and a total of 89 nasal and 57 skin samples remained 
for further analysis (figure S1).
statistical analysis
Differences in baseline characteristics and metadata were statistically tested using the 
Chi-Square or Fisher’s exact test and non-parametric Mann-Whitney U Test for inde-
pendent samples where appropriate (SPSS version 24). Alpha diversity of the nasal and 
skin samples was calculated based on unfiltered OTU tables that were subsampled to 
the sample with the lowest total read count (1160). We calculated richness (number of 
different OTUs) and Shannon index (number of different OTUs and how evenly they are 
distributed) and compared these between nose and skin samples using non-parametric 
independent sample Mann-Whitney-U test. Non-subsampled OTU tables were filtered 
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for further analysis. OTUs present in less than two samples and with less than 10 counts 
in total were excluded for downstream analysis. Species and phylum relative abun-
dances were visualized using stacked bar charts. The most dominant species in the nose 
and skin were estimated based on median relative abundances.
The filtered OTU tables were standardized using Hellinger transformation for further 
ordination analysis.23 To test whether AD severity (SA-EASI) significantly drives differ-
ences in overall microbial composition, we used a permutational multivariable analysis 
of variance (PERMANOVA) based on Bray-Curtis dissimilarity.24 The Bray-Curtis dissimilar-
ity scale measures similarity between communities based on the taxa present and their 
relative abundances. The PERMANOVA tests were adjusted for age, use of antibiotics 
and location of sample collection (only skin), and the number of permutations was set 
on 10000. To identify which species drive the association between the overall microbial 
composition and AD severity, we obtained PERMANOVA coefficients.24
To visualize overall differences in microbial composition between nose and skin sam-
ples, we used nonmetric multidimensional scaling (NMDS) plots based on Bray-Curtis 
dissimilarity. Statistical significance of this difference was assessed using PERMANOVA 
(10000 permutations). To identify correlations between the microbial communities of 
the nose and skin, we carried out regularized canonical correlation analysis (RCCA), 
including the ‘ridge’ method.25 For this RCCA we included OTUs that were present in at 
least 20% of the samples.
The statistical analysis were performed using the R statistical software (RStudio ver-
sion 1.0.153). We used the packages ‘vegan’ (version 2.4-6) for NMDS and PERMANOVA 24, 
‘phyloseq’ (version 1.21.0) for alpha diversity 26, ‘CCA’ (version 1.2) for RCCA 27 and ‘gg-
plot2’ (version 2.2.1) for visualization.28 The set.seed function was used (with seed = 32) 
to obtain reproducible results.
ResulTs
characteristics of the study population
A total of 90 nose and 108 skin samples were collected and all 108 skin samples were 
analysed using qPCR. A total of 89 nose and 57 skin samples were available for analysis 
after 16S rRNA sequencing (figure S1). The 57 skin samples were collected from the an-
tecubital fold (n=36), popliteal fold (n=9), head/neck (n=5), arm (n=4) and an unknown 
location (n=3). For 48 children, samples of both the nose and skin were available. Base-
line characteristics of the children are described in table 1.
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Microbial diversity of nose and skin in children with AD 
A total of 2107454 high quality sequences were obtained from the 89 nasal samples 
(median per sample 22196; range 697-56436). The sequences were assigned to 390 OTUs, 
10 different bacterial phyla and one archaeal phylum. Nasal samples contained mainly 
Proteobacteria (52%), Firmicutes (28%) and Actinobacteria (11%), illustrated in figure 
1a. There seems to be a negative correlation between Proteobacteria and Firmicutes, 
since samples with a high abundance of Firmicutes have lower abundance of Proteo-
bacteria and vice versa. From the 57 skin samples, 1110689 high quality sequences were 
obtained (median per sample 12449; range 1124-106087), belonging to 358 OTUs of 9 
different bacterial phyla and one archaeal phylum. Firmicutes were very predominant 
on the skin samples with a median relative abundance of 92% of all the bacterial phyla. 
Proteobacteria, Actinobacteria and Bacteroidetes followed (figure 1b). A comparison of 
the 10 most abundant OTUs between nose and skin is presented in figure 2. As shown in 
this figure, Moraxella, Dolosigranulum and Corynebacterium were prevalent in the nasal 
microbiome with median relative abundances of 25%, 12% and 7%, respectively. In the 
skin samples staphylococcal species comprised a large part of the microbial community 
with a median relative abundance of 87% (figure 2 and figures S2a-b). Alpha diversity, 
the diversity within a single sample as measured using richness and the Shannon index, 
shows lower Shannon diversity but not richness in the skin samples compared to the 
nose samples (figure 3; p-value <0.001 and 0.366).
Table 1. Patient characteristics
nose cohort (n=89) skin cohort (n=57) p- value
Female sex 
n (%) 42 (47.2) 25 (43.9) 0.694 
Age 
months; median (IQR) 30 (11.1-70.6) 22.9 (9.5-62.5) 0.475 
sA-eAsI 
median (IQR) 30.8 (16.2-52.5) & 36.9 (19.2-58.5) ^ 0.346 
use of medication, n (%)
Topical corticosteroids 67 (75.3) 45 (78.9) 0.609 
Systemic corticosteroids 0 (0)$ 0 (0)^ - 
Topical antibiotics 7 (7.9) 3 (5.3) 0.741 
Systemic antibiotics 2 (2.2) 1 (1.8) 0.663 
^ n=55; 2 missing, & n=88; 1 missing, $ n=87; 2 missing
P-values were calculated using Chi-Square test and Fisher’s Exact Test for categorical data. A non-parametric 
Mann-Whitney U Test for independent samples was used for continuous variables
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Associations between the microbiome and severity of AD 
We found a significant association between the overall microbial composition in the 
nose and the severity of AD measured by SA-EASI (PERMANOVA, R2=2.6%; p=0.017; 
table 2). This association was driven by Staphylococcus (increased in more severe AD) 
and Dolosigranulum (decreased in more severe AD) (figure 4a). Also the variance in 
microbial composition of skin samples was significantly influenced by severity of the AD 
(R2=7.0%, p=0.005). Staphylococci were the strongest drivers of the association between 
skin microbial composition and AD severity. However, other species illustrated in figure 
4b might also be implicated. Interestingly, the contribution of the skin microbiome 
to AD severity is larger than of the nasal microbiome. Next to disease severity, age of 
the patient was also significantly associated with nasal microbial composition while 
use of antibiotics and location of sampling influenced the skin microbiome (table 2). 
To get more insight in the role of the staphylococci on the skin in AD severity, an ad-
ditional qPCR was performed on the 108 collected skin samples to identify S. aureus 
Figure 1a. Distribution of phyla in the nose samples (n=88, one missing sample)
Figure 1b. Distribution of phyla in the skin samples (n=57)
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and S. epidermidis (as a representative for coagulase-negative staphylococci). Of these 
samples, 50.0% and 79.6% were positive for S. aureus and S. epidermidis, respectively. 
Children with moderate and severe AD were colonized with S. aureus on their skin more 
often than children with mild AD (58% and 51% versus 39%), however this was not sig-
nificantly different (p=0.299; Chi-Square test) and the load of S. aureus did not increase 
with AD severity (p=0.291; figures S3a-b). The prevalence of skin colonization with S. 
epidermidis did not differ between mild, moderate and severe AD (86%, 74% and 80% 
respectively; p=0.513). However, the load of S. epidermidis was significantly higher in 
severe AD compared to mild AD (p=0.016; figures S3a-b).
Differences and correlations between nasal and skin microbial communities
To visually inspect differences in the microbiome composition between skin and nose 
we grouped all samples from patients of which both a nose and skin sample were avail-
Figure 2. 10 most abundant OTU’s in the nose and on the skin (n=48)
NOTE: heatmap is based on the logit transformed median relative abundance. Top of blue color gradient bar 
corresponds with a median relative abundance of 90%. The lowest value (white) lays below 0.01%. On the OTU 
level, different members of the same species were identified that could not be further classified. The OTUs were 
named by the species followed by a number (e.g. Moraxella 1 and Moraxella 2).
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able (n=48). As shown in figure 5 microbial communities of the nose and skin clustered 
separately (PERMANOVA: R2=30.9, p<0.001), indicating distinct microbial communities 
at each location. In all 48 patients, staphylococci were found both in the nose and on the 
Table 2. Multivariate analysis showing the influence of different covariates on the variance in the nasal and 
skin microbiome
nose (n=88) skin (n=53)
R2 P- value R2 P- value
SA-EASI # 0.026 0.017* 0.070 0.005*
Age 0.057 <0.001* 0.021 0.212
AB use (topical and oral) 0.006 0.839 0.062 0.007*
Location of sampling ^ - - 0.052 0.017*
* significant p-value
# Predetermined order of variables included in the adonis model: SA-EASI, age and antibiotic use for the nose; 
SA-EASI, sample location, antibiotic use and age for the skin.
^ NB: the homogeneity of dispersion (assumption for adonis) was tested among locations of sampling. P-value 
of 0.714 indicates that our test results are not an artifact of differences in microbial composition between dif-
ferent locations (beta diversity). As only 4 patients used antibiotics, dispersion could not be reliably tested for 
these groups. 
NOTE: 53 of 57 skin samples were included for analysis due to missing sample location (n=3) and missing SA-
EASI score (n=2), one overlapping. 88 nose samples were included, due to one missing SA-EASI score.
Figure 3. Richness (Chao1) and Shannon diversity in nose and skin
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Figure 4. Top 10 OTUs driving the association between microbial composition and disease severity in nose 
(a) and skin (b)
NOTE: The x-axis displays coefficients that represent the contribution of a certain OTU to the association be-
tween microbiome composition and severity of the AD.
Figure 5. NMDS plot of skin and nasal samples (n=48). Data are standardized using Hellinger transformation.
NOTE: The microbial composition of a small group of nasal samples resembled the skin samples. A closer view 
at these four samples showed that these were the samples with highest relative abundance of staphylococci 
in the nose.
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skin, but the predominance of the bacterium on the skin was larger (figure S2a-b). Other 
OTUs that were often found in both niches included Moraxella (n=45), Streptococcus 
(n=41), Pelomonas (n=39) and Dolosigranulum (n=35). To identify correlations between 
nose and skin microbiome composition, RCCA analysis was performed. Canonical corre-
lations of the first and second dimension were 0.99 and 0.98, indicating that a significant 
correlation exists between the nasal and the skin databases (figure 6). Most OTUs are 
placed around the center of the biplot, indicating that these OTUs have a very small 
Figure 6. Results from RCCA analysis showing the correlations between the microbiome composition of the 
nose and skin at OTU level.
NOTE: Canonical correlation dimension 1 and 2: 0.99 and 0.98. Lambda’s were 0.00005 and 0.00003. Red OTUs 
represent the skin and blue represent the nose. Pairs of variables with relatively large weights in the same di-
rection represent positive correlations and variables whose weights have opposite directions exhibit inverse 
correlations.
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contribution to the correlations between the nose and skin samples (in the first two 
components). Many skin and nasal OTUs are placed in the same quadrant of the biplot, 
meaning that they show similar patterns of abundance over the samples. Exceptions are 
OTU1 and OTU32 in the left upper quadrant, both representing Staphylococcus on the 
skin, that seem to be negatively correlated with most nasal and other skin OTUs.
DIscussIon
In this study we found distinct microbial communities in the nose and on skin of children 
with AD. Additionally, we found significant associations between the microbial composi-
tion of both the nose and the skin and AD severity in children. Interestingly, this analysis 
was adjusted for important confounders including age, use of antibiotics and location 
of sampling.
Our finding that the nose and skin harbor distinct microbial communities is in accor-
dance with earlier studies in healthy subjects.29 The nares of the children in our cohort 
were predominated by the phyla Actinobacteria (Corynebacterium spp.), Proteobacteria 
(mainly Moraxella but also other species such as Haemophilus) and Firmicutes (Staphy-
lococcus, Streptococcus and Dolosigranulum spp.) This is consistent with literature in 
healthy subjects that describes that the microbiome of the anterior nares is typically 
enriched for members of these three phyla.30,31
Skin lesions were clearly dominated by staphylococci, consistent with literature about 
skin microbiome in AD.3,32 While the nasal samples also showed staphylococci, only a 
few patients showed staphylococcal dominance in the nose. Other OTUs that followed 
Staphylococcus in abundance on the skin of our patients were Pelomonas, Streptococ-
cus (described especially in young children with AD before) and Janthinobacterium 
(described as an important member in healthy skin microbiome by Grice et al.).32-34 
Although the nose and skin harbor distinct microbial communities based on Bray–Curtis 
dissimilarity, we found that correlations exist between species in the nose and (other) 
species on the skin. The mechanisms that underlie these findings are not clear yet. 
Possible mechanisms, such as cross-transmission of bacteria between the niches, need 
further exploration.
Additional qPCR of the skin samples, showed S. aureus and S. epidermidis in 50% and 
80% of our population, respectively. The prevalence rate of 50% for S. aureus on lesional 
skin is lower compared to a meta-analysis reporting 70%. This might be due to the young 
age of our cohort (median age of 2.5 years compared to 14 years in the meta-analysis). 
Kennedy et al. also found low S. aureus in 2 month old patients with AD.2 Another study 
included infants with AD in the first year of life and found positive lesional skin swabs 
in 21% of the infants, with culture-based analyses.11 In our cohort, the mean age of the 
46 Chapter 2
children that were positive for S. aureus did not significantly differ from the group that 
was negative (Students T-test, p=0.705).
We found that both the nasal and the skin microbial composition were associated 
with AD severity. Cross-sectional studies described associations between an altered 
microbiome and AD severity before for the skin.3 For the nose, a single prospective study 
supports our hypothesis that the nasal microbiome plays a role in (severity of )  inflam-
mation in AD. The authors found a relation between nasal colonization with S. aureus 
at 6 months and the development of AD.10 The timeframe of (nasal) colonization might 
be important as colonization earlier in life (1 month) was not found correlated with AD 
development.11 The strength of the associations between AD severity and microbial 
composition of the nose and skin was 2.6% and 7.0%, which can be regarded of signifi-
cant relevance as a large part of the variance in the microbiome can be be explained by 
host variation.35 Although an association does not mean causality, our results suggest 
that both microbial niches (in terms of OTU composition), might play a role in aggravat-
ing or worsening the inflammation in pediatric AD. Longitudinal studies that include 
sampling around AD flares would be needed to confirm if changes in the microbiome 
precede an increase in AD severity.
Determination of the species that drove the associations between OTU composition and 
AD severity, showed that in both niches increased staphylococci were of influence. We 
further classified staphylococci to the species level and found that children with severe 
AD had S. aureus present on the skin more often than patients with mild AD (58% vs 
39%) as described earlier.2 However, this difference was not statistically significant. 
The presence of S. epidermidis on the skin did not significantly differ between mild and 
severe AD, but the load of S. epidermidis was significantly higher in severe AD compared 
to mild AD. This relates to an earlier study that observed increased bacterial counts 
of S. epidermidis preceding disease flares.5 Besides staphylococci, we identified other 
species that drove the association between microbial composition and AD severity. For 
example, Moraxella was found to positively contribute to the association in the nose. 
An increased abundance of Moraxella in the nares of children was not associated with 
severity of AD before. However, Depner et al. found Moraxella associated with asthma.36 
In our cohort, 28% of the children had symptoms of asthma or bronchial hyper reactiv-
ity (<6 years) reported in their medical file. The association between Moraxella and AD 
severity that we found was not influenced by these diagnosis (p=0.645, data not shown). 
Thereby, certain species were identified of which a decreased abundance contributed to 
the association with AD severity in our study. For example Dolosigranulum in the nose 
and Streptococcus on the skin (figure 4a-b). High abundance of Dolosigranulum was 
suggested to be beneficial for respiratory health before.37 Streptococcus was observed 
in lower relative abundance in skin lesions (compared to non-lesional skin) and during 
flares in children before.3,32 Future studies should further evaluate the influence of these 
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species on a lower taxonomic level, as for example different streptococci can vary widely 
in pathogenic potential.38 The identification of specific species that contribute to AD and 
its severity (or protect) is of importance for the development of new treatment strate-
gies for AD.39,40 Our results can guide future studies in determining their focus for further 
species specific research.
This study has several limitations. The cross-sectional design of this study precludes 
statements on cause–effect relationships between microbiota and disease severity. We 
amplified the V4 variable region using the 806R primer, an often used method at the 
time of analysis. However, this method does not allow classification of staphylococci 
at the species level, and recent literature describes that it can be improved by the use 
of the V1-V3 region or the use of a modified V4 primer.41, 44 To investigate associations 
between staphylococci and disease severity to the species level, we performed addi-
tional qPCR on S. aureus and S. epidermidis.41 Because we were not able to further classify 
staphylococci into other species, we might have missed correlations between specific 
staphylococcal species and AD severity.9 This also holds for strain specific associations 
with disease severity, as suggested by Byrd et al.42 In our study Propionibacterium was 
poorly detected in both the skin and nasal samples, while they are described as part of 
the healthy microbial communities.43  With regard to the skin samples, the low Propioni-
bacteria can still be a true reflection of the eczema lesions as staphylococci are known to 
overgrow other species. Thereby, we sampled mainly the antecubital and popliteal folds 
which are known for a low abundance of Propionibacteria that prefer more sebaceous 
environments, such as upper chest.45 In our study we did not characterize the fungal 
microbiome, which was found altered in patients with AD before.5 Despite the limita-
tions, this study shows the relevance of the nasal microbiome in AD and is as far as we 
know the first to characterize relations between the nose and skin microbiome in AD.
conclusIon
This study shows that the severity of AD in children is influenced by the nasal microbial 
composition. Besides Staphylococcus, also other species seem to contribute to the as-
sociation between skin and nasal microbiome and AD severity. It is important that future 
studies further explore the role of microbial species in AD, their interaction with the 
host and other species, and the interaction between different microbial communities of 
the body, using controlled longitudinal cohorts and adequate sequencing and culture 
based techniques.
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suPPleMenTARy MATeRIAl
Figure s1. Flowchart of the sample collection
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Figure s2a. Distribution of 20 most abundant OTUs in the nose samples (n=89)
Figure s2b. Distribution of 20 most abundant OTUs in the skin samples (n=57)
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Figure s3a. S. aureus load in mild to severe AD
 
 
 
 
NOTE: no significant differences (p=0.291; ANOVA)
Figure s3b. S. epidermidis load in mild to severe AD
 
 
 
 
 
 
 
NOTE: significant differences (p=0.029; ANOVA), mild versus severe AD (p=0.016; Students t-test) 
supplementary methods
Cut-off values were calculated for the SA-EASI based on the objective SCORing Atopic 
Dermatitis (SCORAD), a clinical tool used to assess the severity of eczema.17 The formula 
to calculate the cut-off points for the SA-EASI included the cut-off points of SCORAD 
divided by maximum score of SCORAD multiplied by maximum score of the SA-EASI 
(SA-EASI = cut-off point SCORAD / 83 * 96). Patients with a SA-EASI from 0 to17.35 were 
classified as mild eczema, from 17.35 to 46.27 as moderate eczema and with a SA-EASI 
higher than 46.27 as severe eczema.


Chapter 3
Fecal microbiome and food allergy 
in pediatric atopic dermatitis: a cross-
sectional pilot study
K.B. Fieten
J.e.e. Totté
E. Levin
M. Reyman
Y. Meijer
A.C. Knulst
F.H.J. Schuren
S.G.M.A. Pasmans
Int Arch Allergy Immunol. 2018 Jan 25;175(1-2):77-8465
58 Chapter 3
AbsTRAcT
background
Microbial exposure might be important in the development of atopic disease. Atopic 
diseases have been associated with specific characteristics of the intestinal microbiome. 
The link between intestinal microbiota and food allergy has rarely been studied and 
the gold standard for diagnosing food allergy (double blind placebo controlled food 
challenge (DBPCFC)) has seldom been used. We aimed to distinguish fecal microbial 
signatures for food allergy in children with AD.
Methods
Pediatric patients with AD, with and without food allergy were included in this cross-
sectional observational pilot study. AD was diagnosed according to the UK Working 
Party criteria. Food allergy was defined as a positive DBPCFC or convincing clinical his-
tory in combination with sensitization to the relevant food allergen. Fecal samples were 
analyzed using 16S rRNA microbial analysis. Microbial signature species discriminating 
between presence and absence of food allergy were selected with elastic net regression.
Results
82 children with AD (39 girls, median age 2.5 years old) of which 20 were diagnosed 
with food allergy provided fecal samples. Food allergy to peanut and cow’s milk was the 
most common. Within children with AD, six bacterial species from the fecal microbiome 
were identified that when combined discriminate between children with and without 
food allergy: Bifidobacterium breve, Bifidobacterium pseudocatenulatum, Bifidobacterium 
adolescentis, Escherichia coli, Faecalibacterium prausnitzii and Akkermansia muciniphila 
(AUC 0.83, sensitivity 0.77, specificity 0.80).
conclusions
In this pilot study, we identified a microbial signature in children with AD that dis-
criminates between absence and presence of food allergy. Future studies are needed to 
confirm our findings.
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InTRoDucTIon
The worldwide prevalence of atopic disease has been increasing in recent decades.1 
There is no clear reason for this observed increase in prevalence, but reduced early-
life exposure to different microbes is thought to be a contributing factor.2-4 Microbial 
colonization of the human intestine during infancy is important for the maturation of 
the immune system.5, 6 Intestinal microbiota can regulate metabolic and inflammatory 
responses and also modulate changes in the intestinal barrier. Several studies have 
shown associations between intestinal microbiota and subsequent development of 
atopic disease, including atopic dermatitis, asthma or rhinitis. However, few studies have 
investigated the link between specific patterns of intestinal microbiota and food allergy. 
Furthermore, the gold standard for diagnosing food allergy (double blind placebo con-
trolled food challenge (DBPCFC)) has rarely been used.7
The microbiome can be considered a complex ecosystem where various species 
interact and group-based correlations have been identified.5 Therefore the symbiosis of 
the different bacterial species and their patterns should be taken into account in data 
analysis. To be able to identify individual species and take the existing structures within 
the microbiome into account, advanced statistical modelling techniques are needed. 
Furthermore, assessment of microbial diversity with molecular sequencing techniques, 
as opposed to culture-based techniques, reveals greater diversity and has shown the 
importance of uncultured species.8
We hypothesize that children have distinct microbial patterns in their fecal microbi-
ome that are associated with a clinical diagnosis of food allergy. In this cross-sectional 
pilot study, we aimed to identify microbial species in children with AD, using 16S rRNA 
microbial analysis followed by statistical elastic net regression approaches.
MeTHoDs
study design and study participants
Children with AD who were treated in the outpatient clinic of the Wilhelmina Children’s 
Hospital of the University Medical Center Utrecht participated in this cross-sectional pilot 
study. Inclusion criteria were: diagnosis of AD, age between 0 and 18 years, parental abil-
ity to answer Dutch questionnaires and the availability of a fecal sample for microbiome 
analysis. All study participants participated in a randomized controlled trial that com-
pares shared medical appointments with individual consultations (ISRCTN08506572). 
The medical ethical committee of the University Medical Center Utrecht approved the 
study and written informed consent was obtained from all participants. Clinical history 
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and serum samples were taken on the same day, fecal samples were provided within the 
next days and a DBPCFC was planned within months.
Assessment of AD and food allergy
AD was diagnosed according to the criteria of Williams et al.9 AD severity was estimated 
using the self-administered eczema area and severity index (SA-EASI) by the research 
nurse.10 Sensitization was determined by measurement of specific IgE against common 
food allergens (hen’s egg, cow’s milk, peanut, hazelnut, fish, wheat, soy). Both total and 
specific IgE were measured according to manufacturer’s protocol (Phadia, Uppsala, 
Sweden). Diagnosis of asthma and allergic rhinitis was based on clinical history.
Food allergy was defined as a positive double blind placebo-controlled food challenge 
(DBPCFC) or convincing clinical history in combination with sensitization to that specific 
food or in case of peanut allergy, a sensitization to Ara h 2 above the defined cut off level 
in our clinic (5.17 kU/L).11 A convincing clinical history was defined as a reported Type I 
allergic reaction with acute symptoms within 2 hours after ingestion of the food. DBPCFC 
was considered positive and terminated when persistent objective symptoms occurred 
(e.g. vomiting, generalized urticaria, wheezing or a significant drop in blood pressure) 
or after subjective symptoms (oral allergy symptoms, nausea, abdominal discomfort) on 
three subsequent doses or a severe subjective symptom (abdominal pain/nausea with 
discomfort) lasting for more than 45 minutes, according to the international protocol.12 
Late reactions were assessed using follow-up by telephone the next day.
Fecal samples
Children collected fecal samples at home and sent the samples to the laboratory using 
the regular postal service. The samples were aliquoted and frozen at -20⁰C until further 
processing.
Fecal DnA isolation
Approximately 150 mg of fecal material was directly transferred to the DNA isolation 
plate. Then 0.5 mL phenol pH8.0 (Phenol solution, catalogue P4557, Sigma-Aldrich, St 
Louis, MO) was added and the samples were mechanically disrupted by bead beating 
2 times 3 minutes with a 96-well plate Beadbeater (Biospec Products, Bartlesville). 
Samples were centrifuged at 1880 rcf (4000rpm) for 10 minutes to separate the aqueous 
and phenolic phases. The aqueous phase was transferred to a 96-well plate and DNA was 
purified with the AGOWA mag Mini DNA Isolation Kit (AGOWA, LGC genomics, Berlin, 
Germany) in accordance with the manufacturer’s recommendations. After elution, the 
total bacterial load in each sample was assessed by quantitative PCR using a universal 
bacterial primer-probe set.13
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16s rRnA Illumina sequencing
Analysis of the fecal microbiome composition was performed by mass sequencing of 
the V4 hypervariable region of the 16S rRNA gene on the Illumina MiSeq sequencer (Illu-
mina, San Diego, CA). Barcoded DNA fragments spanning the Archaeal and Bacterial V4 
hypervariable region were amplified with a standardizing level of template DNA (100pg) 
to prevent over-amplification. These amplicons, generated using adapted primers 533F 
and 806R, were bi-directionally sequenced using the MiSeq system.14 Pre-processing 
and classification of sequences was performed using modules implemented in the 
Mothur V.1.20.0 software platform.15 The relative abundance of unique sequences was 
calculated for every fecal sample. The dataset was transformed using zero mean unit 
variance transformation for subsequent statistical analyses. The V4 amplicon of the 16S 
rRNA encoding gene allows for discrimination of several Bifidobacterial species, but not 
all.16 Therefore, relevant sequences were blasted in the Ribosomal Database Platform 
(RDP) to determine a more accurate species level. Shannon diversity indices were calcu-
lated to describe the microbial diversity.
statistical analysis
Descriptive statistics were used to describe patient characteristics. Non-parametric tests 
were used to compare the groups without and with a confirmed food allergy.
Elastic net regression
Bacterial signature species discriminating between absence and presence of food 
allergy were selected using elastic net regression. This is a statistical machine learn-
ing approach, applicable to large scale, structured and higher dimensional data. The 
method is regularization-based and combines the advantages of LASSO regression 
(sparsity, retaining the feature selection property of reducing coefficients to exact zero 
values provided by LASSO) and ridge regression (smoothness, tendency of shrinking 
coefficients to small values for correlated trending towards each other).17, 18 All present 
species and the correlations between them are taken into account, which allows for the 
identification of patterns of species rather than individual species.19 Using elastic net 
regression, it is not possible to correct for other confounding factors which is common 
in other types of regression analyses used in medical statistics.19
Randomization test and ROC/AUC
A randomization test was conducted to test the statistical validity of the results obtained 
with elastic net regression. Receiver-Operating-Characteristics/Area-Under-Curve (ROC/
AUC) scores were generated multiple times after randomly reshuffling the food allergy 
diagnoses, while keeping the corresponding microbial profiles intact.20 The dataset was 
cross-validated by randomly hiding 30% of the children from the model and evaluating 
62 Chapter 3
the prediction quality on that group. The predictive accuracy of the classification model 
was measured with the ROC/AUC score, using a critical value of 0.05.
SPSS (version 22; IBM, Armonk, NY) was used for descriptive data analysis. GraphPad 
Prism (version 6.01; GraphPad Software, La Jolla, CA) was used for providing graphs and 
figures. All other statistical analyses were performed using numerical Python (version 
2.7, Python Software Foundation, https://www.python.org).
ResulTs
Atopic dermatitis and food allergy
We included 82 children in this cross-sectional pilot study. There were no significant dif-
ferences regarding sex or age between the children who were included and those who 
were not (data not shown). All 82 children were diagnosed with AD, 62 children had no 
food allergy (AD+FA-) and 20 children had a confirmed food allergy (AD+FA+) (table 1).
Of the 62 children without food allergy, almost half were sensitized to common food 
allergens without having symptoms of food allergy after ingestions. Among the 20 
children with a food allergy, peanut allergy and cow’s milk allergy were the most com-
mon (table 2). Multiple food allergies were found in two children. On average, a DBPCFC 
was performed within 10 months of providing the fecal samples (minimum 1 month, 
maximum 27 months).
Table 1. Patient characteristics 
no food allergy
(AD+FA-) (n=62)
confirmed food allergy
(n=20) (AD+FA-)
p-value
Age in years [median (IQR)] 3.0 (5) 2.2 (5.5) 0.606
Female [n (%)] 32 (52%) 7 (35%) 0.196
sAeAsI [median (IQR)] 29 (32) 46 (42) 0.283
TARc (pg/ml) [median (IQR)] 1243 (2247) 2251 (5613) 0.013
Total Ige (ku/l) [median (IQR)] 66 (281) 564 (2912) <0.001
sensitization to any food allergen [n (%)] 27 (43%) 20 (100%) <0.001
elimination diet for any food [n (%)] 19 (31%) 20 (100%) <0.001
Diagnosed with asthma [n (%)] 18 (29%) 5 (25%) 0.727
Diagnosed with rhinoconjunctivitis [n (%)] 15 (24%) 5 (25%) 0.942
Data is shown with median and interquartile range or number and percentage. AD = atopic dermatitis, FA = 
food allergy, SAEASI = self-administered eczema area and severity index scored by research nurse, TARC = thy-
mus and activation regulated chemokine.
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sequence and microbiota characteristics
A total of 2.609.478 high quality sequences were obtained (mean=27.182, range=5.825 
to 105.404 of sequences per sample) that could be assigned to 12 different phyla and 
1.000 unique sequences. The most predominant phyla based on mean relative abun-
dance were Firmicutes (47%), Actinobacteria (32%), Bacteroidetes (9%), Proteobacteria 
(8%) and Verrucomicrobia (2%), which is characteristic for the gut microbiome of 
children.21 Predominant families were Bifidobacteriaceae (28%), Lachnospiraceae 
(27%), Ruminococcaceae (10%), Enterobacteriaceae (5%), Streptococcaceae (4%) and 
Coriobacteriaceae (3.5%). Median Shannon diversity indices calculated for the group 
of children with and without a food allergy were 3.61 (IQR 1.16) and 3.93 (IQR 1.09), 
respectively (p=0.430).
Identification of microbial biomarkers related to food allergy
We identified six microbial species from four families that together discriminate between 
the absence and presence of food allergy in children with AD: Bifidobacterium breve, 
Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis (Bifidobacteriaceae), 
Escherichia coli (Enterobacteriaceae), Faecalibacterium prausnitzii (Ruminococcaceae) 
and Akkermansia muciniphila (Verrucomicrobiaceae). On the species level, Bifidobac-
terium breve/longum and Bifidobacterium pseudocatenulatum/ catenulatum/ gallicum/ 
kashiwanohense could not be distinguished after additional blasting in the RDP data-
base, and are referred to as Bifidobacterium breve and Bifidobacterium pseudocatenula-
tum throughout the manuscript.
Table 2. Children with confirmed food allergies
Food allergy confirmed 
n(%)
with DbPcFc* 
n(%)
obvious clinical 
history only 
n(%)
Predicted based 
on elevated sIge to 
arah2 > 5.17 ku/l 
n(%) 11
Peanut 8 (40%) 3 (15%) 1 (5%) 4 (20%)
Hazelnut 1 (5%) 1 (5%)
cow’s milk 8 (40%) 6 (30%) 2 (10%)
Hen’s egg 4 (20%) 3 (15%) 1 (5%)
other nuts 2 (10%) 1 (5%) cashew nut
1 (5%) pistachio
soy 0
Fish / shrimp 0
Total 20 (100%)
Multiple food allergies result in multiple entries. One patient has a confirmed food allergy for cow’s milk, peanut 
and hen’s egg, another patient has a confirmed allergy for hazelnut and hen’s egg.
*including no late reactions
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Figure 1 shows the relative abundance of the six identified signature species. The fecal 
microbiome of children with AD and food allergy harbored relatively more E.coli and 
B.pseudocatenulatum, and less B.breve, B.adolescentis, F.prausnitzii, and A.muciniphila, 
compared to children with AD without food allergy. The randomization test indicates 
that the combination of these six species is significantly different between the two 
groups (p = 0.001), even though the relative abundance of some single species may 
seem similar on a group level (figure 1). Different relative contributions from the single 
species towards the total distinctive properties are distinguished, with a larger influ-
ence of B.breve, B.adolescentis and F.prausnitzii compared to B.pseudocatenulatum, E.coli 
and A.muciniphila, expressed as importance indices based on the elastic net regression 
(figure 2). The overall predictive accuracy of the classification model (area under the 
curve) is 0.83 (figure 3), with a sensitivity of 0.77 and a specificity of 0.80. Supplementary 
figures S1 to S3 show the relative abundance of the signature species, the distribution of 
the 30 most abundant species and the individual distribution of the signature species.
DIscussIon
We analyzed the fecal microbiome of children with AD with or without a concomitant 
food allergy and found that a combination of six microbial species, including E.coli, 
F.prausnitzii, A.muciniphila and three types of Bifidobacteria, discriminates between 
the presence and absence of food allergy in children with AD (p = 0.001). The fecal 
Figure 1. Relative abundance of the microbial signa-
ture species in children with AD, without and with a 
confirmed food allergy
Figure 2. Importance index for signature species in 
the elastic net regression model
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microbiome of children with AD and food allergy harbored relatively more E.coli and 
B.pseudocatenulatum and less B.breve, B.adolescentis, F.prausnitzii and A.muciniphila, 
compared to children with AD without food allergy. We found no differences in microbial 
diversity (according to Shannon index) between the children with AD, with and without 
food allergy.
This is the first pilot study that identifies microbial signatures specific for food allergy in 
a group of children with AD using 16S rRNA sequencing techniques generating unique 
sequences, followed by statistical machine learning approaches. Previous studies mainly 
used culture-based techniques to analyze the intestinal microbiome or used 16S rRNA 
sequencing techniques, but subsequently simplified the data in the analysis stage by 
focusing on key groups of species or analyzing the data on family or genus level. How-
ever, this approach leads to less detailed information. For example, the identification of 
B.pseudocatenulatum, B.breve and B.adolescentis would not have been possible when 
analyzing the data on a family level. Furthermore, the elastic net regression model takes 
group-based species interactions into account. Since interactions between species in 
the gut microbiome occur, this approach may lead to biologically more reliable results 
compared to other statistical regression approaches.22
Our study demonstrates that children with AD and a food allergy had significantly 
less Faecalibacterium prausnitzii and less Akkermansia muciniphila compared to children 
with AD without a food allergy. F. prausnitzii and A. muciniphila have been gaining inter-
est more recently because of their immune-modulatory properties and possible role in 
mucosal tolerance. F. prausnitzii is the most abundant species in the human intestinal 
microbiome. Its decreased abundance has been associated with several diseases, in-
cluding allergic disease and AD. 23-25 F.prausnitzii is the main producer of butyrate in the 
colon, an energy source for colonocytes with important anti-inflammatory effects. It also 
secretes anti-inflammatory molecules that directly modulate the host immune system, 
stimulates IL10 producing regulatory T cells and is involved in the balance between 
 
Figure 3. Receiver operating characteristic 
(ROC) curve of the elastic net regression model
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effector and regulatory T cells. 26, 27 A. muciniphila is also involved in immunological 
homeostasis of the gut mucosa and gut barrier function, via an outer membrane protein 
that stimulates IL10 production.28
Bifidobacteria and E.coli have been associated with food allergy and AD in other stud-
ies.29 Less Bifidobacteria in the feces of children with a confirmed cow’s milk allergy has 
been reported.30 Cow’s milk allergy was a common food allergy in our study population, 
so it is possible that our results regarding Bifidobacterium breve and Bifidobacterium 
adolescentis are mainly contributed by the cow’s milk allergic children. Furthermore, 
we found increased relative abundance of Escherichia coli in the food allergic group. E. 
coli has previously been associated with diagnosis of AD, with increasing numbers of E. 
coli further increasing this risk.31 The children in our study were all diagnosed with AD 
with varying severity. However, the higher TARC levels in the food allergic group suggest 
increased AD severity compared to the non-allergic group. This raises the possibility that 
the selected biomarkers also correlate with AD severity, which fits with the observation 
that prevalence of food allergy is higher in children with more severe disease.32
All microbial species resulting from our analysis have previously been correlated with 
atopic disease in other studies. This might raise the question whether we are looking 
at a food allergy specific microbial profile or a profile that is related to atopic diseases 
in general, as most of these children have or will develop other comorbidities within 
the atopic syndrome. Atopic disease has been defined differently in previous studies. 
In our study, all children were clinically diagnosed with AD and in addition asthma and 
allergic rhinitis was confirmed or ruled out based on clinical history. Food allergy was 
diagnosed based on DCPCFC in the majority of patients. Post-hoc analyses showed no 
significant differences in the presence of other atopic diagnoses between the groups 
with and without food allergy, suggesting that the identified species are indicating food 
allergy rather than general atopy.
Our study supports the hypothesis that within children with AD the intestinal microbi-
ome differs between children with and without food allergy. Intestinal microbiota regu-
late the development of a diverse range of T-cell functions, such as Th17, Th1, Th2 and 
regulatory T cells and modulate innate lymphoid cells.33, 34 By modifying the response of 
the gut-associated lymphoid tissues, intestinal microbiota may influence the develop-
ment of oral tolerance.35 A recent study in humans showed that delayed colonization 
with Bacteroidetes is associated with a poorly developed Th1 response, which is im-
portant in immune tolerance.36 It is also possible that disruption of the gut microbiome 
alters the gut epithelial integrity, thereby increasing the risk of allergic sensitization 
through direct uptake of allergens.7 However, the exact mechanisms through which the 
intestinal microbiome influences food allergy are not elucidated yet. Furthermore, it is 
not clear whether a change in microbiome precedes or follows the development of food 
allergy.
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Long-term dietary intake affects gut microbiome composition, together with host 
genetics, age, medication, and general lifestyle.37 Our study population consumed a 
Western diet. In addition, established food allergies lead to an elimination diet, where 
the specific food allergen is excluded from the general diet. We cannot exclude that 
an elimination diet where one food is excluded from the diet also leads to detectable 
changes in fecal microbial composition, as has been demonstrated with increased con-
sumption of specific foods. 38 However, in our study one third of children in the non-food 
allergic group also reported an elimination diet for a specific food because of various 
reasons. Furthermore, dietary intake varies according to personal preference. Therefore 
it is unlikely that the observed microbial differences are solely attributed to differences 
in the consumed diet. Besides a self-reported elimination diet, dietary intake was not 
further assessed in this study because it is very difficult to assess this accurately.
A limitation of our cross-sectional study is the heterogeneity of the study population. 
All the children in our study were diagnosed with AD, with varying severity, age and 
different food allergies, and no healthy controls were included. As expected in children, 
cow’s milk allergy and peanut allergy were the most common food allergies in our study 
population, so it is possible that our results are influenced by the contribution of these 
food allergies. It is also plausible that distinct microbes are associated with different 
food allergies.29 Due to a lack of statistical power, we were unable to select signature 
species for specific food allergies. Variables that are known to influence the gut micro-
biome, such as use of antibiotics, delivery via caesarian-section, or breast feeding, were 
not assessed in this study.7 Furthermore, because of the time between the acquisition 
of the fecal sample and the DBPCFC, transient food allergies could have resulted in the 
misclassification of some children with cow’s milk and hen’s egg allergy.
Our findings are based on a study population of children with AD from an academic 
center. Identifying the microbes that are related to food allergy may help in the de-
velopment of future interventions. However, future studies are needed to confirm our 
findings in the community population, preferably with prospective study designs using 
well-defined patient populations to further explore the potential of fecal microbial 
colonization patterns associated with specific food allergies in children with AD. Fur-
thermore, future studies should be of sufficient size to allow for stratification of different 
food allergies and include additional control groups: children with food allergy without 
AD, children with severe ‘extrinsic’ AD without food allergy. 
68 Chapter 3
conclusIon
In this pilot study, we identified a microbial signature in children with AD that dis-
criminates between absence and presence of food allergy. Future studies are needed to 
confirm our findings.
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suPPleMenTARy MATeRIAl
Figure s1. Relative abundance of the six signature species in children with AD, without and with food allergy
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Figure s2. Distribution of 30 most abundant microbial species in children with AD, without and with food 
allergy
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Figure s3. Distribution of six signature species in individual children with AD, without and with food allergy
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AbsTRAcT
background
Staphylococcus (S.) aureus is increasingly implicated as a possible causal factor in the 
pathogenesis of atopic dermatitis (AD). However, the reported prevalence rates of skin 
and nasal colonization in the literature vary widely.
objective
This study evaluates the prevalence and odds of skin and nasal colonization with S. 
aureus in patients with AD.
Methods
A systematic literature search was conducted. Odds ratios (ORs) for colonization in 
patients vs. controls and the prevalence of colonization in patients were pooled using 
the random-effects model.
Results
Overall, 95 observational studies were included, of which 30 had a control group. The 
Newcastle-Ottawa Scale was used to assess study quality, with the majority of studies 
being of fair to poor quality. Patients with AD were more likely to be colonized with S. 
aureus than healthy controls [OR 19.74, 95% confidence interval (CI) 10.88-35.81]. Differ-
ences were smaller in nonlesional skin (OR 7.77, 95% CI 3.82-15.82) and in the nose (OR 
4.50, 95% CI 3.00-6.75). The pooled prevalence of S. aureus colonization among patients 
was 70% for lesional skin, 39% for nonlesional skin and 62% for the nose. In lesional skin, 
meta-regression showed that the prevalence of colonization increased with disease 
severity. Study heterogeneity should be taken into consideration when interpreting the 
results.
conclusions
The results demonstrate the importance of colonization with S. aureus in AD. Further 
evaluation of the mechanisms by which S. aureus influences inflammation is required in 
addition to the development of targeted strategies to decrease skin and nasal S. aureus 
load.
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InTRoDucTIon
Increased colonization with S. aureus in the skin of patients with atopic dermatitis (AD) 
was first described in the 1970s. Multiple studies confirmed this finding, reporting 
a prevalence of skin colonization with S. aureus ranging from around 30% to nearly 
100%.1-4 The underlying pathogenic mechanisms of S. aureus in relation to AD have still 
not been fully elucidated. However, recent studies suggest a causal role in the complex 
pathogenesis of AD by showing that S. aureus colonization precedes (flares of ) the dis-
ease.5-9 S. aureus can facilitate skin barrier defects and inflammation in AD using different 
mechanisms.4,10 Examples of this include the stimulation of mast-cell degranulation by 
staphylococcal delta toxin, the induction of keratinocyte apoptosis by alpha toxin, the 
stimulation of T cells by enterotoxins that act as superantigens and the modulation of 
inflammation by staphylococcal surface proteins, protein A and lipoteichoic acid.10-14
As S. aureus contributes to both skin barrier defects and to inflammation, a more pro-
active control of S. aureus in certain patients may help to reduce disease severity. How-
ever, use of antibiotics can result in resistance of S. aureus and perturbation of healthy 
microbiota, which has been shown to have potentially deleterious health effects.15-18 
At present, new targeted anti-microbial therapies (such as lysins) are being developed, 
which are directed against single bacteria (e.g. Staphefekt SA.100 against S. aureus).19-22 
Therefore it is important to identify patients with AD who can potentially benefit from 
antistaphylococcal treatment.
Defining the prevalence of S. aureus skin and mucosal colonization in (subgroups 
of ) patients with AD might provide more insight into the importance of S. aureus as a 
contributor to the disease and its severity.
Current prevalence rates of S. aureus colonization reported in AD vary widely, mainly 
depending on the type of patients included, the sample size and the methods used 
to collect and detect S. aureus or its products. The swab and the scrub method are fre-
quently used to collect microorganisms from the skin.23 Swabs collect bacteria from the 
superficial layer of the skin, whereas a scrub technique allows collection of superficial 
skin cells and associated microbes.24 The detection of S. aureus was predominantly based 
on culture-based methods. In recent years DNA sequencing methods have allowed 
determination of the complete microbial composition at species level and recently 
upcoming metagenomics techniques can be used for identification at strain level.25
In this systematic review we aim to provide an overview and a pooled estimate of the 
prevalence and odds of colonization with S. aureus in patients with AD.
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MATeRIAls AnD MeTHoDs
Type of study
Both experimental and observational (original, human) studies were included, however, 
case reports were excluded. No restrictions were made relating to publication date and 
language.
Type of participants
Patients of all ages with a diagnosis of AD confirmed by a physician were included.
Type of outcome measures
The primary outcome was the proportion of patients with presence of S. aureus on the 
skin (lesional and nonlesional) or in the nose. Secondary outcomes were (i) the presence 
of S. aureus virulence factors on the skin and (ii) the relation between AD severity and 
colonization with S. aureus. In case of intervention studies, only the baseline measure-
ment was included in this review. When studies reported multiple measurements over 
time taken from the same skin site (without treatment regimen), or when multiple loca-
tions were sampled at the same time point, the mean was included in the meta-analysis. 
Studies that reported solely on methicillin-resistant S. aureus were excluded.
search strategy
The search was conducted in Embase (from 1974), Medline (from 1946), OvidSP (from 
1946), Pubmed (from 1947), Web of Science (from 1945) and The Cochrane Central 
Register of Controlled Trials (CENTRAL) up to 16 September 2014 (table S1). A cross-
reference check was performed to identify further relevant studies.
study selection and data extraction
The titles and abstracts were screened for relevance. Articles or abstracts were selected 
based on predefined inclusion and exclusion criteria (appendix S1; see Supporting 
information). Non-English articles were translated by an official translation service 
when considered relevant. The methodological quality of the articles was rated using an 
adapted version of the Newcastle-Ottawa Scale (NOS).26,27 Uncontrolled studies could 
reach a maximum score of 7 points and studies including a control group could reach 
a maximum score of 8 points. Using a scoring algorithm (appendix S2; see Support-
ing information), the controlled studies were classified as being of poor, fair or good 
methodological quality, based on their NOS scores for patient selection, comparability 
and outcome.28 Study selection and quality assessment was conducted independently 
by two researchers (J.E.E.T. and W.T. v.d.F., J.E.E.T. and M.H. or W.T.v.d.F. and M.H.). Dis-
agreements were resolved and consensus was reached. If identical populations were 
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described in different publications within an overlapping time period, the study with 
the most extensive reporting of results was included.
statistical analysis
A meta-analysis was performed using a random-effects model. A weighted prevalence 
of colonization with S. aureus on the skin and in the nose was calculated. In controlled 
studies the prevalence of colonization in patients and controls was compared, expressed 
as an odds ratio (OR) with a 95% confidence interval (CI). Heterogeneity was assessed 
using I2. In cases of substantial heterogeneity between studies (I2 > 50%) the reasons for 
heterogeneity were explored using meta-regression (using the unrestricted maximum 
likelihood method and in cases where there were more than 10 available studies) for the 
variables NOS score, age and AD severity. For the meta-regression on severity, studies 
that used the Eczema Area Severity Index (EASI) score or the SCORing Atopic Dermatitis 
(SCORAD) score were selected. Cut-off values for mild, moderate and severe AD were 
used as previously described.29,30 Subgroup analysis was performed for variables that 
were significant in the meta-regression. Additional subgroup analysis was carried out for 
studies in which patients were not receiving antibiotic treatment. All statistical analyses 
were performed using Comprehensive Meta-Analysis Version 2.2 (Biostat, Englewood, 
NJ, U.S.A.). Publication bias was evaluated using funnel plots, Egger’s regression and 
the trim-and-fill method.31 The present systematic review was conducted and reported 
in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines.32
ResulTs
study characteristics
The search yielded a total of 4909 articles, of which 2990 articles remained after dedupli-
cations. We used article title and abstract to identify 350 studies (figure 1). After reading 
the full article texts, 95 studies met our inclusion criteria. All studies had an observational 
design and 30 studies compared patients with AD with healthy controls. In 77% of the 
studies AD was diagnosed by clinical assessment (dermatologist or another specialized 
physician). The other studies did not clearly report who diagnosed the patients. The 
overall percentage of male patients was 52% and the mean age was 14 years (range 0.8-
68.9) based on 58 studies. A total of 11 studies measured disease severity using the EASI, 
with nine studies reporting a mean EASI [17.7 (range 4.5-51.6)]. Twenty-two of the 40 
studies that used SCORAD reported a mean score [48.2 (range 13.5-73.5)]. The remain-
ing studies did not measure the disease severity, used other measuring methods or did 
not report mean EASI or SCORAD values. Overall, 54% of the studies were conducted 
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in Europe, 27% in Asia and 13% in the U.S. Study characteristics including the methods 
used to collect and identify S. aureus are described in table S2.
Quality of the studies
We rated the quality of the 30 articles that included a control group as good (n=4), fair 
(n=4) and poor (n=22). The quality of the 65 uncontrolled studies varied from 1 to 6 points 
out of 7 points on the NOS. (table S2). The main reason for downgrading the quality of 
controlled studies was incomparability of the patient and control groups. Uncontrolled 
studies were mainly downgraded owing to a limited description of the methods used for 
collection and identification of S. aureus. The low NOS scores were also partly due to the 
inclusion of abstracts in this review, which provided limited information on methods.
Figure 1. Flow chart of the search strategy and study selection.
Records identified through database 
searching
Embase: 2158
Medline (Ovid-SP): 1054 
The Cochrane Central Register of Controlled Trials 
(CENTRAL): 83 
Web of Science (Sciences): 1589 
PubMed recent: 25 
Records after duplicates removed
(n = 2990)
Records screened
(n = 2990)
Full-text articles assessed for eligibility
(n = 350)
Studies included in qualitative synthesis
(n = 95) 
Studies included in quantitative synthesis 
(meta-analysis) 
(n = 91)
The remaining 4 studies included only 
information about the presence of toxins 
(secondary outcome/ no meta-analysis)
Records excluded
(n = 2640)
Full-text articles excluded
- No Staphylococcus aureus per patient: 55
- In vitro research: 1
- Patient group unclear/incorrect: 20                                        
 - Only poster available1: 20
- No original research: 18
- Duplicate patient groups: 27
- Unclear when the sample was taken: 2 
- Lesional/ non-lesional not distinguished: 29
- Different locations analyzed together: 18 
- Case report: 10
- Unclear results (text-table differences): 6
- IgE: 45
- Article not available (could not be retrieved via University 
Library or via first author): 4
1 not enough information available from abstract and/or poster 
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Prevalence of nasal- and skin colonization with S. aureus
Overall, 81 studies (5231 patients) reported on colonization of the lesional skin and 30 
studies (1496 patients) reported on colonization of the nonlesional skin. Pooled analysis 
showed that 70% of the patients with AD carried S. aureus on the lesional skin (95% CI 66-
74; I2= 88.31) and 39% on the nonlesional skin (95% CI 31-47; I2 = 87.39). Pooled results of 
the 43 studies (2476 patients) that address nasal colonization estimated that 62% of the 
patients with AD carry S. aureus in the nose (95% CI 57-68; I2 = 85.20) (table 1 and figure 
S1). The prevalence varied substantially among studies (28% to 99% in lesional skin, 3% 
to 79% in nonlesional skin and 4% to 95% in the nose). This variation probably resulted 
in the considerable heterogeneity among studies and might be partly explained by the 
variation in disease severity and the age of patients included in these studies.
odds of colonization with S. aureus
A total of 26 studies compared colonization of the lesional skin in patients with AD with 
healthy controls. From 10 studies the OR could not be obtained as the reported percent-
age of patients colonized with S. aureus or controls was either 100% or 0%. A pooled OR 
based on the remaining 16 studies (including 823 patients and 688 controls) showed 
that patients were significantly more likely than controls to be colonized with S. aureus 
on the lesional skin (OR 19.74; 95% CI 10.88-35.81; p<0.001; I2 = 66.04). Overall, 12 out 
of 20 studies were eligible for inclusion in the pooled analysis for the nonlesional skin 
(550 patients and 446 controls) (OR 7.77, 95% CI 3.82-15.82; p<0.001; I2 = 63.08). Pooled 
analysis of the 19 of 21 studies that evaluated nasal colonization (1051 patients and 
1263 controls) showed that 57% of the patients was positive for S. aureus in the nose vs. 
23% of the controls (OR 4.50; 95% CI 3.00-6.75; p<0.001; I2 = 70.31) (table 2).
Meta-regression and subgroup analysis
Heterogeneity between the studies was considerable, mainly in the pooled analysis of 
prevalence (>85%). A meta-regression for the variables AD severity, NOS score and age 
was performed to identify possible sources of heterogeneity. The prevalence of lesional 
skin colonization was independent of the NOS score but increased with AD severity 
(1.02; 95% CI 0.21-1.82) and age (0.64; 95% CI 0.15-1.14). A subgroup analysis of the stud-
ies that included patients with mild AD showed colonization of the skin in 43% of the 
patients (95% CI 31-57; I2 =79.15) whereas the pooled prevalence for severe AD was 83% 
(95% CI 74-89; I2 = 65.78). For the nonlesional skin, colonization decreased with a higher 
NOS score (-0.27; 95% CI -0.50-(-0.04)). Subgroup analysis of the studies with a higher 
quality (NOS > 4) showed a pooled prevalence of 31% (95% 23-40; I2 = 64.62), which is 
lower than the overall prevalence of 39%. Colonization of the nose was independent of 
the three variables (table 1).
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The ORs for colonization in patients with AD vs. controls were independent of the 
NOS and age. Severity was not tested as fewer than 10 studies that measured this vari-
able were available (table 2). Additional subgroup analysis, performed with studies that 
excluded patients who used antibiotics and corticosteroids at the time of inclusion, 
showed pooled ORs that were higher than the original pooled estimate of all studies 
(tables 1 and 2).
enterotoxins prevalence
The prevalence of at least one toxin-producing S. aureus strain on the lesional skin in 
patients varied between 31.5% and 80%. Staphylococcal enterotoxin B was the toxin 
found most often, with a prevalence of up to 70%. One study reported a prevalence 
of toxin-producing S. aureus of 11.5% on nonlesional skin. Three studies reported the 
presence of at least one toxin-producing S. aureus in the nose, with prevalence rates 
varying between 32% and 80%. Other studies reported combined results of skin and 
nose samples and were not taken into consideration in this study (table S3).
Publication bias
The funnel plots for the prevalence of skin and nasal S. aureus in patients with AD 
showed asymmetry (figure S2). The Eggers test confirmed the presence of publication 
bias with intercepts of 3.68 (95% CI 2.71-4.65, p<0.001) for lesional skin, 0.76 (95% CI 
-3.06-4.85, p=0.69) for the nonlesional skin and 2.63 (95% CI 0.84-4.42, p=0.005) for the 
nose. Also the pooled analysis of the odds for colonization showed publication bias with 
an Eggers regression intercept of 2.47 (95% CI 1.66-3.28, p<0.001) for lesional skin, 1.71 
(95% CI 0.45-2.97, p=0.010) for nonlesional skin and 2.08 (95% CI 0.64-3.52, p=0.023) for 
the nose. Adjusted prevalence rates and ORs according to the trim-and-fill method were 
all lower than the original estimates (table 1 and 2).
DIscussIon
In this systematic review we demonstrate that patients with AD are significantly more 
likely to be colonized with S. aureus than healthy controls on both the lesional and non-
lesional skin and in the nose. Pooled prevalence of S. aureus carriage among patients is 
70% for lesional skin, 39% for nonlesional skin and 62% for the nose. For lesional skin the 
prevalence appeared to be dependent on disease severity and age, however, this could 
not be confirmed for nonlesional skin or nasal colonization. Substantial to considerable 
heterogeneity, incomparability of patient and control groups, variation in methods used 
for sampling and poor description of exposures (such as treatment) downgraded the 
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quality of the included articles, which should be taken into consideration when inter-
preting the results.33
The typical features of AD skin, such as a comprised barrier integrity, altered sphingo-
lipid metabolism and antimicrobial peptide expression probably facilitate colonization 
with S. aureus.34,35 The meta-regression analysis finds a higher prevalence of colonization 
among patients with more severe AD. However, the causal relationship between coloni-
zation with S. aureus and AD still has to be further clarified. Recent studies often suggest 
colonization with S. aureus as a primary cause rather than only a secondary effect of 
skin damage or an insufficient antistaphylococcal immune status. According to Kong 
et al. flares in AD accompany temporal microbial dysbiosis, dominated by S. aureus.5 
Microbiome analysis of lesions in mice with an eczematous phenotype revealed that 
dysbiosis was a driving factor for dermatitis formation and bacterial inoculation experi-
ments showed that S. aureus could accelerate eczematous inflammation.36 Despite these 
studies that suggest a causal relationship, a systematic review by Bath-Hextall et al. did 
not demonstrate a beneficial clinical effect of untargeted anti-S. aureus therapy com-
bined with steroids over steroids alone.37,38 However, other studies including treatment 
with mupirocin and bleach baths did show a reduction in clinical severity together with 
a reduction of S. aureus skin load.39,40 In our review we did not investigate the relation 
between antistaphylococcal interventions and AD severity. We did conduct a subgroup 
analysis; including patients who were not receiving any antibiotic or corticosteroid treat-
ment. This showed a lower prevalence of S. aureus on the skin and nose, which is not in 
line with the antibacterial effect of both antibiotics and corticosteroids.41,42 One explana-
tion might be that the inclusion of patients who did not require treatment resulted in 
a selection of patients with mild AD who were less likely to be colonized with S. aureus.
Several natural and technical factors that are known to cause variation in microbiome 
outcomes might have influenced our results. There is variation between methods used 
to collect and detect S. aureus and its virulence factors on the human skin.43,44 Also, S. 
aureus might be present not only on the surface of the skin but also in deeper layers.45 
These differences highlight the importance of interpreting the results carefully, taking 
the methods used into consideration. Subgroup analysis for culture- vs. DNA-based 
detection methods were not performed owing to a small number of studies using DNA-
based methods. Although DNA-based methods only include nonviable bacteria, they 
might provide more accurate results for quantifying S. aureus in the microbiome.
Furthermore, the impact of exposures such as treatment regimen and duration of 
the disease at the moment of collection were often poorly reported, which might have 
resulted in performance bias. A subgroup analysis excluding patients using antibiotics 
or steroids was performed to take the influence of treatment on the results into con-
sideration. However, the use of other (aseptic) products might have also influenced the 
microbial composition. The duration of the disease might influence the activity of the 
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host’s immune response, which, in turn, could influence the presence of S. aureus via an 
antimicrobial effect.46 The presence and quantity of microorganisms on the skin is influ-
enced by many factors that naturally give rise to changes in diversity of the microbiota 
over time and skin site (e.g. ethnicity and climate).24,47-50 51,52 It should be noted that our 
review reports on the proportion of S. aureus on the skin and mucosa determined at one 
specific time point.
As a result of underlying factors such as the (genetic) barrier defect and immune path-
ways enhancing a defective skin barrier, dysbiosis dominated by S. aureus is a chronic 
and recurring factor in AD. 8,53-55 It is important to evaluate further the pathways by 
which S. aureus leads to inflammation and how current therapies already influence these 
pathways. Antibiotics and antiseptics are used in infected or severe AD.56,57,58 Functional 
textiles that are used as complementary treatment in AD might also decrease S. aureus 
colonization.59 Glucocorticosteroids might also have an antibacterial effect besides their 
anti-inflammatory effect, probably via an effect on antimicrobial peptides, and even 
emollient monotherapy was shown to reduce bacterial colonization.9,60 The current use 
of antistaphylococcal therapies, together with literature that points to S. aureus as a 
driver in AD pathogenesis, underlines the importance of antistaphylococcal treatment 
in AD. However, long-term (preventive) use of antibiotics and glucocorticosteroids is 
undesirable as they can cause side-effects and antibiotic resistance.16
To date this is the most comprehensive review that systematically summarizes data 
regarding S. aureus colonization in patients with AD. A large number of studies were in-
cluded. These studies were mainly observational and often consisted of small numbers 
of patients. By not restricting the language of the search, selection bias was kept to a 
minimum. However, selection might have occurred owing to the exclusion of studies 
that did not report whether samples were taken from lesional or nonlesional skin. The 
covariate ‘severity’ in the meta-analysis was based on the level of the study, which may 
have led to an aggregation bias. As determining the prevalence of S. aureus colonization 
was not the primary objective in a substantial number of the studies, indirectness of 
evidence with regard to the study population might have occurred. Publication bias 
changed the outcomes considerably according to the trim-and-fill method. The quality 
of a large portion of the individual studies was considered to be low. Future studies into 
the prevalence of S. aureus in patients vs. controls should take these quality criteria into 
consideration to raise the confidence in pooled estimates.
conclusIons
Despite the low quality of the included studies and the presence of publication bias, 
this systematic review and meta-analysis demonstrates that patients with AD are more 
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frequently colonized with S. aureus than healthy controls and that colonization is in-
creased in more severe AD. These results provide an indication of the importance of 
colonization as a factor in the pathogenesis of AD and encourage evaluation of targeted 
antistaphylococcal therapy for the skin (and nose), for example based on the use of anti-
S. aureus lysins. Prospective or experimental studies should further investigate causality 
and the mechanisms by which S. aureus colonization leads to inflammation. Host factors 
such as age and ethnicity, in addition to host-pathogen interaction, should be taken into 
consideration when investigating these mechanisms. The possible relevance of other 
microbes in the pathogenesis of AD should also be explored using metagenomic ap-
proaches. Additional examination of colonization in patients with different phenotypes 
(sensitized and non-sensitized, early onset vs. late onset) might provide insight in the 
type of patients who are likely to benefit most from targeted therapy against S. aureus.
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suPPoRTIng InFoRMATIon
Appendix s1. Criteria for selecting studies
Types of studies
• All original human studies that assess the incidence of (virulence factors of ) S. aureus 
on the skin and/or nares in patients with atopic dermatitis
• All study designs, except for case reports (<10 studies)
Participants
• Patients with atopic dermatitis of all ages, diagnosed by a medical doctor, included 
in hospital setting or general population. All disease severity states were included.
Controls
• Subjects with no known skin disease
Outcome measures
• Primary: S. aureus (both MRSA and MSSA) on skin (either lesional or non-lesional) 
and/or nares, isolated through culture or DNA based methods. Samples taken at 
any time during the disease or treatment were included. Studies that only report on 
MSSA were excluded.
• Secondary: Incidence rate of S. aureus and virulence factors on the skin and/or in the 
nares, measured by PCR.
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Appendix s2. Quality assessment score
Modified Newcastle – Ottawa quality assessment scale for cohort or cross sectional 
studies
Stars indicate the points allocated if the item criterion is met. A maximum score of 8 can 
be allocated to each article. Uncontrolled studies can reach a maximum score of 7.
Selection
1. Representativeness of the exposed cohort
a) Truly representative of the general atopic dermatitis population *
b) Somewhat representative of the general atopic dermatitis population *
c) Selected group of atopic dermatitis patients (hospital based, tertiary center, inpa-
tients, outpatients)
d) No description of the derivation of the cohort
2. Selection of the non-exposed cohort
a) Representative of the average community (healthy control, community control)*
b) Selected group of controls (hospital controls, other dermatological condition)
c) No control group or no description of control group
3. Ascertainment of atopic dermatitis
a) Diagnosed by dermatologist *
b) Diagnosed by physician other than dermatologist*
c) Diagnosed by clinical assessment*
d) Based on self-report
e) No description of atopic dermatitis case definition
4. Assessment of disease severity
a) Disease severity was assessed with validated score (doctor assessed) EASI, SCORAD, 
EASI, TIS, POEM*
b) Disease severity was assessed with a validated score (patient assessed). PO-SCORAD, 
SA-EASI*
c) Disease severity was assessed using another score
d) No disease severity reported
Comparability
1. Comparability of atopic dermatitis and healthy controls on the basis of design or 
analysis
a) Study controls for confounding using a multivariate model*
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b) Atopic dermatitis patients and healthy controls are matched (for age/gender)*
c) No controlling for confounding or matching
Outcome
1. Assessment of outcome: colonization or presence of virulence factors (measure-
ment)
a) Determined by culture, PCR, ELISA or sequencing*
b) Not mentioned
2. Assessment of outcome: method of sample taking
a) Method or sample taking was well described*
b) Not well described or not mentioned
3. Was there treatment during sampling
a) No treatment *
b) Systemic treatment
c) Topical treatment
d) Not mentioned
4. Adequacy of follow up (only in case of cohort studies (prospective))
a) complete follow-up*
b) subjects loss to follow-up unlikely to introduce bias (<10% lost)*
c) follow-up > 10%
d) no statement
Modified Scoring algorithm controlled studies 28
Quality rating Points in selection Domain Points in comparability Domain Points in outcome domain
Good ≥ 3 ≥ 1 ≥ 2
Fair 2 0 ≥ 2
Poor 0-1 0 0-1
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suPPleMenTARy FIguRes
Figure s1a. Forest plot: Odds of lesional skin colonization (all studies)
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Figure s1b. Forest plot: Odds of non-lesional skin colonization (all studies)
Figure s1c. Forest plot: Odds of nasal colonization (all studies)
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Figure s2a. Funnel plot of studies reporting prevalence of lesional skin colonization with S. aureus in patients
Figure s2b. Funnel plot of studies reporting prevalence of non-lesional skin colonization with S. aureus in 
patients with AD
Figure s2c. Funnel plot of studies reporting prevalence of nasal skin colonization with S. aureus in patients 
with AD
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Figure s2d. Funnel plot of studies reporting odds of lesional skin colonization with S. aureus in patients
Figure s2e. Funnel plot of studies odds prevalence of non-lesional skin colonization with S. aureus in patients 
with AD
Figure s2f. Funnel plot of studies reporting odds of nasal skin colonization with S. aureus in patients with AD
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suPPleMenTARy TAbles
Table s1. Digital search strategy (last updated 16th of September 2014)
Database search string
Embase (‘Staphylococcus aureus’/exp OR ‘Staphylococcal skin infection’/de OR ‘Microbiome’/de OR ‘Skin flora’/de 
OR ‘Staphylococcus alpha toxin’/de OR ‘Staphylococcus toxin’/de OR ‘Staphylococcus enterotoxin’/de OR 
‘Staphylococcus enterotoxin A’/de OR ‘Staphylococcus enterotoxin B’/de OR ‘Staphylococcus enterotoxin C’/
de OR ‘Staphylococcus protein A’/de OR ‘Panton Valentine leukocidin’/de OR ‘Superantigen’/de OR (((cutan* 
OR skin* OR derma* OR nasal OR nose OR nare* OR mucos*) NEAR/3 (flora* OR microflora* OR microbio* 
OR bacteri* OR staph*)) OR ((staph* OR S OR St) NEAR/3 (aureus* OR pyogenes))):ab,ti OR ((staph*:ab,ti 
OR ‘Staphylococcus infection’/exp OR ‘Staphylococcus’/exp) AND (‘Alpha toxin’/de OR ‘Bacterial toxin’/
de OR ‘Exfoliatin’/de OR ‘Leukocidin’/de OR ‘Leukotoxin’/de OR ‘Bacterial antigen’/de OR ‘Cytotoxin’/de OR 
‘Enterotoxin’/de OR ‘Hemolysin’/de OR ‘Exotoxin’/de OR (superantigen* OR toxin* OR cytotoxin* OR hemoly* 
OR haemoly* OR enterotoxin* OR exotoxin* OR exfoliatin* OR leucotoxin* OR leukotoxin* OR leukocidin* 
OR leucocidin* OR epidermoly* OR dermoly*):ab,ti))) AND (‘Atopic Dermatitis’/de OR ‘Hand eczema’/de OR 
‘Eczema’/de OR ‘Neurodermatitis’/de OR (((atopic* OR infant* OR flexur* OR constitution*) NEAR/3 dermatit*) 
OR neurodermatit* OR eczema*):ab,ti) NOT ([animals]/lim NOT [humans]/lim) NOT nare*:ab,ti
Medline via 
OvidSP
(exp “Staphylococcus aureus”/ OR “Staphylococcal skin infections”/ OR exp “Microbiota”/ OR (staphylococcal 
alpha toxin OR enterotoxin A, staphylococcal OR enterotoxin B, staphylococcal OR enterotoxin C, 
staphylococcal OR enterotoxin D, staphylococcal OR enterotoxin E, staphylococcal OR enterotoxin G, 
staphylococcal OR enterotoxin I, staphylococcal OR staphylococcal enterotoxin J OR staphylococcal 
enterotoxin H OR SEIO enterotoxin, Staphylococcus aureus OR SEIM enterotoxin, Staphylococcus aureus OR 
Hlb protein, Staphylococcus aureus OR Gamma-hemolysin, Staphylococcus aureus OR Panton-Valentine 
leukocidin).mp. OR “Staphylococcal protein A”/ OR “Superantigens”/ OR (((cutan* OR skin* OR derma* OR 
nasal OR nose OR nare* OR mucos*) ADJ3 (flora* OR microflora* OR microbio* OR bacteri* OR staph*)) OR 
((staph* OR S OR St) ADJ3 (aureus* OR pyogenes))).ab,ti. OR ((staph*.ab,ti. OR “Staphylococcal infections”/ 
OR “Staphylococcus”/) AND (“Bacterial toxins”/ OR “Leukocidins”/ OR “Leucocidins”/ OR leukotoxin.mp. OR 
“Antigens, Bacterial”/ OR exp “Cytotoxins”/ OR “Enterotoxins”/ OR “Hemolysin Proteins”/ OR exp “Exotoxins”/ 
OR (superantigen* OR toxin* OR cytotoxin* OR hemoly* OR haemoly* OR enterotoxin* OR exotoxin* OR 
exfoliatin* OR leucotoxin* OR leukotoxin* OR leukocidin* OR leucocidin* OR epidermoly* OR dermoly*).ab,ti.))) 
AND (“Dermatitis, Atopic”/ OR exp”Eczema”/ OR “Neurodermatitis”/ OR (((atopic* OR infant* OR flexur* OR 
constitution*) ADJ3 dermatit*) OR neurodermatit* OR eczema*).ab,ti.) NOT (animals NOT humans).sh.
Web of 
Science
TS=((((cutan* OR skin* OR derma* OR nasal OR nose OR nare* OR mucos*) NEAR/3 (flora* OR microflora* OR 
microbio* OR bacteri* OR staph*)) OR ((staph* OR S OR St) NEAR/3 (aureus* OR pyogenes)) OR (staph* AND 
(superantigen* OR toxin* OR cytotoxin* OR hemoly* OR haemoly* OR enterotoxin* OR exotoxin* OR exfoliatin* 
OR leucotoxin* OR leukotoxin* OR leukocidin* OR leucocidin* OR epidermoly* OR dermoly*))) AND (((atopic* 
OR infant* OR flexur* OR constitution*) NEAR/3 dermatit*) OR neurodermatit* OR eczema*) NOT ((animal* OR 
pig* OR sheep* OR horse*) NOT (human* OR patient*)))
Cochrane 
Central
((((cutan* OR skin* OR derma* OR nasal OR nose OR nare* OR mucos*) NEAR/3 (flora* OR microflora* 
OR microbio* OR bacteri* OR staph*)) OR ((staph* OR S OR St) NEAR/3 (aureus* OR pyogenes))):ab,ti OR 
(staph*:ab,ti AND ((superantigen* OR toxin* OR cytotoxin* OR hemoly* OR haemoly* OR enterotoxin* OR 
exotoxin* OR exfoliatin* OR leucotoxin* OR leukotoxin* OR leukocidin* OR leucocidin* OR epidermoly* OR 
dermoly*):ab,ti))) AND ((((atopic* OR infant* OR flexur* OR constitution*) NEAR/3 dermatit*) OR neurodermatit* 
OR eczema*):ab,ti)
Pubmed (((cutan*[tiab] OR skin*[tiab] OR dermal[tiab] OR dermatol*[tiab] OR nasal[tiab] OR nose[tiab] OR nare*[tiab] 
OR mucos*[tiab]) AND (flora*[tiab] OR microflora*[tiab] OR microbio*[tiab] OR bacterial[tiab] OR bacterio*[tiab] 
OR staph*[tiab])) OR ((staph*[tiab] OR S[tiab] OR St[tiab]) AND (aureus*[tiab] OR pyogenes[tiab])) 
OR (staph*[tiab] AND (superantigen*[tiab] OR toxin*[tiab] OR cytotoxin*[tiab] OR hemoly*[tiab] OR 
haemoly*[tiab] OR enterotoxin*[tiab] OR exotoxin*[tiab] OR exfoliatin*[tiab] OR leucotoxin*[tiab] OR 
leukotoxin*[tiab] OR leukocidin*[tiab] OR leucocidin*[tiab] OR epidermoly*[tiab] OR dermoly*[tiab]))) 
AND (((atopic*[tiab] OR infant*[tiab] OR flexur*[tiab] OR constitution*[tiab]) AND dermatit*[tiab]) OR 
neurodermatit*[tiab] OR eczema*[tiab]) AND publisher[sb]
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Table S2 can be found in the published article online: https://onlinelibrary-wiley-com.
eur.idm.oclc.org/doi/abs/10.1111/bjd.14566
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AbsTRAcT
background
Staphylococcus (S.) aureus plays a role in the pathogenesis of atopic dermatitis (AD), 
possibly via the expression of various virulence antigens. An altered antibody response 
towards these antigens might contribute to inflammation.
objective
To provide an overview of the varying prevalences and odds of antibody responses 
against S. aureus antigens in patients with AD.
Methods
Data were systematically obtained from Embase, MEDLINE, Web of Science, Scopus, 
Cochrane, PubMed and Google Scholar up to 12 February 2016. We selected all original 
observational and experimental studies assessing antistaphylococcal antibodies in se-
rum of patients with AD. Prevalences and odds ratios (ORs) of IgE, IgG, IgM, IgA against 
S. aureus in patients with AD vs. healthy controls were pooled using the random-effects 
model. We calculated I2 statistics to assess heterogeneity and rated study quality using 
the Newcastle-Ottawa Scale.
Results
Twenty-six articles (2369 patients) were included, of which 10 were controlled studies. 
Study quality was fair to poor. Patients with AD had higher prevalences of IgE against 
staphylococcal enterotoxin (SE)A (OR 8.37, 95% confidence interval 2.93-23.92) and SEB 
(OR 9.34, 95% confidence interval 3.54-24.93) compared with controls. Prevalences of 
antistaphylococcal IgE were 33% for SEA, 35% for SEB and 16% for toxic shock syndrome 
toxin-1. However, study heterogeneity and imprecision should be taken into consider-
ation when interpreting the results. Data on IgG, IgM and IgA, as well as other antigens, 
are limited.
conclusions
Patients with AD more often show an IgE antibody response directed against S. aureus 
superantigens than healthy controls, supporting a role for S. aureus in AD pathogenesis.
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InTRoDucTIon
Atopic dermatitis (AD) is a multifactorial disorder that arises from interactions between 
immune dysregulations, genetic predisposition, skin barrier defects and environmental 
factors.1,2 Both the lesional and nonlesional skin and the noses of patients with AD are 
more likely to be colonized with Staphylococcus (S.) aureus compared with healthy 
controls.3 Recent studies have shown that abundance of S. aureus is associated with AD 
severity, suggesting a causal role for S. aureus in the pathogenesis of AD.2,4-9 However, 
the exact mechanisms by which S. aureus aggravates inflammation in AD are not fully 
understood.10 S. aureus expresses a variety of virulence factors that could contribute to 
AD inflammation. Based on their biological function these antigens can be divided in 
four groups: (i) microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs) such as clumping factor A (ClfA), which helps S. aureus adhere to the host 
cells, (ii) cell-membrane damaging molecules such as alpha toxin, which can induce 
keratinocyte cell death, (iii) household enzymes such as lipase, which provides cell nutri-
tion and (iv) immunomodulatory proteins (superantigenic and nonsuperantigenic).10-13 
The latter include the group of staphylococcal superantigens, which have the ability 
to activate mast cells and T cells directly, resulting in the release of proinflammatory 
cytokines.14-16 Expression of these S. aureus antigens varies between the different S. au-
reus isolates. However, it has been proven difficult to identify associations between the 
genetic composition of S. aureus strains and AD.17-22
Evaluation of the antibody response to these S. aureus antigens gives an indication of 
the antigens that are expressed by the bacterium in vivo and will give insight into how 
the immune system of patients with AD counteracts these antigens. This might help 
us to understand the role of S. aureus in AD pathogenesis as well as the mechanisms 
by which S. aureus causes inflammation. Since 1982 several studies have reported se-
rum antibodies against S. aureus in patients with AD.23-35 However, the prevalences of 
antistaphylococcal antibodies in these studies vary widely. This is probably due to low 
sample sizes and different methods used to detect antibodies [e.g. enzyme-linked im-
munosorbent assay (ELISA) or AlaSTAT]. Moreover, studies often focus on few antigens 
and/or antibody classes.
The aim of this systematic review was to provide an overview of the pooled preva-
lence and odds of antibodies (IgE, IgG, IgM and IgA) against S. aureus antigens in serum 
of patients with AD compared with healthy controls. Additionally, we reviewed the 
relationship between AD severity and anti-S. aureus antibodies.
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MATeRIAls AnD MeTHoDs
study participants and outcomes
All original observational and experimental human studies were included. No restric-
tions were made on publication date or language. Case reports were excluded. Patients 
of all ages with AD, irrespectively of disease severity, in which anti-S. aureus antibodies 
were measured. Healthy controls were defined as persons who had neither AD nor an 
atopic constitution (food allergy, asthma, allergic rhinitis) nor another skin disease. The 
primary outcome was the proportion of patients with AD with antibodies (IgE, IgG, IgM, 
IgA) in serum against S. aureus antigens compared with healthy controls. The secondary 
outcome was the relationship between AD severity and antistaphylococcal antibodies.
search strategy
The systematic electronic search was conducted in Embase, MEDLINE, Web of Science, 
Scopus, Cochrane, PubMed and Google Scholar up to 12 February 2016 (table S1). A 
cross-reference check was performed to identify other relevant studies.
study selection and data extraction
Initially, all studies identified in the systematic search were screened for relevance by 
title and abstract. Duplicates and studies that did not meet our inclusion criteria were 
excluded (appendix S1, see Supporting information). The remaining articles were as-
sessed for eligibility by full-text review. Translation of non-English studies was conducted 
officially. Study selection and data extraction were performed independently by two 
researchers (F.J.M.vB. and either J.E.E.T. or J.dW). Disagreements were resolved and con-
sensus was reached. If one population was described in different articles, we included 
the study with the most detailed description of the results. The methodological quality 
of the articles was scored based on an adapted version of the Newcastle-Ottawa Scale 
(NOS).3 Studies could reach a maximum score of nine points for case-control studies and 
five points for uncontrolled studies. Using a scoring algorithm, the controlled studies 
were classified as being of poor, fair or good methodological quality, based on their NOS 
scores (appendix S2, see Supporting information).36 The overall quality of evidence was 
discussed according to the principles of the GRADE approach (i.e. limitations in study 
design or execution, inconsistency of results, indirectness of evidence, imprecision and 
publication bias).37
statistical analysis
A meta-analysis was performed using a random-effects model in case of at least two 
available studies. We extracted the prevalences of antistaphylococcal antibodies in 
patients with AD and controls from the included studies. If required we calculated 
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prevalences with the available raw data. The prevalences of antistaphylococcal antibod-
ies were pooled. Furthermore, in controlled studies these prevalences in patients and 
controls were compared, expressed as ORs with a 95% confidence intervals (CIs). Anti-
body prevalences were descriptively presented for single studies. When the antibody 
prevalence in the control group was 0% an OR could not be calculated and a continuity 
correction factor using the Mantel-Haenszel method was added to both the patient and 
control groups (based on the unbalanced group ratio).38,39 Heterogeneity was assessed 
using the Higgins I2 test.40,41 However, I2-values should be interpreted cautiously in 
small meta-analyses.42 In case of substantial (I2 = 50-90%) or considerable (I2 = 75-100%) 
heterogeneity, sources were explored using subgroup analyses for the variables age, 
method of antibody identification and geographical region of the study centres (≥10 
available studies). Possible publication bias was assessed in case of ≥10 studies using 
funnel plots and Egger’s test (P-value <0.05).43,44 Analyses were performed using Com-
prehensive Meta-Analysis Version 2.2 (Biostat, Englewood, NJ, U.S.A.). This systematic 
review was conducted and reported according to the Meta-Analysis of Observational 
Studies in Epidemiology (MOOSE) guidelines.45
ResulTs
study characteristics and quality
The literature search identified 2789 studies. After removal of duplicates, 1323 studies 
remained. Screening on title and abstract yielded 113 full-text articles. Finally, 26 articles 
with a total of 2369 patients were included for further analysis (figure 1).24,25,27-35,46-60 
Twenty-one articles reported the sex of the patients, with a mean percentage of males of 
53.4% (range 28.1-81.8).25,28-30,33-35,46-49,51-60 The mean age was 24.1 years (range 4.4-68.9), 
reported in 15 articles.25,28-30,33,34,46-49,51,53-55,58 Thirteen articles scored the AD severity us-
ing the SCORing Atopic Dermatitis (SCORAD) with three articles reporting a mean of 
33.6 (range 32.2-36.0), corresponding with moderate AD.30,32-35,46,47,49-52,57,59,61 Nine articles 
used other scoring criteria for AD severity.25,28,29,31,48,54-56,58 Most studies were conducted 
in Europe and Asia. Methods for identification of antistaphylococcal antibodies consist 
mainly of radioimmunoassay (RIA) tests, ELISA and AlaSTAT, an enzyme immunoassay 
method for the measurement of allergen-specific IgE (table S2). One study measuring 
multiple antibodies used both a RIA test for IgE and an ELISA for IgG.31 NOS scores of the 
11 controlled studies were rated as good (n=1), fair (n=5) and poor (n=5).24,25,27-33,36,53,60 
The main reason for downgrading the quality of these studies was incomparability of 
the patient and control groups. The quality scores of the 15 studies without a control 
group varied between 2 and 4 points out of 5 (table S2 and appendix S2).34,35,46-52,54-59
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Prevalence of antibodies against Staphylococcus aureus
IgE
Twenty-four studies including 2206 patients reported the prevalence of antistaphylococ-
cal IgE. 24,25,27-31,33-35,46-59 These studies predominantly determine the antibody response 
against staphylococcal enterotoxin (SE)A, SEB, SEC, SED and toxic shock syndrome 
toxin (TSST)-1 (19, 23, seven, three and 10 studies, respectively) (table S3).24,25,27-31,34,35,46-59 
Pooled prevalences of antistaphylococcal IgE in patients were 33% for SEA (95% CI 23-
45; I2 94.23)24,25,27-30,34,35,46-48,50,51,53,54,56-59, 35% for SEB (95% CI 27-43; I2 91.36)24,25,27-31,34,35,46-59, 
14% for SEC (95% CI 8-22; I2 78.26)24,34,46,47,52,56,58, 5% for SED (95% CI 1-16; I2 70.49)24,34,47 
and 16% for TSST-1 (95% CI 10-25; I2 85.28)24,27,34,35,46-48,52,56,58 (table 1 and figure S1a-e). 
There was a great variation in prevalence between studies (0.8-78.8% for SEA, 1.4-72.9% 
for SEB, 5.4-40.0% for SEC, 0.0-10.7% for SED and 1.4-53.3% for TSST-1), probably result-
ing in the substantial to considerable heterogeneity. One study showed a prevalence 
of 35.8% of fibronectin-binding protein (FBP)-specific IgE, while another study found a 
prevalence of 48.1% of IgE against lipoteichoic acid (LTA).27,33 Undetectable to very low 
prevalences of IgE against the staphylococcal antigens SEE, SEI, SEH, SEK, SEJ, exfoliative 
toxin (ET)-1 and ETA were found in several single studies (table 2).24,31,47
Figure 1. Flow chart of search strategy and study selection
Records identified through database 
searching
Embase: 874 (861)
Medline via OvidSP: 419 (71)
Web of Science: 516 (218)
Scopus: 765 (81)
Cochrane: 13 (1)
PubMed: 2 (2)
Google Scholar: 200 (89)
Records after duplicates removed
n = 1323
Records screened
n = 1323
Full-text articles assessed for eligibility
n = 113
Records excluded
n = 1210
Studies included in qualitative 
synthesis
n = 26
Studies included in quantitative 
synthesis (meta-analysis)
n = 24
Full-text articles excluded
Animal study: 1
Duplicate study or patient group: 15
No specific anti-Staphylococcus aureus antigens in results: 51
No original research: 10
Case report: 2
No anti-Staphylococcus aureus antibody response in atopic dermatitis: 3
Not available (could not be retrieved via University Library or first author): 5
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Table 1. IgE against SEA, SEB, TSST-1, SEC and SED in patients with atopic dermatitis
Staphylococcus aureus antigen 
(subgroup)
studies Patients
Pooled proportion 
of patients 
with detectable 
antigens (95% cI)
Heterogeneity 
(I2)
SEA
All studies 19 1852 0.33 (0.23-0.45) 94.23 
Studies including age <18 6 507 0.31 (0.11-0.63) 96.56 
Studies including age ≥18 7 859 0.27 (0.17-0.42) 88.22 
Studies including RIA methods* 8 1139 0.19 (0.12-0.29) 86.36 
Studies including ELISA method 3 169 0.61 (0.34-0.82) 86.83 
Studies including AlaSTAT method 6 461 0.42 (0.28-0.57) 89.04 
Studies including Immunoblot method 1 27 0.48 (0.30-0.66) - 
Studies performed in Europe 11 1220 0.24 (0.16-0.34) 87.87 
Studies performed in Asia 7 576 0.51 (0.33-0.70) 93.75 
Studies performed in USA 1 56 0.32 (0.21-0.45) - 
SEB
All studies 23 2111 0.35 (0.27-0.43) 91.36 
Studies including age <18 8 631 0.25 (0.13-0.43) 92.73 
Studies including age ≥18 8 968 0.38 (0.29-0.48) 84.70 
Studies including RIA methods* 11 1418 0.25 (0.18-0.34) 86.77 
Studies including ELISA method 4 209 0.47 (0.24-0.72) 89.39 
Studies including AlaSTAT method 6 461 0.48 (0.33-0.64) 90.42 
Studies including Immunoblot method 1 27 0.63 (0.44-0.79) - 
Studies performed in Europe 12 1304 0.28 (0.21-0.36) 84.70 
Studies performed in Asia 10 751 0.48 (0.36-0.61) 90.06 
Studies performed in USA 1 56 0.18 (0.10-0.30) - 
SEC
All studies 7 540 0.14 (0.08-0.22) 78.26 
SED
All studies 3 317 0.05 (0.01-0.16) 70.49 
TSST-1
All studies 10 1110 0.16 (0.10-0.25) 85.28 
Studies including age <18 5 631 0.13 (0.05-0.28) 85.00 
Studies including age ≥18 3 1039 0.12 (0.05-0.27) 84.65 
Studies including RIA methods* 6 918 0.12 (0.05-0.25) 90.38 
Studies including ELISA method 2 109 0.18 (0.11-0.26) 0.00 
Studies including Immunoblot method 1 27 0.41 (0.24-0.60) - 
Studies performed in Europe 7 945 0.15 (0.07-0.28) 90.09 
Studies performed in Asia 2 109 0.18 (0.11-0.26) 0.00 
Studies performed in USA 1 56 0.21 (0.13-0.34) - 
SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin; RIA, radioimmunoassay; ELISA, enzyme-
linked immunosorbent assay; CI, confidence interval
* CAP fluorescent enzyme immunoassay, ImmunoCAP, and UniCAP
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IgG, IgM and IgA
Prevalences of IgG against S. aureus antigens were determined in four studies.31,32,55,60 
The pooled prevalences of IgG against SEB, reported in two studies (114 patients), was 
64% (95% CI 42-81; I2 78.84) (figure S1f ).55,60 In single studies the IgG prevalences were 
77.0% for SEA, 77.0% for TSST-1 and 34.6% for ETA.31,60 IgG subclass 2 (IgG2) was found in 
87.0% of the patients with AD against SEB and in 61.5% against SEC1.32 Only one study 
determined antistaphylococcal IgM, and detect antibodies against SEB in 62.5% of the 
patients with AD (table 2).55 None of the selected articles studied antistaphylococcal IgA.
odds of antibodies against S. aureus
Of the 26 articles, 11 studies compared patients with AD against healthy controls (759 
patients vs. 328 controls).24,25,27-33,53,60 Nine studies reported the prevalence of antistaphy-
lococcal IgE (596 patients vs. 189 controls).24,25,27-31,33,53 These studies mainly described 
antibody responses against SEA and SEB (seven and eight articles, respectively).24,25,27-31,53 
Pooled analyses showed that antistaphylococcal IgE was found significantly more 
Table 2. IgE, IgG and IgM against Staphylococcus aureus antigens in patients with atopic dermatitis
Antibody and
Staphylococcus aureus antigen
studies Patients
(Pooled) proportion of patients with 
detectable antigens (95% cI)
IgE
SEE 1 140 0.01 
SEI 1 140 0.01 
SEH 1 140 0.00 
SEK 1 140 0.00 
SEJ 1 140 0.00 
ETA 1 26 0.00 
FBP 1 95 0.36 
LTA 1 27 0.48 
IgG
SEA 1 74 0.77 
SEB 2 114 0.64 (0.42-0.81)a 
TSST-1 1 74 0.77 
ETA 1 26 0.35 
IgG2
SEB 1 77 0.87 
SEC1 1 78 0.62 
IgM
SEB 1 40 0.63 
Ig, immunoglobulin; SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; ET, exfoliative toxin; 
FBP, fibronectin-binding protein; LTA, lipoteichoic acid; CI, confidence interval; a Heterogeneity: I2 = 78.8
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often in the serum of patients compared with controls, with ORs of 8.37 for SEA (95% 
CI 2.93-23.92; P<0.001; I2 0.00)24,25,27-30,53 and 9.34 for SEB (95% CI 3.54-24.93; P<0.001; I2 
0.00)24,25,27-31,53 (table 3 and figure S2a-b). A pooled OR of IgE against TSST-1, reported in 
two studies (83 patients vs. 20 controls), was 23.33 (95% CI 0.47-1153.93, P=0.114, I2 0.00) 
(table 3 and figure S2c).24,27 Prevalences of other antigens, including SEC, SED, ETA, ET-1, 
FBP and LTA, were described in single controlled studies and pooled estimates could 
not be provided.24,27,31,33 The prevalences of all these S. aureus antigens were equal or in-
creased in patients vs. controls (table 4). As most antibody prevalences in control groups 
were 0% the ORs could not be calculated. Prevalences of IgG in patients and controls 
were compared in three studies.31,32,60 Compared with controls, patients were found to 
Table 3. IgE against SEA, SEB and TSST-1 in patients with atopic dermatitis versus healthy controls
Staphylococcus 
aureus antigen
studies Patients controls
Pooled oR in patients 
vs controls (95% cI)
Heterogeneity 
(I2)
SEA 7 475 139 8.37 (2.93-23.92)* 0.00
SEB 8 501 172 9.34 (3.54-24.93)* 0.00
TSST-1 2 83 20 23.33 (0.47-1153.93) 0.00
OR, odds ratio; CI, confidence interval. * Significant result
Table 4. IgE and IgG against Staphylococcus aureus antigens in patients with atopic dermatitis versus healthy 
controls
Antibody and 
Staphylococcus 
aureus antigen
studies Patients controls
Mean proportion 
of patients with 
detectable antigens
Mean proportion 
of controls with 
detectable antigens
IgE
SEC 1 56 15 0.05 0.0 
SED 1 56 15 0.05 0.0 
ETA 1 26 33 0.00 0.0 
ET 1 56 15 0.02 0.0 
FBP 1 95 17 0.36 0.0 
IgG
SEA 1 74 111 0.77 0.88 
SEB 1 74 111 0.73 0.69 
TSST-1 1 74 111 0.77 0.85 
ETA 1 26 14 0.35 0.14 
IgG2
SEB 1 77 27 0.87 0.78 
SEC1 1 78 28 0.62 0.86 
SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; ET, exfoliative toxin; FBP, fibronectin-bind-
ing protein
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have higher IgG prevalences to ETA and SEB and lower prevalences of IgG to SEA and 
TSST-1.31,60 In patients, the IgG2 prevalence to SEC1 was lower and to SEB higher than 
in controls.32 However, most differences in prevalences between patients and controls 
were small. No studies compared the antistaphylococcal IgM or IgA responses between 
patients and controls.
subgroup analysis
Subgroup analyses of the variables age, method of antibody identification and geo-
graphical region of the study centres were performed to detect possible sources of het-
erogeneity. The prevalences of IgE against SEA, SEB and TSST-1 did not significantly differ 
between children and adults (31% vs. 27%, 25% vs. 38% and 13% vs. 12%, respectively). 
Studies using the ELISA method showed higher pooled prevalences of IgE against SEA, 
SEB and TSST-1 than studies using RIA tests (61% vs. 19%, 47% vs. 25% and 18% vs. 12%, 
respectively). Lastly, studies conducted in Asia showed higher pooled prevalences of IgE 
to SEA, SEB an TSST-1 compared to studies conducted in Europe (51% vs. 24%, 48% vs. 
28% and 18% vs. 15%, respectively) (table 1).
Relationship between AD severity and antibodies against S. aureus
Considering the low number of studies reporting a mean SCORAD we could not calculate 
an overall association between AD severity and antistaphylococcal antibodies. However, 
several individual studies reported a significant association between superantigen-
specific (e.g. SEA, SEB) IgE and AD severity, measured by SCORAD, the criteria of Rajka 
or the modified Leicester system.29,32,55,58 This association could not be confirmed in 
four comparable studies.25,28,46,58 Sohn et al. looked at IgG against SEB and did not find a 
relationship with AD severity.55 However, Mrabet-Dahbi et al. found that patients with a 
deficiency of antistaphylococcal IgG2 to SEC1 had a more severe AD phenotype.32 Based 
on these contradictory studies, no conclusions can be drawn about the association 
between the antistaphylococcal antibody response and severity of AD.
Publication bias
Funnel plots of the pooled prevalence of IgE against SEA, SEB and TSST-1 showed no 
asymmetry (figure S3). Egger’s tests had intercepts of 0.52 for SEA (95% CI -4.40-5.44, P = 
0.826), -0.44 for SEB (95% CI -3.78-2.91, P = 0.789) and -0.82 for TSST-1 (95% CI -4.40-2.76, 
P = 0.611), confirming no publication bias.
119Systematic review on anti-S. aureus antibodies in atopic dermatitis
DIscussIon
This systematic review includes 26 studies and 2352 patients with AD. IgE responses 
against SEA and SEB in serum were found more often in patients with AD than in healthy 
controls. IgE, IgG and IgM against a very limited panel of other antigens were reported 
in single studies. No data are available on antistaphylococcal IgA. Pooled prevalences 
of antistaphylococcal IgE in patients with AD are 33% for SEA, 35% for SEB and 16% for 
TSST-1. Substantial to considerable heterogeneity and imprecision (small studies) limit 
the quality of evidence and should be taken into consideration when interpreting the 
results. Subgroup analysis were performed to account for differences in outcome mea-
sures (indirectness). The quality of evidence was probably not influenced by publication 
bias.
Subgroup analyses suggest that the antibody prevalence is dependent on the method 
of antibody identification (ELISA vs. RIA) and the geographic region of the study centres 
(Asia vs. Europe). This is in accordance with the study of Taylor et al. that found ELISA more 
sensitive than RIA to detect IgG1 in mouse.62 It might also explain the higher prevalence 
of antibodies in Asia compared to Europe, as Asian studies use ELISA techniques more 
often. Furthermore, an ethnicity-dependent antibody response has been suggested, at 
least for TSST-1.63 Because heterogeneity in subgroup analyses remains high, pooled 
prevalences and odds were probably also influenced by other variables, like AD severity. 
Unfortunately, we were not able to explore this as only a few studies reported a mean 
SCORAD. These individual studies showed contradictory results about the association 
between AD severity and IgE against predominantly superantigens.
The S. aureus antigens SEA and SEB belong to the group of immune modulators and 
act as superantigens. This indicates that they have the ability to stimulate T cells directly, 
resulting in T-cell proliferation and cytokine release, causing epithelial damage.14-16 The 
increased anti-SEA and anti-SEB IgE responses could be the result of increased expres-
sion of these antigens by the S. aureus bacteria in patients with AD, indicating SEA and 
SEB as possible bacterial mechanisms to aggravate or even initiate inflammation in AD. 
However, the studies included in this systematic review predominantly examined the 
prevalence of antibodies against the superantigens SEA, SEB and TSST-1 and other com-
mon antigens such as clumping factor A and lipase were not tested. In addition, SEA, 
SEB and TSST-1 were present in only 14%, 24% and 14%, respectively, of the S. aureus 
isolates.64 These data suggest a bias in the assessment of staphylococcal antigens and in-
dicate also a large genetic diversity among the colonizing S. aureus strains. Furthermore, 
the increased IgE responses against these antigens may be the result of immunological 
cross-reactivity, where the corresponding antigen-coding genes of SEA, SEB and/or 
TSST-1 are not present in the isolate.65-67
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This is the first systematic review summarising the available data on the prevalence of 
antistaphylococcal antibodies in patients with AD and the involved antigens. The broad 
selection criteria (e.g. all languages, exclusion only of case reports and nonoriginal 
studies) resulted in collecting the majority of articles about this subject and limiting 
selection bias. However, there are still some limitations in this study. Firstly, most articles 
did not report the AD treatment at the time of antibody measurement. The use of an-
timicrobial therapy might decrease the S. aureus load and S. aureus antibody titres.4,68 
In addition, the anti-inflammatory effect of systemic glucocorticosteroids could both 
cause a decrease in serum antibody concentrations and might also reduce S. aureus.6,69,70 
Even emollient monotherapy showed a decrease of S. aureus on the skin.71,72 In the stud-
ies that did report the treatment at baseline, the therapies consisted mainly of topical 
corticosteroids or no treatment at all (n=9). Secondly, the cut-off values of antibody 
identification methods were highly variable, not mentioned or unclear in and between 
several methods. Through subgroup analysis we tried to correct for this variability partly. 
Last, mainly antistaphylococcal IgE was assessed, of which the choice for determination 
was often unsubstantiated or based on results of previous studies. Patients with AD have 
frequent high IgE responses to environmental antigens, for example S. aureus. In addi-
tion, IgG is the most common antibody in the extravascular fluid and among others it 
plays a role in the neutralization of toxins.73,74
To further investigate the role of (the immune response against) S. aureus in AD patho-
genesis, future studies should focus on other antibody subtypes and other S. aureus 
antigens. IgG subclasses should be measured to detect possible biomarkers for AD se-
verity, such as a selective deficiency in IgG2 against SEC1 in the study of Mrabet-Dahbi et 
al.32 Furthermore, assessment of the antibody response against other S. aureus antigens, 
like MSCRAMMs, membrane-damaging molecules, housekeeping antigens and other 
types of immunomodulatory proteins, might give more insight in whether an increased 
IgE response is a secondary phenomenon of increased S. aureus colonization of AD skin.
conclusIon
In conclusion, this systematic review with meta-analysis shows that patients with AD 
have higher prevalences of IgE against the S. aureus antigens SEA and SEB than healthy 
controls, taking the large heterogeneity into consideration. These antigens, belonging 
to the group of immune modulators, are known as superantigens and have the ability 
to cause inflammation and epithelial damage. This supports a role for S. aureus in the 
pathogenesis of AD. IgE, IgG and IgM against a very limited panel of other antigens were 
studied in single studies. No data are available on antistaphylococcal IgA.
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suPPoRTIng InFoRMATIon
Appendix s1. Inclusion criteria for selecting studies for this systematic review
Types of studies
• All original observational and experimental human studies which assess the pres-
ence of antistaphylococcal antibodies in the serum of patients with atopic dermatitis, 
reported per Staphylococcus aureus antigen.
• All study designs, except for case reports.
Participants
• Patients of all ages with atopic dermatitis irrespective of disease severity, and pres-
ence of antistaphylococcal antibodies. Atopic dermatitis diagnosed by a medical 
doctor.
Controls
• Persons who does not have atopic dermatitis neither an atopic constitution (asthma, 
allergic rhinitis, food allergy) or another skin disease.
Outcome measures
• Primary: Specific antibodies (IgE, IgG, IgM, IgA) against Staphylococcus aureus anti-
gens.
• Secondary: The relationship between atopic dermatitis disease severity and specific 
antibodies (IgM, IgG, IgA, IgE) antibodies against Staphylococcus aureus antigens.
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Appendix s2. Quality assessment score
Modified Newcastle-Ottawa quality assessment scale for cohort or cross sectional 
studies.
Stars indicate the points allocated if the item criterion is met. A maximum score of 9 can 
be allocated to each article. Uncontrolled studies can reach a maximum score of 5.
Selection
1. Representativeness of the exposed cohort
a) Truly representative of the general atopic dermatitis population *
b) Somewhat representative of the general atopic dermatitis population *
c) Selected group of atopic dermatitis patients (hospital based, tertiary center, inpa-
tients, outpatients)
d) No description of the derivation of the cohort
2. Selection of the non-exposed cohort
a) Representative of the average community (healthy control, community control) *
b) Selected group of controls (hospital controls, other dermatological condition
c) No description of the derivation of the cohort
3. Ascertainment of atopic dermatitis
a) Diagnosed by dermatologist *
b) Diagnosed by physician other than dermatologist *
c) Diagnosed by clinical assessment*
d) Based on self-report
e) No description of atopic dermatitis case definition
4. Definition of the non-exposed cohort
a) No history of disease (endpoint) *
b) No description of source
Comparability
1. Comparability of exposed and non-exposed cohorts on the basis of design or analy-
sis
a) Patients with AD and healthy controls are matched for age *
b) Patients with AD and healthy controls are matched for any additional factor *
c) No controlling for confounding or matching
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Outcome
1. Assessment of outcome: measurement method of antibody response against 
Staphylococcus aureus antigens
a) Determined by ELISA, CAP, RAST, micro-array, AlaSTAT *
b) Not mentioned
2. Treatment during sampling 
a) No treatment *
b) Systemic treatment
c) Topical treatment 
d) Not mentioned
3. Missing data
a) Same rate for both patients with AD and healthy controls / no missing data *
b) Different rate for both patients with AD and healthy controls, but well described/
missing data, but well described *
c) Different rate for both patients with AD and healthy controls and not explained
d) Not mentioned
Modified Scoring algorithm controlled studies 36
Quality rating Points in selection 
Domain
Points in comparability 
Domain
Points in outcome domain
Good ≥ 3 ≥ 1 ≥ 2
Fair 2 0 ≥ 2
Poor 0-1 0 0-1
130 Chapter 5
Appendix s3. Supplementary references
 22. Leung DY, Harbeck R, Bina P et al. Presence of IgE antibodies to staphylococcal exotoxins on the 
skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993; 
92: 1374-80.
 23. Tada J, Toi Y, Akiyama H et al. Presence of specific IgE antibodies to staphylococcal enterotoxins in 
patients with atopic dermatitis. Eur J Dermatol 1996; 6(8): 552-4.
 25. Nissen D, Pedersen LJ, Skov PS et al. IgE-binding components of staphylococcal enterotoxins in 
patients with atopic dermatitis. Ann Allergy Asthma Immunol 1997; 79: 403-8.
 26. Morishita Y, Tada J, Sato A et al. Possible influences of Staphylococcus aureus on atopic dermati-
tis-- the colonizing features and the effects of staphylococcal enterotoxins. Clin Exp Allergy 1999; 
29: 1110-7.
 27. Lin YT, Shau WY, Wang LF et al. Comparison of serum specific IgE antibodies to staphylococcal 
enterotoxins between atopic children with and without atopic dermatitis. Allergy 2000; 55: 641-6.
 28. Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigen-producing Staphylo-
coccus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000; 30: 
994-1000.
 29. Yagi S, Wakaki N, Ikeda N et al. Presence of staphylococcal exfoliative toxin A in sera of patients 
with atopic dermatitis. Clin Exp Allergy 2004; 34: 984-93.
 30. Mrabet-Dahbi S, Breuer K, Klotz M et al. Deficiency in immunoglobulin G2 antibodies against 
staphylococcal enterotoxin C1 defines a subgroup of patients with atopic dermatitis. Clin Exp 
Allergy 2005; 35: 274-81.
 31. Reginald K, Westritschnig K, Linhart B et al. Staphylococcus aureus fibronectin-binding protein 
specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for 
cellular immune responses. J Allergy Clin Immunol 2011; 128: 82-91 e8.
 32. Bozek A, Fisher A, Filipowska B et al. Clinical features and immunological markers of atopic der-
matitis in elderly patients. Int Arch Allergy Immunol 2012; 157: 372-8.
 33. Jinnestal CL, Belfrage E, Back O et al. Skin barrier impairment correlates with cutaneous Staphy-
lococcus aureus colonization and sensitization to skin-associated microbial antigens in adult 
patients with atopic dermatitis. Int J Dermatol 2014; 53: 27-33.
 43. Rojo A, Aguinaga A, Monecke S et al. Staphylococcus aureus genomic pattern and atopic derma-
titis: may factors other than superantigens be involved? Eur J Clin Microbiol Infect Dis 2014; 33: 
651-8.
 44. Ott H, Weissmantel S, Kennes LN et al. Molecular microarray analysis reveals allergen- and 
exotoxin-specific IgE repertoires in children with atopic dermatitis. J Eur Acad Dermatol Venereol 
2014; 28: 100-7.
 45. Sonesson A, Bartosik J, Christiansen J et al. Sensitization to skin-associated microorganisms in 
adult patients with atopic dermatitis is of importance for disease severity. Acta Derm Venereol 
2013; 93: 340-5.
 46. Kou K, Aihara M, Matsunaga T et al. Association of serum interleukin-18 and other biomarkers 
with disease severity in adults with atopic dermatitis. Arch Dermatol Res 2012; 304: 305-12.
 47. Golysheva E, Pampura A, Mokronosova M. Clinical relevance of IgE-antibodies to staphylococcal 
enterotoxins and malassezia spp in patients with atopic dermatitis. Allergy 2012; 67: 452-586.
 48. Langer K, Breuer K, Kapp A et al. Staphylococcus aureus-derived enterotoxins enhance house 
dust mite-induced patch test reactions in atopic dermatitis. Exp Dermatol 2007; 16: 124-9.
131Systematic review on anti-S. aureus antibodies in atopic dermatitis
 49. Gutová V, Liška M. [Atopic eczema and specific IgE antibodies to Staphylococcal enterotoxins in 
children]. Alergie 2006; 8: 16-20.
 50. Tabuchi K, Inada N, Shoji J et al. [The relationship between Staphylococcus aureus and atopic 
keratoconjunctivitis]. Nippon Ganka Gakkai Zasshi 2004; 108: 397-400.
 51. Ide F, Matsubara T, Kaneko M et al. Staphylococcal enterotoxin-specific IgE antibodies in atopic 
dermatitis. Pediatr Int 2004; 46: 337-41.
 52. Sohn MH, Kim CH, Kim WK et al. Effect of staphylococcal enterotoxin B on specific antibody 
production in children with atopic dermatitis. Allergy Asthma Proc 2003; 24: 67-71.
 53. Nomura I, Katsunuma T, Tomikawa M et al. Hypoproteinemia in severe childhood atopic dermati-
tis: a serious complication. Pediatr Allergy Immunol 2002; 13: 287-94.
 54. Breuer K, Wittmann M, Bosche B et al. Severe atopic dermatitis is associated with sensitization to 
staphylococcal enterotoxin B (SEB). Allergy 2000; 55: 551-5.
 55. Nomura I, Tanaka K, Tomita H et al. Evaluation of the staphylococcal exotoxins and their specific 
IgE in childhood atopic dermatitis. J Allergy Clin Immunol 1999; 104: 441-6.
 56. Bunikowski R, Mielke M, Skarabis H et al. Prevalence and role of serum IgE antibodies to the 
Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J 
Allergy Clin Immunol 1999; 103: 119-24.
 57. Campbell DE, Kemp AS. Production of antibodies to staphylococcal superantigens in atopic 
dermatitis. Arch Dis Child 1998; 79: 400-4.
132 Chapter 5
suPPleMenTARy FIguRes
Figure s1. Forest plots of prevalence meta-analyses 
a. IgE against SEA in patients with atopic dermatitis
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Rojo 2014 0.47 0.30 0.64
Ott 2014 0.06 0.03 0.12
Jinnestal 2014 0.30 0.16 0.48
Sonesson 2013 0.18 0.15 0.22
Golysheva 2012 0.16 0.11 0.23
Bozek 2012 0.01 0.00 0.06
Langer 2007 0.44 0.28 0.61
Tabuchi 2004 0.50 0.30 0.70
Ide 2004 0.18 0.12 0.25
Nomura 2002 0.20 0.07 0.47
Zollner 2000 0.23 0.14 0.35
Lin 2000 0.70 0.57 0.80
Breuer 2000 0.44 0.33 0.55
Nomura 1999 0.79 0.69 0.86
Morishita 1999 0.54 0.46 0.62
Bunikowski 1999 0.19 0.11 0.31
Nissen 1997 0.48 0.30 0.66
Tada 1996 0.66 0.56 0.74
Leung 1993 0.32 0.21 0.45
0.33 0.23 0.45
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
b. IgE against SEB in patients with atopic dermatitis
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Rojo 2014 0.27 0.14 0.45
Ott 2014 0.01 0.00 0.05
Jinnestal 2014 0.20 0.09 0.38
Sonesson 2013 0.25 0.21 0.29
Kou 2012 0.49 0.39 0.58
Golysheva 20120.31 0.24 0.39
Bozek 2012 0.40 0.31 0.49
Langer 2007 0.47 0.31 0.64
Gutová 2006 0.06 0.03 0.14
Yagi 2004 0.19 0.08 0.39
Tabuchi 2004 0.50 0.30 0.70
Ide 2004 0.29 0.22 0.37
Sohn 2003 0.68 0.52 0.80
Nomura 2002 0.07 0.01 0.35
Zollner 2000 0.29 0.19 0.41
Lin 2000 0.70 0.57 0.80
Breuer 2000 0.39 0.29 0.51
Nomura 1999 0.35 0.26 0.45
Morishita 1999 0.65 0.57 0.72
Bunikowski 19990.31 0.20 0.44
Nissen 1997 0.63 0.44 0.79
Tada 1996 0.73 0.63 0.81
Leung 1993 0.18 0.10 0.30
0.35 0.27 0.43
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
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c. IgE against SEC in patients with atopic dermatitis
 
d. IgE against SED in patients with atopic dermatitis
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e. IgE against TSST-1 in patients with atopic dermatitis
 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit l imit
Rojo 2014 0.53 0.36 0.70
Ott 2014 0.01 0.00 0.05
Jinnestal  2014 0.20 0.09 0.38
Sonesson 20130.18 0.15 0.22
Bozek 2012 0.03 0.01 0.08
Gutová 2006 0.10 0.05 0.18
Nomura 2002 0.13 0.03 0.41
Nomura 1999 0.18 0.12 0.27
Nissen 1997 0.41 0.24 0.60
Leung 1993 0.21 0.13 0.34
0.16 0.10 0.25
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Meta Analysis
f. IgG against SEB in patients with atopic dermatitis
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Figure s2. Forest plots of odds meta-analyses
a. IgE against SEA in patients with atopic dermatitis versus healthy controls
b. IgE against SEB in patients with atopic dermatitis versus healthy controls
c. IgE against TSST-1 in patients with atopic dermatitis versus healthy controls
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Figure s3. Funnel plots for publication bias
a. IgE against SEA in patients with atopic dermatitis
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b. IgE against SEB in patients with atopic dermatitis
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c. IgE against TSST-1 in patients with atopic dermatitis
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suPPleMenTARy TAbles
Table s1. Electronic search
Database search
Embase (eczema/exp OR ‘atopic dermatitis’/exp OR (eczem* OR ((atopic OR constitutional*) 
NEAR/3 (dermatit* OR neurodermatit*))):ab,ti) AND (‘Staphylococcus aureus’/de OR 
(‘Staphylococcus aureus’ OR ‘s aureus’ OR ‘Staph aureus’):ab,ti) AND (antibody/exp OR 
immunoglobulin/exp OR antigen/exp OR microbiome/de OR ‘skin flora’/de OR (antibod* 
OR immunoglobulin* OR IGA OR IGE OR IGG OR IGM OR IGAs OR IGEs OR IGGs OR IGMs 
OR antigen* OR superantigen* OR microbiome* OR ‘skin flora’):ab,ti)
Medline (OvidSP) (eczema/ OR “Dermatitis, Atopic”/ OR (eczem* OR ((atopic OR constitutional*) 
ADJ3 (dermatit* OR neurodermatit*))).ab,ti.) AND (“Staphylococcus aureus”/ 
OR (“Staphylococcus aureus” OR “s aureus” OR “Staph aureus”).ab,ti.) AND (exp 
immunoglobulin/ OR exp antigens/ OR microbiota/ OR (antibod* OR immunoglobulin* 
OR IGA OR IGE OR IGG OR IGM OR IGAs OR IGEs OR IGGs OR IGMs OR antigen* OR 
superantigen* OR microbiome* OR “skin flora”).ab,ti.)
Pubmed (eczema[mh] OR (eczem*[tiab] OR ((atopic OR constitutional*[tiab]) AND (dermatit*[tiab] 
OR neurodermatit*[tiab])))) AND (Staphylococcus aureus[mh] OR (Staphylococcus 
aureus*[tiab] OR s aureus*[tiab] OR Staph aureus*[tiab])) AND (immunoglobulin[mh] 
OR antigens[mh] OR microbiota[mh] OR (antibod*[tiab] OR immunoglobulin*[tiab] OR 
IGA[tiab] OR IGE[tiab] OR IGG[tiab] OR IGM[tiab] OR IGAs[tiab] OR IGEs[tiab] OR IGGs[tiab] 
OR IGMs[tiab] OR antigen*[tiab] OR superantigen*[tiab] OR microbiome*[tiab] OR skin 
flora*[tiab])) AND publisher[sb]
Web of Science TS=(((eczem* OR ((atopic OR constitutional*) NEAR/3 (dermatit* OR neurodermatit*)))) 
AND ((“Staphylococcus aureus” OR “s aureus” OR “Staph aureus”)) AND ((antibod* OR 
immunoglobulin* OR IGA OR IGE OR IGG OR IGM OR IGAs OR IGEs OR IGGs OR IGMs OR 
antigen* OR superantigen* OR microbiome* OR “skin flora”)))
Scopus TITLE-ABS-KEY(((eczem* OR ((atopic OR constitutional*) W/3 (dermatit* OR 
neurodermatit*)))) AND ((“Staphylococcus aureus” OR “s aureus” OR “Staph aureus”)) AND 
((antibod* OR immunoglobulin* OR IGA OR IGE OR IGG OR IGM OR IGAs OR IGEs OR IGGs 
OR IGMs OR antigen* OR superantigen* OR microbiome* OR “skin flora”)))
Google scholar Eczema|”atopic dermatitis” “Staphylococcus|s|Staph aureus” antibody|antibodies|immuno
globulin|antigen|antigens|microbiome|”skin flora”|superantigen|superantigens
Cochrane Library ((eczem* OR ((atopic OR constitutional*) NEAR/3 (dermatit* OR neurodermatit*))):ab,ti) 
AND ((‘Staphylococcus aureus’ OR ‘s aureus’ OR ‘Staph aureus’):ab,ti) AND ((antibod* OR 
immunoglobulin* OR IGA OR IGE OR IGG OR IGM OR IGAs OR IGEs OR IGGs OR IGMs OR 
antigen* OR superantigen* OR microbiome* OR ‘skin flora’):ab,ti)
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Table s2. Study characteristics per study
NOTE: Full reference details are provided in Appendix S3 (see Supporting Information)
country Patients controls Antibody cut-off detection 
method
nos Patients controls
n % Male Mean 
age (y)
Treatment at baseline Mean AD 
severity score
n % Male Mean 
age (y)
Prevalence 
positive anti-S. 
aureus antibodies
Prevalence 
positive anti-S. 
aureus antibodies
Rojo
201443
Spain 32/ 30b 65.6 23 -
SCORAD
-
IgE
UniCAP
10 kU/L
2
SEA: 0.47
SEB: 0.27
SEC: 0.40
TSST-1: 0.53
Ott
201444
Germany 140 60.7 6.2 -
SCORAD
36
IgE
FEIA
-
3
SEA: 0.06
SEB: 0.01
SEC: 0.12
SED: 0.00
SEE: 0.01
SEI: 0.01
SEH: 0.00
SEK: 0.00
SEJ: 0.00
TSST-1: 0.01
Jinnestål
201433
Sweden 30 30.0
32.5 
(med)
Topical treatment, no UV treatment
SCORAD
-
10c 30.0
41 
(med)
IgE
ImmunoCAP
0.35 kU/L
4
SEA: 0.30
SEB: 0.20
TSST-1: 0.20
Sonesson
201345
Sweden 513 32.6 26.6 -
Rajka & 
Langeland 
5.7
IgE
ImmunoCAP
0.35 kU/L
3
SEA: 0.18
SEB: 0.25
TSST-1: 0.15
Kou
201246
Japan 121/109b 57.0 35.7
Topical corticosteroid, 24 patients 
used cyclosporine
SCORAD
42 (med)
50c 54.0 31.0 IgE
UniCAP
0.70 UA/mL
3 SEB: 0.49
Golyshevaa
201247
Russia 133 -
Range 
1-55
-
SCORAD
-
IgE
ImmunoCAP
-
2
SEA: 0.16
SEB: 0.31
Bozek
201232
Poland 121 63.6 68.9 -
SCORAD
32.2
106c - 68.1 IgE
CAP assay
0.35 kU/L
2
SEA: 0.01
SEB: 0.40
SEC: 0.07
SED: 0.11
TSST-1: 0.03
Reginald
201131
Austria & 
Germany
95 47.4 34.4 -
SCORAD
-
17 29.4 36.2 IgE
ELISA
-
3 FBP: 0.36 FBP: 0.00
Langer
200748
Germany 32 28.1 31.5 -
SCORAD
33.4
9 - - IgE
CAP FEIA
0.35 kU/L
2
SEA: 0.44
SEB: 0.47
Gutová
200649
Czech 
Republic
84 50.0
Range 
4 mo – 
9 y
-
SCORAD
- 
10c - - IgE
CAP (SEC, TSST-1) 
-
Immulite 2000 (SEB)
-
2
SEB: 0.06
SEC: 0.11
TSST-1: 0.10
Mrabet-
Dahbi
200530
Germany 89 -
31 
(med)
No corticosteroid and systemic or 
topical AB 4 weeks prior to the study
SCORAD
45 (med)
28 -
27 
(med)
IgG2
CAP (IgE)
0.35 kU/L
ELISA (IgG2)
-
6
SEB: 0.87 (IgG2)
SEC1: 0.62 (IgG2)
SEB: 0.78 (IgG2)
SEC1: 0.86 (IgG2)
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Table s2. Study characteristics per study
NOTE: Full reference details are provided in Appendix S3 (see Supporting Information)
country Patients controls Antibody cut-off detection 
method
nos Patients controls
n % Male Mean 
age (y)
Treatment at baseline Mean AD 
severity score
n % Male Mean 
age (y)
Prevalence 
positive anti-S. 
aureus antibodies
Prevalence 
positive anti-S. 
aureus antibodies
Rojo
201443
Spain 32/ 30b 65.6 23 -
SCORAD
-
IgE
UniCAP
10 kU/L
2
SEA: 0.47
SEB: 0.27
SEC: 0.40
TSST-1: 0.53
Ott
201444
Germany 140 60.7 6.2 -
SCORAD
36
IgE
FEIA
-
3
SEA: 0.06
SEB: 0.01
SEC: 0.12
SED: 0.00
SEE: 0.01
SEI: 0.01
SEH: 0.00
SEK: 0.00
SEJ: 0.00
TSST-1: 0.01
Jinnestål
201433
Sweden 30 30.0
32.5 
(med)
Topical treatment, no UV treatment
SCORAD
-
10c 30.0
41 
(med)
IgE
ImmunoCAP
0.35 kU/L
4
SEA: 0.30
SEB: 0.20
TSST-1: 0.20
Sonesson
201345
Sweden 513 32.6 26.6 -
Rajka & 
Langeland 
5.7
IgE
ImmunoCAP
0.35 kU/L
3
SEA: 0.18
SEB: 0.25
TSST-1: 0.15
Kou
201246
Japan 121/109b 57.0 35.7
Topical corticosteroid, 24 patients 
used cyclosporine
SCORAD
42 (med)
50c 54.0 31.0 IgE
UniCAP
0.70 UA/mL
3 SEB: 0.49
Golyshevaa
201247
Russia 133 -
Range 
1-55
-
SCORAD
-
IgE
ImmunoCAP
-
2
SEA: 0.16
SEB: 0.31
Bozek
201232
Poland 121 63.6 68.9 -
SCORAD
32.2
106c - 68.1 IgE
CAP assay
0.35 kU/L
2
SEA: 0.01
SEB: 0.40
SEC: 0.07
SED: 0.11
TSST-1: 0.03
Reginald
201131
Austria & 
Germany
95 47.4 34.4 -
SCORAD
-
17 29.4 36.2 IgE
ELISA
-
3 FBP: 0.36 FBP: 0.00
Langer
200748
Germany 32 28.1 31.5 -
SCORAD
33.4
9 - - IgE
CAP FEIA
0.35 kU/L
2
SEA: 0.44
SEB: 0.47
Gutová
200649
Czech 
Republic
84 50.0
Range 
4 mo – 
9 y
-
SCORAD
- 
10c - - IgE
CAP (SEC, TSST-1) 
-
Immulite 2000 (SEB)
-
2
SEB: 0.06
SEC: 0.11
TSST-1: 0.10
Mrabet-
Dahbi
200530
Germany 89 -
31 
(med)
No corticosteroid and systemic or 
topical AB 4 weeks prior to the study
SCORAD
45 (med)
28 -
27 
(med)
IgG2
CAP (IgE)
0.35 kU/L
ELISA (IgG2)
-
6
SEB: 0.87 (IgG2)
SEC1: 0.62 (IgG2)
SEB: 0.78 (IgG2)
SEC1: 0.86 (IgG2)
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NOTE: Full reference details are provided in Appendix S3 (see Supporting Information) (continued)
country Patients controls Antibody cut-off detection 
method
nos Patients controls
n % Male Mean 
age (y)
Treatment at baseline Mean AD 
severity score
n % Male Mean 
age (y)
Prevalence 
positive anti-S. 
aureus antibodies
Prevalence 
positive anti-S. 
aureus antibodies
Yagi
200429
Japan 105/26b - - -
Modified 
Leicester system
-
33 - - IgE, IgG
UniCAP (IgE)
0.35 kU/L
ELISA (IgG)
-
3
SEB: 0.19 (IgE)
ETA: 0.00 (IgE)
ETA: 0.35 (IgG)
SEB: 0.06 (IgE)
ETA: 0.00 (IgE)
ETA: 0.15 (IgG)
Tabuchi
200450
Japan 22 81.8 27.5 - - 8 50.0 31.9 IgE
AlaSTAT
0.10 IU/mL
3
SEA: 0.50
SEB: 0.50
SEA: 0.00
SEB: 0.00
Ide
200451
Japan 140 65.0 4.4 According to guidelines
1999 Japanese 
Therapeutic 
Guidelines 
for Atopic 
Dermatitis
-
IgE
ImmunoCAP
0.7 U/mL
2
SEA: 0.18
SEB: 0.29
Sohn
200352
South-
Korea
40 45.0 5.2 -
Criteria of Rajka
-
40c 65.5 6.6
IgE, IgG, 
IgM
ELISA
12.11 U/mL (IgE)
26.11 U/mL (IgG)
19.83 U/mL (IgM)
3
SEB: 0.68 (IgE)
SEB: 0.53 (IgG)
SEB: 0.63 (IgM)
Nomura
200253
Japan 15 73.3
6 mo 
(med)
Systematic washing of skin using 
soap and topical corticosteroid, 
antihistamines and some patients 
used systemtic AB
Modified 
Leicester system
-
IgE
ELISA
1.07 U (SEA)
12.6 U (SEB)
7.4 U (SEC)
8.3 U (TSST-1)
2
SEA: 0.20
SEB: 0.07
SEC: 0.13
TSST-1: 0.13
Zollner
200028
Germany 65 41.5 41
No AB or systemic 
immunosuppressives 4 weeks prior 
to the study
SCORAD
-
65 - - IgE
AlaSTAT
0.7 U/mL
5
SEA: 0.23
SEB: 0.29
SEA: 0.00
SEB: 0.00
Lin
200027
Taiwan 60 66.7 7.2 -
Criteria of Rajka
-
24 41.7 8.4 IgE
ELISA
0.16 kU/L (SEA)
0.7 kU/L (SEB)
7
SEA: 0.70
SEB: 0.70
SEA: 0.25
SEB: 0.17
Breuer
200054
Germany 71 40.8
32 
(med)
No treatment
SCORAD
-
IgE
AlaSTAT
0.35 kU/L
4
SEA: 0.44
SEB: 0.39
Nomura
199955
Japan 94 59.6 7.8 -
Modified 
Leicester system
35.4
IgE
ELISA
1.07 U (SEA)
12.4 U (SEB)
7.8 U (SEC)
8.3 U (TSST-1)
3
SEA: 0.79
SEB: 0.35
SEC: 0.21
TSST-1: 0.18
Morishita
199926
Japan 149 44.3 21.4 -
Criteria of Rajka
-
11 27.3 26.9 IgE
AlaSTAT
0.35 IU/mL
5
SEA: 0.54
SEB: 0.65
SEA: 0.00
SEB: 0.00
Bunikowski
199956
Germany 58 65.5
30 mo 
(med)
No topical or systemic antimicrobial 
drugs 2 weeks prior to the study
SCORAD
-
22c -
73 mo 
(med)
IgE
AlaSTAT
0.7 kU/L
3
SEA: 0.19
SEB: 0.31
Campbell 
199857
Australia 74 59.5 - - - 111 - - IgG
ELISA
2.1 LU (SEA)
2.4 LU (SEB)
8.7 LU (TSST-1)
3
SEA: 0.77
SEB: 0.73
TSST-1: 0.77
SEA: 0.88
SEB: 0.69
TSST-1: 0.85
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NOTE: Full reference details are provided in Appendix S3 (see Supporting Information) (continued)
country Patients controls Antibody cut-off detection 
method
nos Patients controls
n % Male Mean 
age (y)
Treatment at baseline Mean AD 
severity score
n % Male Mean 
age (y)
Prevalence 
positive anti-S. 
aureus antibodies
Prevalence 
positive anti-S. 
aureus antibodies
Yagi
200429
Japan 105/26b - - -
Modified 
Leicester system
-
33 - - IgE, IgG
UniCAP (IgE)
0.35 kU/L
ELISA (IgG)
-
3
SEB: 0.19 (IgE)
ETA: 0.00 (IgE)
ETA: 0.35 (IgG)
SEB: 0.06 (IgE)
ETA: 0.00 (IgE)
ETA: 0.15 (IgG)
Tabuchi
200450
Japan 22 81.8 27.5 - - 8 50.0 31.9 IgE
AlaSTAT
0.10 IU/mL
3
SEA: 0.50
SEB: 0.50
SEA: 0.00
SEB: 0.00
Ide
200451
Japan 140 65.0 4.4 According to guidelines
1999 Japanese 
Therapeutic 
Guidelines 
for Atopic 
Dermatitis
-
IgE
ImmunoCAP
0.7 U/mL
2
SEA: 0.18
SEB: 0.29
Sohn
200352
South-
Korea
40 45.0 5.2 -
Criteria of Rajka
-
40c 65.5 6.6
IgE, IgG, 
IgM
ELISA
12.11 U/mL (IgE)
26.11 U/mL (IgG)
19.83 U/mL (IgM)
3
SEB: 0.68 (IgE)
SEB: 0.53 (IgG)
SEB: 0.63 (IgM)
Nomura
200253
Japan 15 73.3
6 mo 
(med)
Systematic washing of skin using 
soap and topical corticosteroid, 
antihistamines and some patients 
used systemtic AB
Modified 
Leicester system
-
IgE
ELISA
1.07 U (SEA)
12.6 U (SEB)
7.4 U (SEC)
8.3 U (TSST-1)
2
SEA: 0.20
SEB: 0.07
SEC: 0.13
TSST-1: 0.13
Zollner
200028
Germany 65 41.5 41
No AB or systemic 
immunosuppressives 4 weeks prior 
to the study
SCORAD
-
65 - - IgE
AlaSTAT
0.7 U/mL
5
SEA: 0.23
SEB: 0.29
SEA: 0.00
SEB: 0.00
Lin
200027
Taiwan 60 66.7 7.2 -
Criteria of Rajka
-
24 41.7 8.4 IgE
ELISA
0.16 kU/L (SEA)
0.7 kU/L (SEB)
7
SEA: 0.70
SEB: 0.70
SEA: 0.25
SEB: 0.17
Breuer
200054
Germany 71 40.8
32 
(med)
No treatment
SCORAD
-
IgE
AlaSTAT
0.35 kU/L
4
SEA: 0.44
SEB: 0.39
Nomura
199955
Japan 94 59.6 7.8 -
Modified 
Leicester system
35.4
IgE
ELISA
1.07 U (SEA)
12.4 U (SEB)
7.8 U (SEC)
8.3 U (TSST-1)
3
SEA: 0.79
SEB: 0.35
SEC: 0.21
TSST-1: 0.18
Morishita
199926
Japan 149 44.3 21.4 -
Criteria of Rajka
-
11 27.3 26.9 IgE
AlaSTAT
0.35 IU/mL
5
SEA: 0.54
SEB: 0.65
SEA: 0.00
SEB: 0.00
Bunikowski
199956
Germany 58 65.5
30 mo 
(med)
No topical or systemic antimicrobial 
drugs 2 weeks prior to the study
SCORAD
-
22c -
73 mo 
(med)
IgE
AlaSTAT
0.7 kU/L
3
SEA: 0.19
SEB: 0.31
Campbell 
199857
Australia 74 59.5 - - - 111 - - IgG
ELISA
2.1 LU (SEA)
2.4 LU (SEB)
8.7 LU (TSST-1)
3
SEA: 0.77
SEB: 0.73
TSST-1: 0.77
SEA: 0.88
SEB: 0.69
TSST-1: 0.85
142 Chapter 5
NOTE: Full reference details are provided in Appendix S3 (see Supporting Information) (continued)
country Patients controls Antibody cut-off detection 
method
nos Patients controls
n % Male Mean 
age (y)
Treatment at baseline Mean AD 
severity score
n % Male Mean 
age (y)
Prevalence 
positive anti-S. 
aureus antibodies
Prevalence 
positive anti-S. 
aureus antibodies
Nissen
199725
Denmark 34/ 27b -
31 
(med)
- - 5 - - IgE
Immunoblot
-
2
SEA: 0.48
SEB: 0.63
TSST-1: 0.41
LTA: 0.48
SEA: 0.00
SEB: 0.00
TSST-1: 0.00
LTA: 0.00
Tada
199623
Japan 96 42.7 20.2 -
Criteria of Rajka
-
11 27.7 29.4 IgE
AlaSTAT
0.35 IU/L
5
SEA: 0.66
SEB: 0.73
SEA: 0.00
SEB: 0.00
Leung
199322
USA 56 - - - - 15 - - IgE
ELISA
-
9
SEA: 0.32
SEB: 0.18
SEC: 0.05
SED: 0.05
TSST-1: 0.21
ET: 0.02
SEA: 0.00
SEB: 0.00
SEC: 0.00
SED: 0.00
TSST-1: 0.00
ET: 0.00
a Only abstract available
b Number of patients included in study (characteristics refer to this number) / number of patients included in 
the outcome 
c Control group included in the study but the outcome was not reported 
Abbreviations: N, number of patients or controls; y, year; mo, months; AD, atopic dermatitis; NOS, Newcastle-
Ottawa Scale; S. aureus, Staphylococcus aureus, med, median; AB, antibiotics; UV, ultraviolet, SCORAD, SCORing 
Atopic Dermatitis; Ig, immunoglobulin; FEIA, fluorescent enzyme immunoassay; SE, staphylococcal enterotoxin; 
TSST-1, toxic shock syndrome toxin 1; FBP, fibronectin-binding protein; ET, exfoliative toxin; LTA, lipoteichoic acid
143Systematic review on anti-S. aureus antibodies in atopic dermatitis
NOTE: Full reference details are provided in Appendix S3 (see Supporting Information) (continued)
country Patients controls Antibody cut-off detection 
method
nos Patients controls
n % Male Mean 
age (y)
Treatment at baseline Mean AD 
severity score
n % Male Mean 
age (y)
Prevalence 
positive anti-S. 
aureus antibodies
Prevalence 
positive anti-S. 
aureus antibodies
Nissen
199725
Denmark 34/ 27b -
31 
(med)
- - 5 - - IgE
Immunoblot
-
2
SEA: 0.48
SEB: 0.63
TSST-1: 0.41
LTA: 0.48
SEA: 0.00
SEB: 0.00
TSST-1: 0.00
LTA: 0.00
Tada
199623
Japan 96 42.7 20.2 -
Criteria of Rajka
-
11 27.7 29.4 IgE
AlaSTAT
0.35 IU/L
5
SEA: 0.66
SEB: 0.73
SEA: 0.00
SEB: 0.00
Leung
199322
USA 56 - - - - 15 - - IgE
ELISA
-
9
SEA: 0.32
SEB: 0.18
SEC: 0.05
SED: 0.05
TSST-1: 0.21
ET: 0.02
SEA: 0.00
SEB: 0.00
SEC: 0.00
SED: 0.00
TSST-1: 0.00
ET: 0.00
a Only abstract available
b Number of patients included in study (characteristics refer to this number) / number of patients included in 
the outcome 
c Control group included in the study but the outcome was not reported 
Abbreviations: N, number of patients or controls; y, year; mo, months; AD, atopic dermatitis; NOS, Newcastle-
Ottawa Scale; S. aureus, Staphylococcus aureus, med, median; AB, antibiotics; UV, ultraviolet, SCORAD, SCORing 
Atopic Dermatitis; Ig, immunoglobulin; FEIA, fluorescent enzyme immunoassay; SE, staphylococcal enterotoxin; 
TSST-1, toxic shock syndrome toxin 1; FBP, fibronectin-binding protein; ET, exfoliative toxin; LTA, lipoteichoic acid
Table s3. Studies reporting IgE antibodies against Staphylococcus aureus antigens in patients with atopic der-
matitis
Staphylococcus aureus antigen number of studies number of controlled studies
SEA 19 7
SEB 23 8
SEC 7 1
SED 3 1
SEE 1
SEI 1
SEH 1
SEK 1
SEJ 1
TSST-1 10 2
ETA 1
FBP 1
LTA 1
ET1 1 1
Abbreviations: SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; ET, exfoliative toxin; FBP, 
fibronectin-binding protein; LTA, lipoteichoic acid
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AbsTRAcT
background
An altered immune response against Staphylococcus (S.) aureus might contribute to 
inflammation and barrier damage in atopic dermatitis (AD).
objectives
To profile IgG antibodies against 55 S. aureus antigens in sera of children with mild-to-
severe AD and to evaluate the association between IgG levels and disease severity.
Methods
In this cross-sectional study, we included children with AD from two interventional 
study cohorts, the Shared Medical Appointment (SMA) cohort (n = 131) and the older 
DAVOS cohort (n = 76). AD severity was assessed using the Self Administrated-Eczema 
Area and Severity Index (SA-EASI) and levels of thymus and activation-regulated chemo-
kine (TARC) in serum. IgG antibody levels against 55 S. aureus antigens were quantified 
simultaneously using a Luminex assay. Pair-wise correlations were calculated between 
the 55 IgG levels using the Spearman rank correlation test. Linear regression analysis 
was performed to test for associations between 55 IgG levels and SA-EASI and TARC, 
adjusting for age, sex and S. aureus colonization.
Results
In the SMA cohort 16 antigens were associated with SA-EASI and 12 antigens were asso-
ciated with TARC (10 overlapping antigens; P-values 0.001 to 0.044). The associated IgG 
antibodies targeted mainly secreted proteins with immunomodulatory functions. In the 
DAVOS study, IgG levels against only four and one S. aureus antigen(s) were associated 
with SA-EASI and TARC, respectively (no overlap).
conclusions
In young children, severity of AD is associated with an IgG response directed against S. 
aureus antigens with mainly immunomodulatory functions. These findings encourage 
further evaluation of the role of S. aureus in the pathogenesis of AD.
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InTRoDucTIon
Staphylococcus (S.) aureus is involved in the multifactorial pathogenesis of atopic der-
matitis (AD).1 Approximately 70% of the skin lesions in AD are colonised with S. aureus, 
and bacterial density was found to be associated with the severity of AD.2 The exact 
mechanisms through which S. aureus causes inflammation are not fully understood, 
but the bacterium expresses different virulence factors that can trigger T-cell immune 
responses in AD and contribute to the inflammatory response.3 For example, staphylo-
coccal enterotoxins (SE) have the ability to act as superantigens via direct stimulation of 
T cells.4 Colonization with staphylococcal strains that produce these virulence factors, 
including SEA, SEB, SEC and SED, is thought to be related to AD severity.5,6 To date, the 
role of other staphylococcal antigens in AD has barely been investigated.7 
There is increasing interest in understanding the immune response against S. aureus 
in AD as an altered immune response might contribute to inflammation and barrier 
damage. The current literature focuses on IgE antibody titers directed against some 
of the S. aureus antigens. Increased IgE-specific antibodies against S. aureus antigens, 
mainly SEA and SEB, have been described in patients with AD vs. healthy controls. 
Furthermore, an association between IgE levels and AD severity has been confirmed 
in some studies.8-10 Although IgG is known for its involvement in the neutralization and 
elimination of microbes, little is known about anti-S. aureus IgG antibody patterns in 
patients with AD.11 Previous studies measured IgG against two antigens, exfoliative toxin 
A and SEB, and reported higher IgG levels in patients vs. controls (significant for SEB).12,13 
Other antigens were not studied. Two studies performed detailed IgG subclass analysis 
and found an IgG2 deficiency against SEC1 and an elevated IgG4 against SEB in patients 
with AD.14,15 Although studies are limited in number and focus on a few single antigens, 
they emphasize the possible relevance of IgG in the response against S. aureus in AD.
To gain more insights into the IgG-mediated immune response against S. aureus in 
patients with AD, we profiled IgG antibodies against 55 S. aureus antigens in sera of 
children with mild-to-severe AD, using a Luminex assay.16 Additionally, we evaluated the 
association between IgG levels and disease severity.
MATeRIAls AnD MeTHoDs 
study design and population
This cross-sectional study was embedded in two interventional studies: the Shared 
Medical Appointment (SMA) study and the DAVOS study.17,18 SMA included patients with 
mild-to-severe AD, aged between 0 and 18, between November 2009 and December 
2011. The DAVOS study included children with difficult-to-treat eczema, aged 8-18 years, 
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between January 2011 and June 2015. Both studies were conducted at the Wilhelmina 
Children’s Hospital in The Netherlands and were approved by the University Medical 
Centre Utrecht’s medical and ethical review board (09-192/K, 08-368/K). Written in-
formed consent was obtained from all patients. Serum samples, microbial swabs, eczema 
severity scores and patient characteristics, obtained at baseline in both the SMA and 
DAVOS studies, were analysed in this study. In both studies, AD was diagnosed accord-
ing to the UK Working Party criteria.19-21 Severity was assessed by the parents using the 
Self-Administrated Eczema Area and Severity Index (SA-EASI).22 Apart from the SA-EASI, 
the levels of thymus and activation-regulated chemokine (TARC) in serum were used as 
a marker for AD severity.23,24 Age of AD onset, treatment history and diagnosis of asthma 
and allergic rhinitis were based on clinical history. Food allergy was diagnosed based on 
convincing clinical history in the SMA study and/or double-blind food provocation test 
in the DAVOS study.
Microbial samples
Skin microbial samples were taken from the nose and lesional skin according to a 
standardized procedure using a sterile swab (Sterile Dryswab™) moistened with NaCl 
0.9%. Skin samples were collected from lesions at the antecubital fold or the popliteal 
fossa. Bacterial cultures for S. aureus were performed using routine diagnostic culture 
procedures using S. aureus-specific Mannitol salt agar plates.
Measurement of antibodies against S. aureus
Antigens and coupling procedure
In a pilot experiment, the IgG antibody titers against a set of 57 S. aureus antigens were 
measured in sera of 23 AD patients. It was decided to include 55 antigens in the pres-
ent study as the signals for two antibodies (ESAT-6 secretion system extracellular A and 
SA2097) were very low in the pilot study (data not shown). The 55 antigens used in this 
study were divided into four categories based on their biological function: household 
enzymes, immune modulators (superantigens and nonsuperantigens), cell membrane-
damaging molecules and microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs) (table S1). All used antigens were recombinant proteins, 
expressed with a histone tag in the Escherichia coli XL1-blue strain and purified under 
denaturing conditions with nickelnitrilotriacetic acid agarose. They were coupled to the 
SeroMAP carboxylated beads (Luminex Corporation) as described previously.25,26 The 
final bead concentration was adjusted to 3000 beads/μL and they were stored at 6°C 
in the dark. As a negative control, the coupling procedure was performed in absence of 
any antigen.
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Luminex assay
Serum samples were stored at -80°C until quantification of IgG antibody levels against 
S. aureus antigens with a fluorescent bead-based flow cytometry technique (xMapâ, 
Luminex).16 In the wells of a 96-well filter microtiter plate (Millipore Corporation), 50 
μL bead mix (containing the different antigen-coupled beads each at a concentration 
of 3000 beads/μL) was mixed with 50 μL 1:100 diluted patient serum. Follow-up steps 
have previously been described in detail.27 Each measurement lasted 1 minute; during 
this time a minimum of 100 beads had to be analysed for each antigen-coupled bead, 
otherwise the data were excluded from further analysis. IgG antibody levels against S. 
aureus antigens were expressed as median fluorescence intensity (MFI). A without non-
protein-coupled control bead was included to determine nonspecific antibody binding. 
The nonspecific MFI values were subtracted from the results.26 The MFI values of the two 
independent experiments, reflecting semi-quantitative antibody levels, were averaged. 
The coefficient of variation (CV) was calculated for the duplicate experiments. Measure-
ments were excluded if the CV value was >25% and average MFI values were >1000. 
Failures of the Luminex per well were defined as missing values.
statistical analysis
For this study, a convenience sample was obtained from the SMA and the DAVOS 
studies. As the DAVOS and SMA studies used different inclusion criteria regarding AD 
severity and age, the study cohorts were analysed separately. For further analysis the 
IgG data were preprocessed by replacing negative and zero MFI values (resulting from 
correction for nonspecific binding) by 1. Absolute IgG levels per antigen are presented 
as median [interquartile range (IQR)]. The IgG data were log-transformed to obtain a 
parametric distribution, and standardised using a zero mean unit variance method. 
Pairwise correlations were calculated between the 55 IgG levels using the Spearman 
rank correlation test. A hierarchical clustering analysis with the 55 antigens was carried 
out to identify main antibody clusters, but no robust clusters were identified (data not 
shown). Therefore, for further analysis the 55 antibodies were analysed separately.
Linear regression analysis
Severity scores and patient age were tested for normal distributions with the one-
sample Kolmogorov–Smirnov test and transformed when necessary, to obtain a normal 
distribution. Multivariable linear regression analyses were carried out using the stan-
dardized IgG levels (described above) for each of the 55 S. aureus antigens against the 
SA-EASI score as a main predictor, adjusted for age, sex and colonization with S. aureus 
on skin and/or in nose (S. aureus present, ‘yes’ or ‘no’). The multivariable linear regression 
was repeated in a separate model using TARC as a main predictor instead of SA-EASI 
to validate our results with an intrinsic marker for AD severity. For antibodies that did 
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not follow linear distribution after transformation, bootstrapping (iteration 1000) was 
used to obtain regression coefficients and 95% confidence intervals (CIs). Given the 
exploratory nature of this study and the observed correlations between the 55 tested 
antibody levels, we used a P-value <0.05 to indicate significant associations between 
antibody levels and SA-EASI/ TARC. Analyses were performed using SPSS version 23.0 for 
Windows (IBM, Armonk, NY, U.S.A.).
ResulTs
Population characteristics
We included 136 and 76 children from the SMA and DAVOS studies, respectively (figure 
S1). The median age of the children from the SMA cohort was 2 years (IQR 1-5). The 
DAVOS population consisted of older children with a median age of 13 years (IQR 11-15). 
Eczema severity measured with the SA-EASI gave a median of 27 (IQR 16-42) in the SMA 
cohort and 24 (IQR 12-42) in the DAVOS cohort. Median TARC values were also higher in 
the SMA cohort [1441 in pg/ml (IQR 713-2794) vs. 1119 (IQR 696-2400). Skin and nasal 
colonization with S. aureus was found in 36% and 34% of the children in the SMA cohort, 
respectively, and in 47% and 67% of the children in the DAVOS cohort. Detailed baseline 
characteristics, including use of medication, are given in table 1.
Antibody characteristics
Median IgG levels against 55 S. aureus antigens measured in the sera of the children 
from both study cohorts are presented in table S1. In the DAVOS cohort, the medians of 
the absolute antibody levels were higher and showed less variation than the SMA study 
cohort. Figure 1 shows that the IgG antibody responses do not clearly differ between 
the four main biological groups of antigens (immune modulators (superantigens and 
non-superantigens), household enzymes, cell-membrane-damaging molecules and 
MSCRAMMs). A Spearman correlation test showed correlations between the IgG levels 
of the staphylococcal superantigen-like (SSL) proteins 3, 5, 9 and 10 (coefficients >0.7). 
High correlations (>0.7) were also identified between leukotoxin (Luk) E, LukD, LukS and 
between extracellular fibrinogen-binding protein and alanine transaminase 2. Addition-
ally, some enterotoxins were correlated: SEB with SEC (>0.7), SEI with SEM (>0.8), SEN 
with SEI (0.69) and SEA with SEE (0.69) (figure 2).
Association between antistaphylococcal Igg levels and atopic dermatitis 
severity measured with sA-eAsI and TARc
We found significant associations between IgG levels and AD severity in the SMA cohort. 
Sixteen antigens were associated with SA-EASI and 12 with TARC (table 2). Ten of the 
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12 antigens associated with TARC were also associated with SA-EASI (P-values 0.001 to 
0.044). The associated IgG antibodies targeted mainly secreted proteins with immuno-
modulatory functions (e.g. LukD and LukE; table 2). The described associations between 
antigen levels and AD severity were independent of age, sex and colonization of the skin 
and/or nose with S. aureus. In the DAVOS study, IgG levels against only four and one S. 
aureus antigen(s) were associated with SA-EASI and TARC, respectively, and there was no 
overlap between the two markers for AD (tables S2).
Table 1. Baseline characteristics
sMA cohort (n=131) DAVos cohort (n=76)
Age in years; median (IQR) 2 (1-5) 13 (11-15)
sex (male) 63 (48.1) 39 (51.3)
ethnicity 
Dutch 95 (72.5) 54 (71.1) 
Other ethnicity 19 (14.5) 22 (28.9) 
Missing 17 (13.0) 0 (0) 
Age of onset AD
0-<2 years 106 (80.9) 66 (86.8) 
2-<6 years 6 (4.6) 8 (10.5) 
Missing 19 (14.5) 2 (2.6) 
Atopy
Food allergy 53 (40.4)1 49 (64.5)1 
Allergic asthma 40 (30.5)2 59 (77.6) 
Allergic rhinoconjunctivitis 36 (27.5)2 67 (88.2) 
sA-eAsI; median (IQR) 27.00 (16.00-42.20)3 24.00 (11.95-41.75)2
TARc pg/mL; median (IQR) 1441 (713-2794) 1119 (696-2400)2
corticosteroid treatment
Topical corticosteroid 101 (77.1) 70 (92.1) 
Systemic corticosteroid 0 (0) 3 (3.9) 
Neoral 0 (0) 7 (9.2) 
Antibiotic treatment
Topical antibiotic 11 (8.4) 2 (2.6) 
Systemic antibiotic 3 (2.3) 1 (1.3) 
Staphylococcus aureus positive (> 10 CFU)
Skin 47 (35.9)4 36 (47.4)3 
Nose 45 (34.4)2 51 (67.1)3 
Data are n (%) unless otherwise indicated. SMA, Shared Medical Appointment; IQR, interquartile range; AD, 
atopic dermatitis; SA-EASI, Self-Administered Eczema Area and Severity Index; TARC, thymus and activation-
regulated chemokine; CFU, colony-forming unit.
Missings SMA: 1 = 4 (3.1%); 2 = 2 (1.5%); 3 = 41 (31.3%); 4 = 3 (2.3%)
Missings DAVOS: 1 = 2 (2.6%); 2 = 3 (3.9%); 3 = 6 (7.9%)
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Figure 1. Boxplots showing the levels of IgG against 55 antigens in the SMA study (normalized data)
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NOTE: Blue indicates MSCRAMMs, green the membrane-damaging molecules, orange the housekeeping anti-
gens, red the superantigens and yellow the immunomodulating proteins.
Figure 2. Spearman’s rank correlation coefficients of the IgG values (MFI) against 55 antigens (SMA cohort).
NOTE: The size and intensity of the red dots reflects the height of the correlation coefficients, identifying high 
correlations for example between the SSL 3, 5, 9 and 10 antigens. 
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DIscussIon
For the first time, IgG immune responses against a large panel of 55 S. aureus antigens 
were profiled in children with AD, showing that the children are exposed to the antigens 
and develop an IgG-mediated humoral immune response towards them. Additionally, 
AD severity was found to be associated with IgG antibodies directed against S. aureus 
antigens with mainly immunomodulatory functions. LukD and LukE are commonly 
expressed by strains of S. aureus and are involved in cell lysis of neutrophils.28 SSL3, SSL5, 
SSL9 and SSL10 are variably expressed and are all involved in immunomodulation, for 
example by inhibiting complement activation.29 Iron-responsive surface determinants A 
is a cell-surface protein that may function in both iron acquisition and adhesion.30 SEA is 
more rarely expressed and has a strong immunostimulatory function. As a superantigen 
it can cause cytokine release and epithelial damage, but the literature also describes 
(anti-inflammatory) cytokine downregulating functions (interleukin-4).28,31 Staphylococ-
cus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like 
are potent FcyR antagonists that inhibit IgG-mediated effector functions.32 
Only Sohn et al. have studied the staphylococcal IgG response in relation to AD severity. 
They measured SEB only and found no correlation with AD severity, which corresponds 
with our findings (table 2).13 The finding that the antibodies that were associated with AD 
severity in this study are known to target antigens with an immunomodulatory function 
suggests that S. aureus downregulates the immune system locally to help it maintain its 
colonization on the skin, a theory that was recently suggested by Biedermann et al.33 
In contrast to the associations between AD severity and IgG levels for specific antigens 
found in the SMA study, few associations were found in the DAVOS cohort. In addition, 
there was no overlap between the antibodies associated with the SA-EASI and these 
associated with TARC in the DAVOS cohort, which suggests that these associations were 
false-positive results. The lack of associations found in the DAVOS cohort could be the 
result of the older age of the DAVOS participants, who may have been more chroni-
cally exposed to S. aureus (see tables 1 and S1) and therefore exhibited higher levels of 
IgG.12,34 Furthermore, IgG antibody levels are known to increase with age (which is also 
true for patients with AD), reaching a plateau around adulthood.34-36 Indeed, comparison 
between IgG levels of the SMA cohort and a sample of healthy adult pooled serum (ap-
pendix S1), showed higher levels for most of the tested IgG antibodies in the healthy 
^ N = 90 for SA-EASI analysis due to missing SA-EASI scores
* Regression coefficients and CI were obtained using bootstrapping iteration 1000
- = no significant association between the antigen and the severity parameter.
SMA, Shared Medical Appointment; AD, atopic dermatitis; SA-EASI, Self-Administered Eczema Area and Severity 
Index; TARC, thymus and activationregulated chemokine; SE, standard error; CI, confidence interval. Please find 
abbreviations of the antigens in table S1. 
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pooled serum (figure S2). The DAVOS cohort had higher values than the healthy adult 
sample for a large part of the antibodies (figure S1). It could be argued that a plateau 
could have been reached in the older patients of the DAVOS cohort resulting in a lack of 
found associations. However, the DAVOS study included patients with difficult-to-treat 
(severe) eczema, most of whom were treated with topical corticosteroids or even sys-
temic immunosuppressive therapy (table 1). Hence, the SA-EASI scores at baseline may 
have been biased towards lower scores, which could have hampered the associations. 
Most likely the lack of association is a combination of both biased scores and the older 
age of the cohort.
IgG levels against specific antigens showed correlations (Spearman’s correlation test). 
SSL antigens and the superantigens SEI, SEM and SEN are known to be co-produced 
by S. aureus.37,38 The combined presentation of these antigens to the immune system 
probably contributed to the observed correlations between IgG responses. However, 
other factors probably also drive the height and correlations of the IgG-specific immune 
responses.
This study has several limitations. Firstly, a control group of children without AD that 
would allow investigating the normal range of IgG antibodies was not available. There-
fore, our conclusion focusses on a comparison between different severity phenotypes 
in a well-characterized cohort of children with AD. Due to the cross-sectional design we 
cannot conclude whether AD severity is the result of an altered IgG response. In addition, 
owing to the small sample size of this study, we could not perform multivariate analysis, 
such as unsupervised clustering, which would have allowed us to better understand the 
correlations found for different antibodies. Although we tested 55 different associations, 
we did not correct for multiple testing. Owing to the high correlations found between 
some of the antibodies, multiple testing correction is rather conservative. Because of this, 
and the hypothesis-generating nature of this study, our associations were kept nomi-
nally significant. Although cross-reactivity with other staphylococcal antigens cannot be 
completely ruled out, it is highly unlikely as S. aureus produces species-specific virulence 
factors that have not been found in Staphylococcus epidermidis.39 Despite these limita-
tions, the present study is the first to evaluate antibody responses against a broad panel 
of S. aureus antigens. Our study sheds light on the IgG-mediated immune response to 
S. aureus in children with AD and it highlights the relevance of other antigens (adhesins 
and immune modulators) next to the often studied superantigens. Further studies need 
to be conducted to validate the associations we found.
Interestingly, the association between IgG against S. aureus antigens and the severity 
of AD was independent of skin and nasal colonization with S. aureus. This suggests that 
the immune response against S. aureus might be altered, irrespective of the bacteria 
present on the skin at that time, and raises the question whether anti-S. aureus treat-
ment should be guided by a positive culture. To further explore the significance of our 
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findings, future studies should relate our findings to IgE and IgG subclass responses to S. 
aureus antigens in AD. These findings could also be related to S. aureus strain differences 
as different strains might have different ability to elicit immunological alterations in the 
host.40 In vitro experiments should reveal the functional effect of the relevant S. aureus 
antigens on T-cell differentiation.
conclusIon
In a cohort of young children with AD, we identified significant associations between 
disease severity and IgG antibodies directed against S. aureus antigens with mainly 
immunomodulatory functions. The results of this study encourage more detailed evalu-
ation of the role of S. aureus in the pathogenesis of AD.
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suPPleMenTARy MATeRIAl 
Appendix s1. Measurement of antibodies against S. aureus in human pooled serum.
Human pooled serum (HPS) is a mix of serum samples from 35 healthy adults (25% 
male, age between 19 and 61 years). The serum of all the AD patients included in this 
study (SMA=137 and DAVOS=76) was analysed for detection of IgG antibodies against 
55 S. aureus antigens by Luminex assay. Detailed description of the Luminex assay is 
described in the methods section of the main manuscript. This analysis included three 
samples of the HPS mix, resulting in three HPS measurements per S. aureus antigen. After 
quality control as described the methods section of the main manuscript, the HPS IgG 
measurements were averaged per antigen for further analysis. 
Figure s1. Flowchart of the study population, SMA study and DAVOS study
Included and randomised in SMA study 
n=140
Included and randomised in DAVOS study 
n=80 
Included for analysis in this cross-
sectional study
n=131
SMA study DAVOS study
Included for analysis in this cross-
sectional study 
n=76
Excluded because of drop-out 
between randomisation and baseline 
visit 
- not content with care (n=6)
- distance to hospital (n=1)
- no disease-activity (n=2)
Excluded 
 - No serum available (n=1)
 - Also included in SMA (n=2)
 - Rediagnosed with psoriasis 
after inclusion (n=1)
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Figure s2. IgG levels of the 55 antigens in SMA, DA-
VOS and HPS
 
 
Figure S2 shows the absolute IgG levels of the 55 an-
tigens for the SMA cohort (median), DAVOS cohort 
(median) and the human pooled serum (HPS). HPS 
signals for two antigens, SEJ and IsdH, were excluded 
according to the exclusion criteria described in the 
methods section of the main manuscript (e.g. coef-
ficient of variation for duplicate experiment >25%). 
Overall, HPS levels are higher than the SMA levels for 
all 53 antigens. HPS levels are higher than the DAVOS 
samples for only 31 antigens. NOTE: as the IgG values 
are not standardized, the IgG levels between the dif-
ferent antigens cannot be compared. Figure 1 of the 
manuscript includes a boxplot with standardized IgG 
levels.
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Table s1. Overview of 55 S. aureus antigens with function and MFI values 
S. aureus antigen Description n
Igg sMA 
(median, IQR)
n
Igg DAVos 
(median, IQR)
P- value 
*
Immune modulators (superantigens)
SEA (Staphylococcal 
enterotoxin A)
Superantigen 1 127
702.50 (228.50-
4005.50)
63
5011.25 (931.00-
11820.00)
< 0.001
SEB (Staphylococcal 
enterotoxin B)
Superantigen 1 126 203.75 (9.25-3283.44) 62
3803.50 (780.25-
13750.69)
< 0.001
SEC (Staphylococcal 
enterotoxin C)
Superantigen 1 126
1179.38 
(87.88-12018.94)
62
12330.63 
(7764.56-14071.19)
< 0.001
SED (Staphylococcal 
enterotoxin D)
Superantigen 1 119 24.00 (6.00-185.50) 68 222.50 (109.25-975.31) < 0.001
SEE (Staphylococcal 
enterotoxin E)
Superantigeni 1 119 12.50 (0.00-394.50) 67 764.00 (56.50-2279.00) < 0.001
SEG (Staphylococcal 
enterotoxin G)
Superantigen 1 125
323.00 (107.50-
1410.13)
76
2156.5 (565.88-
3468.13)
< 0.001
SEH (Staphylococcal 
enterotoxin H)
Superantigen 1 120 30.50 (13.94-494.69) 69 232.75 (23.63-7071.25) = 0.001
SEI (Staphylococcal 
enterotoxin I)
Superantigen 1 120 95.63 (38.00-1012.75) 68
2920.38 (1034.13-
5347.13)
< 0.001
SEJ (Staphylococcal 
enterotoxin J)
Superantigen 1 119 223.50 (96.50-553.75) 68
490.50 (195.81-
1071.88)
= 0.001
SEM 
(Staphylococcal 
enterotoxin M)
Superantigen 1 127 72.50 (18.00-374.50) 63
2424.75 (480.75-
4780.50)
< 0.001
SEN (Staphylococcal 
enterotoxin N)
Superantigen 1 128 92.38 (28.81-328.06) 63
1769.00 (384.00-
3827.50)
< 0.001
SEO (Staphylococcal 
enterotoxin O)
Superantigen 1 127 34.00 (10.50-140.00) 63 305.25 (90.25-546.50) < 0.001
SEQ (Staphylococcal 
enterotoxin Q)
Superantigen 1 119 34.75 (12.75-130.50) 67 591.50 (47.00-4981.75) < 0.001
SER (Staphylococcal 
enterotoxin R)
Superantigen 1 123 147.75 (59.50-424.50) 49
429.00 (168.38-
1488.75)
< 0.001
TSST-1 (Toxic shock 
syndrome toxin 1)
Superantigen 1 125
163.75 (53.13-
7202.00)
74
2626.00 (67.63-
6578.75)
= 0.152
Immune modulators (non-superantigen)
HlgB (Gamma-
hemolysin 
component B)
Pore forming toxin 1 128
8217.13 
(4881.06-11112.38)
62
12963.00 
(9359.13-14555.13)
< 0.001
LukD (Leukotoxin D)
Cell lysis of 
neutrophils 1
127
8894.00 
(3666.75-12978.50)
62
14705.13 
(12837.31-15792.00)
< 0.001
LukE (Leukotoxin E)
Cell lysis of 
neutrophils 1
127
10373.75 
(5276.75-14596.75)
62
15897.13 
(14282.13-16821.13)
< 0.001
LukS (Leukotoxin S)
Cell lysis of 
neutrophils 1
126
4648.50 
(2034.31-8396.38)
62
9663.00 
(5065.19-12566.82)
< 0.001
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Table s1. Overview of 55 S. aureus antigens with function and MFI values  (continued)
S. aureus antigen Description n
Igg sMA (median, 
IQR)
n
Igg DAVos (median, 
IQR)
P- value 
*
SSL1 
(Staphylococcal 
superantigen like-
protein 1)
Immune-
modulation. 
Limits neutrophil 
chemotaxis2
125
3587.50 
(491.38-13491.00)
75
12624.13 
(6916.50-15991.94)
< 0.001
SSL3 
(Staphylococcal 
superantigen like-
protein 3)
TLR signalling 
inhibition3
125
7765.50 
(1355.75-12847.38)
75
12696.00 
(9673.75-15214.75)
< 0.001
SSL5 
(Staphylococcal 
superantigen like-
protein 5)
Prevents neutrophil 
rolling on activated 
endothelial cells3
125
1983.25 
(891.63-4833.00)
75
4066.00 
(2792.75-5798.00)
< 0.001
SSL9 
(Staphylococcal 
superantigen like-
protein 9)
Complement 
inhibitor4
125
11502.50 
(5653.50-14845.38)
76
14879.38 
(11952.56-15889.25)
< 0.001
SSL10 
(Staphylococcal 
superantigen like-
protein 10)
Phagocytosis 
inhibition3
124
5597.88 
(2168.06-10963.44)
76
13037.25 
(11159.19-14609.50)
< 0.001
SSL11 
(Staphylococcal 
superantigen like-
protein 11)
Chemotaxis 
inhibition3
125 179.50 (37.88-647.75) 75
1239.25 (480.75-
2996.50)
< 0.001
SCIN 
(Staphylococcal 
complement 
inhibitor)
Chemotaxis 
inhibitory, inhibits C3 
convertase 1
123
4420.00 
(1442.00-10108.50)
49
14291.00 
(11844.75-15457.75)
< 0.001
CHIPS (Chemotaxis 
inhibitory protein of 
Staphylococci)
Chemotaxis 
inhibition3
122
5442.13 
(621.44-8926.31)
60
11027.63 
(7898.25-12846.00)
< 0.001
SAK 
(Staphylokinase)
Binding/ inactivate 
complement C3b 
and IgG bound to 
surface bacterial 
cells 5
118
646.88 (75.94-
3691.31)
63
2433.00 (936.25-
5507.50)
< 0.001
EsxB (ESAT-6 
secretion system 
extracellular B)
Interferes with 
host cell apoptotic 
pathways 6
125 28.00 (6.25-71.38) 76 53.50 (25.75-97.00) = 0.001
FlipR (Formyl 
peptide receptor-
like 1 inhibitor)
Inhibition of 
opsonophagacytosis 
and killing by 
neutrophils5 
Chemotaxis 
inhibition3
122
4336.88 
(499.81-9194.56)
66
10812.25 
(7690.13-13461.31)
< 0.001
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Table s1. Overview of 55 S. aureus antigens with function and MFI values  (continued)
S. aureus antigen Description n
Igg sMA (median, 
IQR)
n
Igg DAVos (median, 
IQR)
P- value 
*
FlipR-like (Formyl 
peptide receptor-
like1 inhibitor like)
Chemotaxis 
inhibition3
123
3537.00 
(748.00-8240.00)
74
10785.00 
(6972.56-13626.94)
< 0.001
Efb (Extracellular 
fibrinogen-binding 
protein)
Inhibits complement 
activation and blocks 
opsonophagocytosis 
3, 5
119
1551.25 
(688.50-3872.00)
67
6621.75 
(3033.50-9304.75)
< 0.001
Eap (Extracellular 
adhesive protein)
Phagocytic killing 
inhibition3
Prevent neutrophil 
attachment to and 
migration through 
endothelial cells 5
128
8878.63 
(3729.81-12629.06)
64
11957.38 
(8675.69-14846.63)
< 0.001
EapH1 (Extracellular 
adherence protein 
homolog 1)
Phagocytic killing 
inhibition3
128
39.75  
(0.00-552.38)
64
1853.00  
(509.69-4266.69)
< 0.001
EapH2 (Extracellular 
adherence protein 
homolog 2)
Phagocytic killing 
inhibition3
117
4953.25 
(646.13-13314.88)
61
11998.25 
(8251.13-14424.38)
< 0.001
ETA (Exfoliative 
toxin A)
Serine proteases: 
hydrolyze 
desmosomal 
proteins in the skin 7
126
68.25  
(18.88-332.12)
62
2969.75  
(164.75-10600.31)
< 0.001
ETB (Exfoliative 
toxin B)
Serine proteases: 
hydrolyze 
desmosomal 
proteins in the skin 7
127
52.00  
(20.75-127.75)
62
162.88  
(42.38-5042.50)
< 0.001
MscRAMMs
ClfA (Clumping 
factor A)
Adhesin: (fibrinogen) 
1 120
572.75  
(145.25-2259.31)
69
3876.50  
(1739.38-6289.63)
< 0.001
ClfB (Clumping 
factor B)
Adhesin: (fibrinogen) 
1 101
417.75  
(55.75-1104.75)
24
7453.25  
(3470.50-9834.63)
< 0.001
FnbpA (Fibronectin-
binding protein A)
Adhesin: 
(fibronectin) 1
108
214.25  
(90.75-1061.00)
64
3342.25  
(854.50-4989.19)
< 0.001
FnbpB (Fibronectin-
binding protein B)
Adhesin: 
(fibronectin) 1
119
102.00  
(48.25-346.50)
68
425.25  
(194.75-1090.81)
< 0.001
SdrD (Serine-
aspartate repeat 
protein D)
S.aureus adhesion8 120
144.88  
(63.38-288.94)
68
395.13  
(138.63-659.38)
< 0.001
SdrE (Serine-
aspartate repeat 
protein E)
S.aureus adhesion9 120
177.25  
(50.50-1186.38)
64
2414.63  
(1144.19-5548.81)
< 0.001
SasG (S. aureus 
surface protein G)
Biofilm formation 10 120
101.63  
(18.38-387.75)
69
620.00  
(342.63-1548.00)
< 0.001
165IgG against S. aureus is associated with severe atopic dermatitis
Table s1. Overview of 55 S. aureus antigens with function and MFI values  (continued)
S. aureus antigen Description n
Igg sMA (median, 
IQR)
n
Igg DAVos (median, 
IQR)
P- value 
*
Membrane damaging molecules
Alpha toxin Pore forming toxin 1 128
1357.88 
(348.06-3391.19)
62
4356.75 
(2713.56-6074.63)
< 0.001
Hlb (Beta-
hemolysin)
Pore forming toxin 1 127
669.50  
(181.00-4042.75)
64
6608.13  
(2150.88-11467.31)
< 0.001
Housekeeping function
IsaA 
(Immunodominant 
Staphylococcal 
antigen A)
Assist in cell wall 
expansion, turnover, 
growth, and cell 
separation 11
117
5435.25 
(2779.50-9894.38)
69
10696.75 
(6047.63-14414.50)
< 0.001
LytM 
(Peptidoglycan 
hydrolase)
Assist in cell wall 
expansion, turnover, 
growth, and cell 
separation 12
120
104.00  
(40.50-877.13)
68
830.25  
(80.81-4097.06)
< 0.001
Alt2 (alanine 
transaminase 2)
Unknown 128
9086.13 
(4358.75-13817.69)
64
15067.00 
(13257.38-16258.88)
< 0.001
proAlt Unknown 128
72.25  
(0.00-475.06)
76
3094.75  
(404.38-10124.19)
< 0.001
Aly Unknown 83
216.50  
(76.75-506.75)
24
1662.13  
(656.13-4573.75)
< 0.001
Lipase
Enzyme: lipase 13
(spreading, nutrition)
124
1815.63 
(378.13-5336.38)
75
6898.00 
(3489.50-11195.25)
< 0.001
Nuc (Nuclease)
Enzyme: nuclease 
(nutrition)14
126
1580.13 
(447.81-6626.31)
63
5543.25 
(2052.31-9983.75)
< 0.001
IsdA (Iron-
responsive surface 
determinants A)
Ferritin uptake 1 117
6535.25 
(3178.00-9277.75)
65
8648.25 
(4964.63-11689.13)
= 0.001
IsdH (Iron-
responsive surface 
determinants H)
Ferritin uptake 1 115
373.75  
(39.50-1041.50)
53
1686.50  
(664.88-2499.88)
< 0.001
N = number of patients of which the MFI values could be included for calculation of medians (see exclusion 
criteria for measurements in the methods section of the manuscript)
* P-value SMA vs. DAVOS, Mann-Whitney U test
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Table s2a. Results linear regression analysis GMA 
study – association with SA-EASI
Antigen Regression
 coefficient (SE)
95% CI P-value
CHIPS 0.015 (0.052) -0.088-0.115 0.770
SKIN 0.080 (0.058) -0.037-0.193 0.171
Alpha toxin -0.031 (0.053) -0.135-0.073 0.564
Hlb -0.032 (0.065) -0.156-0.106 0.608
Nuc 0.026 (0.065) -0.118-0.139 0.693
ETA 0.017 (0.062) -0.102-0.134 0.793
ETB 0.043 (0.060) -0.076-0.167 0.484
SAK 0.035 (0.059) -0.095-0.143 0.537
SSL11 0.063 (0.047) -0.031-0.156 0.181
Lipase 0.021 (0.062) -0.109-0.140 0.721
Aly 0.077 (0.092) -0.108-0.244 0.418
Alt2 0.069 (0.055) -0.045-0.166 0.214
ProAlt -0.029 (0.064) -0.152-0.105 0.634
EsxB -0.062 (0.068) -0.189-0.081 0.356
SEB -0.043 (0.061) -0.164-0.074 0.482
SEC -0.060 (0.062) -0.184-0.067 0.322
SED -0.035 (0.071) -0.169-0.114 0.633
SEE 0.121 (0.061) -0.003-0.243 0.051
SEG 0.041 (0.048) -0.053-0.142 0.405
SEH 0.028 (0.069) -0.106-0.171 0.683
SEI 0.032 (0.046) -0.057-0.125 0.473
SEJ -0.105 (0.071) -0.248-0.035 0.142
SEM 0.032 (0.045) -0.053-0.126 0.497
SEN 0.104 (0.057) -0.009-0.217 0.069
SEO 0.012 (0.049) -0.079-0.112 0.802
SEQ -0.041 (0.066) -0.167-0.089 0.557
SER  0.089 (0.058) -0.017-0.203 0.152
TSST-1 0.067 (0.067) -0.071-0.187 0.322
FnbpA 0.007 (0.060) -0.110-0.124 0.905
FnbpB -0.059 (0.075) -0.202-0.097 0.435
SdrD -0.027 (0.078) -0.179-0.117 0.723
ClfA 0.006 (0.059) -0.110-0.115 0.914
ClfB 0.063 (0.077) -0.095-0.217 0.397
IsdH 0.137 (0.068) 0.013-0.284 0.054
EfB 0.043 (0.047) -0.042-0.148 0.368
SasG -0.075 (0.062) -0.204-0.051 0.062
LytM -0.056 (0.066) -0.178-0.078 0.398
EapH1 0.035 (0.066) -0.090-0.172 0.586
EapH2 0.038 (0.066) -0.092-0.166 0.568
Bootstrapping iter 1000 for all antigens, except SEN
Table s2b. Results linear regression analysis SMA 
study – association with TARC
Antigen Regression
coefficient (SE)
95% CI P-value
LukS 0.259 (0.144) -0.017-0.541 0.064
CHIPS 0.174 (0.196) -0.207-0.572 0.382
SKIN 0.273 (0.165) -0.052-0.596 0.099
Alpha toxin 0.075 (0.154) -0.205-0.402 0.630
Hlb -0.130 (0.217) -0.563-0.311 0.559
HlgB 0.207 (0.109) -0.009-0.424 0.059
Nuc -0.097 (0.179) -0.459-0.227 0.600
ETA -0.106 (0.248) -0.590-0.412 0.668
ETB -0.070 (0.216) -0.522-0.350 0.744
SAK 0.217 (0.196) -0.190-0.589 0.268
SSL1 0.315 (0.196) -0.047-0.734 0.113
SSL11 0.105 (0.155) -0.177-0.411 0.504
FlipR 0.328 (0.190) -0.031-0.725 0.088
Lipase 0.04 (0.168) -0.283-0.329 0.981
Aly 0.480 (0.349) -0.187-1.188 0.179
Alt2 0.237 (0.133) -0.011-0.514 0.074
ProAlt -0.051 (0.196) -0.440-0.333 0.802
EsxB -0.334 (0.201) -0.740-0.064 0.096
SEB 0.069 (0.200) -0.362-0.460 0.720
SEC -0.106 (0.207) -0.525-0.277 0.625
SED -0.379 (0.200) -0.805-0.020 0.062
SEG -0.062 (0.203) -0.452-0.344 0.765
SEH 0.205 (0.221) -0.237-0.654 0.351
SEI 0.237 (0.186) -0.100-0.643 0.193
SEJ -0.233 (0.256) -0.761-0.258 0.360
SEM 0.274 (0.206) -0.100-0.703 0.183
SEN 0.131 (0.190) -0.245-0.507 0.493
SEO -0.169 (0.192) -0.533-0.220 0.384
SEQ 0.238 (0.207) -0.183-0.643 0.259
SER -0.086 (0.224) -0.545-0.351 0.707
TSST-1 0.090 (0.210) -0.331-0.497 0.659
FnbpA 0.160 (0.205) -0.224-0.581 0.448
FnbpB -0.265 (0.215) -0.708-0.154 0.233
SdrD -0.402 (0.243) -0.883-0.054 0.106
SdrE- 0.155 (0.244) -0.633-0.309 0.522
ClfA 0.128 (0.197) -0.249-0.518 0.507
ClfB 0.215 (0.217) -0.170-0.678 0.307
IsdH 0.243 (0.199) -0.132-0.629 0.233
SasG -0.295 (0.231) -0.734-0.153 0.203
IsaA 0.128 (0.167) -0.201-0.456 0.457
LytM -0.186 (0.242) -0.684-0.266 0.450
EapH1 0.270 (0.200) -0.127-0.664 0.179
EapH2 0.365 (0.255) -0.066-0.950 0.156
Bootstrapping iter 1000 for all antigens, except SEN
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Table s2c. Results linear regression analysis DAVOS 
study – association with SA-EASI
Antigen Regression
coefficient (SE)
95% CI P-value
LukD 0.058 (0.067) -0.060-0.197 0.413
LukE 0.107 (0.078) -0.038-0.216 0.224
LukS 0.103 (0.064) -0.014-0.233 0.118
CHIPS -0.009 (0.071) -0.162-0.109 0.898
SKIN -0.034 (0.099) -0.191-0.194 0.762
Alpha toxin 0.074 (0.095) -0.116-0.277 0.462
Hlb 0.155 (0.058) 0.041-0.262 0.010 *
HlgB 0.022 (0.051) -0.088-0.120 0.658
Nuc 0.030 (0.063) -0.099-0.154 0.642
ETA 0.079 (0.059) -0.049-0.180 0.168
ETB 0.029 (0.067) -0.119-0.149 0.655
SAK -0.005 (0.068) -0.124-0.138 0.938
SSL1 0.080 (0.071) -0.042-0.242 0.290
SSL3 0.080 (0.094) -0.052-0.306 0.519
SSL5 0.085 (0.094) -0.048-0.291 0.473
SSL9 0.095 (0.097) -0.026-0.323 0.474
SSL10 0.090 (0.093) -0.029-0.299 0.449
SSL11 0.058 (0.069) -0.057-0.225 0.384
FlipR 0.085 (0.089) -0.044-0.293 0.372
FlipRL 0.117 (0.083) -0.006-0.308 0.299
Lipase 0.111 (0.087) -0.039-0.298 0.257
Aly 0.149 (0.122) -0.121-0.367 0.245
Alt2 0.015 (0.065) -0.109-0.142 0.800
ProAlt 0.010 (0.049) -0.087-0.111 0.842
EsxB 0.055 (0.064) -0.066-0.201 0.393
SEA 0.078 (0.066) -0.046-0.206 0.247
SEB 0.023 (0.072) -0.122-0.161 0.760
SEC 0.068 (0.067) -0.082-0.182 0.346
SED 0.074 (0.074) -0.074-0.224 0.313
SEE 0.119 (0.069) -0.033-0.248 0.102
SEG 0.165 (0.069) 0.050-0.326 0.019 *
SEH -0.024 (0.063) -0.152-0.091 0.703
SEI 0.054 (0.065) -0.065-0.183 0.409
SEJ 0.067 (0.075) -0.075-0.223 0.380
SEM -0.017 (0.072) -0.0156-0.120 0.819
SEN 0.009 (0.062) -0.0113-0.133 0.902
SEO 0.098 (0.056) -0.015-0.209 0.083
SEQ 0.010 (0.063) -0.113-0.137 0.877
SER 0.023 (0.080) -0.132-0.179 0.795
TSST-1 0.045 (0.064) -0.079-0.176 0.479
FnbpA 0.050 (0.067) -0.099-0.167 0.448
FnbpB 0.151 (0.060) 0.029-0.261 0.015 *
SdrD -0.045 (0.065) -0.166-0.091 0.470
SdrE 0.050 (0.064) -0.086-0.160 0.418
ClfA 0.142 (0.067) 0.023-0.291 0.040 *
ClfB -0.047 (0.094) -0.246-0.131 0.618
Table s2d. Results linear regression analysis DAVOS 
study – association with TARC
Antigen Regression
coefficient (SE)
95% CI P-value
LukD 0.022 (0.349) -0.785-0.576 0.929
LukE 0.148 (0.538) -0.573-0.871 0.665
LukS 0.400 (0.239) -0.117-0.840 0.091
CHIPS 0.014 (0.379) -0.810-0.704 0.965
SKIN 0.065 (0.335) -0.592-0.755 0.865
Alpha toxin 0.593 (0.341) -0.043-1.303 0.092
Hlb 0.437 (0.333) -0.270-1.073 0.192
HlgB 0.054 (0.204) -0.374-0.448 0.801
Nuc 0.335 (0.292) -0.240-0.957 0.256
ETA -0.233 (0.393) -1.078-0.519 0.528
ETB 0.067 (0.381) -0.755-0.754 0.850
SAK 0.695 (0.302) 0.084-1.285 0.027 * 
SSL1 0.110 (0.392) -0.882-0.658 0.795
SSL3 0.413 (0.374) -0.061-1.310 0.435
SSL5 0.300 (0.358) -0.257-1.071 0.495
SSL9 0.315 (0.358) -0.207-1.197 0.480
SSL10 0.243 (0.355) -0.273-1.071 0.557
SSL11 0.515 (0.347) -0.109-1.212 0.155
FlipR 0.108 (0.395) -0.654-0.888 0.818
FlipRL 0.375 (0.343) -0.206-1.149 0.380
Lipase 0.661 (0.351) 0.094-1.454 0.058
Aly 0.485 (0.709) -0.889-1.879 0.485
Alt2 0.405 (0.324) -0.258-1.043 0.228
ProAlt 0.035 (0.315) -0.598-0.646 0.906
EsxB 0.257 (0.297) -0.363-0.858 0.363
SEA 0.154 (0.354) -0.557-0.861 0.655
SEB 0.326 (0.297) -0.203-0.923 0.286
SEC 0.167 (0.272) -0.312-0.751 0.535
SED -0.146 (0.267) -0.685-0.360 0.576
SEE -0.001 (0.341) -0.724-0.605 0.998
SEG 0.138 (0.335) -0.511-0.832 0.673
SEH 0.284 (0.338) -0.417-0.892 0.402
SEI 0.375 (0.288) -0.161-1.001 0.176
SEJ 0.215 (0.320) -0.355-0.886 0.521
SEM 0.110 (0.356) -0.617-0.749 0.756
SEN 0.123 (0.391) -0.609-0.926 0.760
SEO 0.324 (0.364) -0.427-1.085 0.353
SEQ 0.298 (0.336) -0.372-0.944 0.385
SER 0.270 (0.441) -0.664-1.128 0.536
TSST-1 0.074 (0.323) -0.541-0.706 0.809
FnbpA 0.040 (0.340) -0.659-0.723 0.910
FnbpB 0.522 (0.305) -0.059-1.122 0.092
SdrD 0.387 (0.320) -0.257-0.988 0.237
SdrE 0.000 (0.303) -0.564-0.596 0.998
ClfA 0.355 (0.263) -0.180-0.910 0.181
ClfB -0.346 (0.506) -0.1.328-0.627 0.508
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Table s2c. Results linear regression analysis DAVOS 
study – association with SA-EASI (continued)
Antigen Regression
coefficient (SE)
95% CI P-value
IsdH 0.113 (0.076) -0.028-0.260 0.138
EfB -0.023 (0.062) -0.139-0.101 0.707
IsdA 0.077 (0.082) -0.040-0.270 0.428
SasG 0.065 (0.066) -0.064-0.196 0.331
IsaA -0.045 (0.073) -0.184-0.105 0.513
LytM 0.026 (0.063) -0.101-0.151 0.643
Eap -0.006 (0.069) -0.133-0.140 0.936
EapH1 0.073 (0.072) -0.061-0.219 0.322
EapH2 0.026 (0.069) -0.087-0.182 0.711
* = significant P-value, Bootstrapping iter 1000 for all 
antigens
Table s2d. Results linear regression analysis DAVOS 
study – association with TARC (continued)
Antigen Regression
coefficient (SE)
95% CI P-value
IsdH 0.358 (0.329) -0.240-1.065 0.279
EfB -0.074 (0.384) -0.843-0.692 0.858
IsdA 0.416 (0.271) -0.008-1.031 0.223
SasG 0.215 (0.239) -0.225-0.751 0.383
IsaA 0.074 (0.284) -0.487-0.654 0.769
LytM -0.164 (0.385) -0.863-0.611 0.683
Eap -0.229 (0.307) -0.800-0.412 0.464
EapH1 0.625 (0.336) -0.027-1.287 0.078
EapH2 0.079 (0.221) -0.343-0.498 0.741
* = significant P-value, Bootstrapping iter 1000 for all 
antigens
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AbsTRAcT 
background
Collecting high quality samples for skin microbial analysis is challenging due to the 
low number of microorganisms on the skin. Studies comparing different available tech-
niques for skin sampling are scarce.
objective
This study compares the detection of total bacterial DNA, Staphylococcus (S.) aureus 
DNA, microbial diversity and fungi by two different methods, namely dry flocked swab-
bing and scrubbing.
Methods
As part of an ongoing study in atopic dermatitis, we collected 39 swab and 39 scrub 
samples from 16 patients. S. aureus specific and total bacterial DNA were measured with 
quantitative (q)PCR. To identify bacteria and fungi we sequenced the 16S rRNA gene and 
the fungal internal transcribed spacer region 1.
Results
The qPCR showed a higher absolute amount of total bacterial DNA in the scrubs 
(p<0.001). Sequencing of 16S rRNA identified 323 and 318 different genera in the swabs 
scrubs, respectively. The majority was identified equally well with the two techniques 
and biodiversity was not significantly different. Interestingly, we found fungal DNA more 
often in the scrubs than in the swabs (36% versus 9%).
conclusion
Scrubs result in a higher collection of bacterial and especially fungal DNA. Therefore, 
they are preferable for studying low-biomass skin areas or fungi.
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InTRoDucTIon 
Changes in the cutaneous microbial ecosystem are associated with skin diseases. For 
example, atopic dermatitis (AD) is characterized by overgrowth of Staphylococcus (S.) 
aureus.1 Advances in sequencing technologies and metagenomics have enabled more 
precise studies of the microbial composition of the skin, including the interactions be-
tween microbes.2 Together with these advances, questions arose about the optimal ap-
proaches to study the skin microbiota.3 Recent studies focused on primer selection and 
the quality control of sequencing runs.3-6 In addition, consistency in the sampled skin site 
was shown to be important, as bacterial communities appear to be body-site specific.7 
However, collecting a valid sample of the skin still remains a challenge due to the low 
number of microorganisms on skin compared to other body sites.8 There are different 
techniques to profile the skin microbiota, with skin punch biopsy, swabs, tape-stripping 
and scrubs being the most widely used. Punch biopsy gives a complete microbial profile 
of all the skin layers, but its use is limited by the invasiveness.9 Superficial swabs are 
practical and the smooth surfaced cotton swabs (premoistened) are often used for skin 
sampling.7 However, flocked (brush like) swabs could increase the detection of bacteria 
compared to smooth swabs. 10,11 The scrub was pioneered for culture-based studies and 
its use in microbiome studies has only been investigated in a single pilot study with 
three healthy volunteers.7,12,13 Compared to the swab, this technique might profile 
microbes at a deeper level of the skin, where bacterial composition and behaviour 
could be different.14-16 Each technique has its own specific sampling depth and usability 
characteristics, leading to possible variation in the type and density of the collected 
micro-organisms. The choice of sampling method depends on the research question, 
sampling site, the feasibility of the method and the amount of total DNA required for 
further analyses. Selecting the right technique is crucial. However, studies that compare 
sampling methods in relation to different skin microbial outcomes are scarce.
As part of an ongoing interventional study to understand the role of microbes in AD 
and changes in skin microbial populations after treatment, we compared total bacterial 
DNA, S. aureus DNA, microbial diversity and the presence of fungi between dry nylon-
flocked swabs and scrubs.
MeTHoDs
study design and patients
The aim of the study was to investigate skin microbial collection methods for use in 
a future interventional study in patients with AD.17,18 Patients were recruited between 
June 2014 and January 2015 in the Erasmus Medical Center and the Havenziekenhuis, 
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Rotterdam. Inclusion criteria were diagnosis of AD, age above 18 years and the abil-
ity to read the relevant patient information and provide informed consent. Criteria for 
exclusion were the use of systemic antibiotics, corticosteroids or immunosuppressive 
medication 6 months before the study and the use of topical antibiotics or steroids 7 
days before the study. AD was diagnosed according to the UK Working Party’s diagnostic 
criteria.19 Severity of AD was scored by the patient using the self-administrated eczema 
area and severity index (SA-EASI).20 Additional information about medication use and the 
presence of atopic diseases was retrieved via medical history. Swab- and scrub samples 
were collected from skin lesions in patients that met the criteria for inclusion (visit 1). A 
second, third and fourth swab- and scrub sample were taken one, two and three weeks 
after visit 1 (visit 2, 3, and 4), only in those patients that were positive for S. aureus at visit 
1 (figure S1). The medical ethical committee of the Erasmus Medical Center approved 
the study and written informed consent was obtained from all participants.
skin microbiome samples – swab and scrub
Microbial skin samples were collected from a skin lesion, preferably located at the 
antecubital fold. In case of absence of antecubital lesions, the most predominant skin 
lesion was chosen. Two types of samples were obtained, a swab and a scrub sample. 
These two samples were collected simultaneously from non-overlapping areas of the 
same skin lesion. First, a sterile dry nylon-flocked swab (Copan480CE) was rubbed along 
the antecubital crease for 30 seconds and put back in the tube containing liquid Amies 
Medium. The liquid medium was additionally extracted into an eppendorf. Second, a 
modified scrub method was used, based on the method of Williamson and Kligman.12,21 
A sterile PVC sampling ring with an internal diameter of 4 cm was placed just below the 
antecubital crease and 0.75 mL of sterile wash fluid (0,85% NaCl, 0.1% bacteriological 
peptone, 0.1% Tween 80) was added. After scrubbing the surface of the skin within the 
ring with a sterile swab for 1 min, the fluid was collected in a 2 ml eppendorf. Samples 
were stored at -80⁰C until further processing for DNA based analysis. All samples were 
collected by a medical doctor wearing sterile gloves.
The patients were informed to avoid bathing or showering in the 12 hours before 
sampling and could not use personal antibacterial hygiene products from 48 hours 
before sampling.
DnA isolation and qPcR
For cutaneous DNA isolation approximately 150 uL material was directly transferred 
to a DNA isolation plate and 0.5 mL phenol pH8.0 (Phenol solution, catalogue P4557, 
Sigma-Aldrich, St Louis, MO) was added. The samples were mechanically disrupted by 
bead beating twice for 3 minutes with a 96-well plate Beadbeater (Biospec Products, 
Bartlesville). Following bead beating, samples were centrifuged at 1880 rcf (4000rpm) 
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for 10 minutes to separate the aqueous and phenolic phases. The aqueous phase was 
transferred to a new 96-well plate and DNA was purified with the AGOWA mag Mini 
DNA Isolation Kit (AGOWA, LGC genomics, Berlin, Germany) in accordance with the 
manufacturer’s recommendations. After elution, the total bacterial load in each sample 
was assessed by quantitative (q)PCR using an universal bacterial primer-probe set.22 The 
total load of S. aureus DNA was assessed by qPCR using the following primers : 16S-S.
aur-F1 (5’-GCG AAG AAC CTT ACC AAA TCT TG-3’) and 16S-S.aur-R1 (5’-TGC ACC ACC TGT 
CAC TTT GTC-3’), and the 16S-S.aur MGB Taqman® probe (5’-CAT CCT TTG ACA ACT CT-3’) 
with a FAM label.
16s rRnA sequencing 
Analysis of the microbiome composition was performed by massively parallel sequenc-
ing of the archaeal and bacterial V4 hypervariable region of the 16s rRNA gene on an 
Illumina MiSeq sequencer (Illumina, San Diego, CA). To prevent over-amplification, the 
barcoded DNA fragments spanning the V4 hypervariable region were amplified from a 
standardized level of template DNA (1 ng). Amplicons generated using adapter primers 
F515 and 806R (using 30 PCR cycles), were bidirectionally sequenced as described previ-
ously.24 Pre-processing, analysis of unique sequences and classifications were performed 
using modules implemented in the Mothur software platform.25 Standardized mock 
communities were included to check for technical performance of all experimental 
steps. Sequences were grouped with the OTU clustering module in MOTHUR with a 
0% cut-off leading to separate clusters for each unique sequence. To assign taxonomic 
information to the different unique sequences, they were blasted in the Ribosomal Data-
base Platform (RDP).26 Negative control samples of the lysis buffer contained substantial 
amounts of Schlegelella, and Enhydrobacter, both described as contaminant genera 
before.23 Therefore, these genera were excluded for further analysis. Shannon diversity 
index was determined to describe the microbial diversity for the swabs and the scrub 
samples.
sequencing of Fungal ITs amplicons
Barcoded amplicons of fungal internal transcribed spacer regions (ITS) were generated 
using a two step PCR approach. Fungal ITS-1 regions were first amplified with the fol-
lowing primers: nex-ITS-BITS-F: TCGTCGGCAGCGTCACCTGCGGARGGATCA and nex-ITS-
B58S3-R GTCTCGTGGGCTCGGGAGATCCRTTGYTRAAAGTT (adapted from Bokulich &   
Mills27). Each reaction contained 5ul undiluted stock DNA, 1 unit Phusion Hot start II (F-
549L) enzyme, 1x High Fidelity buffer, 200nM deoxynucleotide triphosphates (Thermo 
Scientific) and nuclease free PCR grade water to a  25 µl final reaction volume. PCR reac-
tions consisted of an initial denaturation step of 98 °C, for 5 min and 30 amplification 
cycles (98 °C  for 10 sec,  annealing 48 °C for 30 sec and elongation 72 °C for 30 sec and 
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final extension step ( 72 °C for 5 min) followed by cool down (10 min at 4 °C). A negative 
control (blank) was included for each set of 24 PCR reactions. Reactions were cleaned 
by solid-phase reversible immobilization (SPRI) using AMPure XP SPRI beads (Beckman 
Coulter, Inc.). Dual barcodes (8 bp) and Illumina Sequencing adapters were attached 
using the Nextera XT Index Kit (Illumina, San Diego, CA) according to the manufacturer’s 
protocols. Barcoded amplicons were quantified using the Caliper LabChip GX II system 
(Perkin Elmer, Hopkinton, USA), normalized to the same concentrations, pooled, and gel 
purified using the Qiaquick spin kit (Qiagen) and AMPure XP SPRI beads. Pooled ampli-
cons were 250-bp paired-end sequenced using the MiSeq (Illumina). Raw Illumina fastq 
files were demultiplexed, quality filtered, and analyzed using modules implemented in 
the Mothur software platform.25 Unique sequences were taxonomically classified by the 
RDP-II Naïve Bayesian Classifier 26 using a 60% confidence threshold against the Mothur 
formated UNITE Database (Version No. 7).25 The mock samples confirmed good technical 
performance.
statistical analysis 
Patient and sample characteristics are presented with median and interquartile range 
(IQR) for continuous data and counts and percentages for categorical data. Total bacte-
rial DNA, S. aureus specific DNA and Shannon diversity were compared between baseline 
swabs and baseline scrubs, using a non-parametric Wilcoxon signed rank test for related 
samples. A linear mixed effects model was used to account for the repeated measure-
ments (different time points) for each patient.28 This mixed effects model determined 
if there was a significant difference between scrubs and swabs regarding uptake of S. 
aureus specific DNA, total bacterial DNA and Shannon diversity, adjusted for the use of 
antibiotics (during the study), use of antibacterial products (before/during the study) 
and the time variable. P-values were corrected for multiple testing (3 tests) and therefore 
a P-value of ≤0.0167 was considered significant. To display the microbial composition 
per sample, as measured using 16S rRNA, the different genera were expressed using 
the mean relative abundance per sample. SPSS version 21 was used for descriptive data 
analysis. Microsoft Excel 2010 was used to generate graphs and figures.
ResulTs
Patient characteristics 
For this study, 21 patients with AD were screened for participation (visit 1). Of these, 
17 patients were included for analysis as four patients did not meet the diagnostic 
criteria for AD. Ten of these 17 patients were positive for S. aureus at the screening. To 
mimic the longitudinal design of the intervention study and to take into account the 
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microbial variation over time, a follow-up including three measurements was performed 
in these ten patients (visits 2 to 4; one week between each visit; figure S1). The mean 
self-reported eczema severity at baseline, measured with the SA-EASI 20, was 23.2 (IQR 
17.48; scale 0-96). Patient characteristics are shown in table 1.
sample characteristics
The screening of 17 patients and follow-up of ten patients yielded a total of 47 swab- 
and 42 scrub samples. For an optimal comparison between swab and scrub samples, 
we included only swab-scrub pairs that were taken at the same skin site at the same 
time. Thirty-nine swab-scrub pairs could be included, of which 37 were taken from 
the antecubital fold, one from the knee and one from the upper arm. Of the 39 paired 
swab-scrub samples, 38 and 35 (obtained from 16 patients) could be included for qPCR 
and sequencing analysis, respectively. One swab and four scrub samples did not contain 
sufficient bacterial DNA to generate a PCR amplicon for qPCR or sequencing respectively 
(figure S1).
Table 1. Patient characteristics (n=17)
Male : female 6 : 11
Age 
Median (IQR) 38 (26) 
Atopy (n (%)) 
Asthma 9 (52.9) 
Rhinitis 13 (76.5) 
Food allergy 9 (52.9) 
Age of onset (n (%)) 
Early childhood 14 (82.4) 
Adult 3 (17.6) 
sA-eAsI baseline (range 0-96)†
Median (IQR) 23.2 (17.48) 
use of medication at start of the study (n(%))
Emollient 17 (100) 
Topical calcineurin inhibitor 2 (11.8) 
Topical steroids 14 (82.4) 
Topical OTC antibacterial (shower) product 1 (5.9) 
use of medication during the study (other than emollient) (n(%))
Topical calcineurin inhibitor 2 (11.8) 
Topical steroids 5 (29.4) 
Topical OTC antibacterial (shower) product 10 (58.9) 
Systemic antibiotics 1 (5.9) 
† n=15 due to missing data, OTC = over the counter
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Total bacterial DnA and S. aureus DnA – swab vs. scrub (qPcR) 
Comparison of the scrubs and the swabs that were collected at baseline in 13 patients, 
showed that the absolute amount of both total bacterial DNA and S. aureus DNA was 
higher in the scrub samples, indicating a better resolution/sensitivity of the scrub mea-
surement. However, when the variation at different time points and use of antiobiotics/
antibacterial products (during the study) was taking into account (Methods section; 
38 samples), only the total amount of bacterial DNA found with qPCR was significantly 
higher in the scrubs (log1.23fg/ul; p<0.001; table 2a-b).
Microbial diversity – swab vs. scrub (16s rRnA sequencing)
In the 35 swabs that could be analysed with 16S rRNA sequencing, a total of 441044 
reads could be assigned to 321 genera. These belonged to 20 different phyla of which 
Firmicutes, Proteobacteria, Actinobacteria and Bacteriodetes were most abundant. The 
five most predominant genera found at baseline (visit 1), available from 13 patients, 
were Staphylococcus (60%), Corynebacterium (6%), Streptococcus (5%), Micrococcus (2%) 
and Paracoccus(2%). In the 35 scrub samples, 533004 high quality reads belonging to 
316 different unique sequences and 15 different phyla were obtained. Staphylococcus 
(76%), Corynebacterium (7%), Micrococcus (2%), Streptococcus (2%) and Acinetobacter 
(1%) were the five most predominant genera. Figure 1 shows the mean relative abun-
dances of the 5 predominant genera per sample per technique. Of the 356 detected 
genera, 281 were identified by both sampling methods (78.9%). These represented over 
99% of the total reads, showing that dominant genera are detected equally well by the 
Table 2a. Baseline scrubs versus baseline swabs 
swab (median (IQR)) scrub (median (IQR)) P- value
total bacterial DnA (fg/ul) 14888 (6355-26192) 144828 (79881-589027) 0.001*
S. aureus DnA (fg/ul) 83 (0-453) 547 (107-9518) 0.008*
shannon-diversity 2.93 (2.37-4.29) 2.31 (1.50-3.82) 0.019
The analysis includes 13 baseline samples from 13 individuals. All p values are calculated using Wilcoxon signed 
rank test for related samples. * significant P-value (<0.0167)
NOTE: The table presents absolute amounts. The relative amount of S. aureus compared to the complete micro-
biome cannot be calculated due to primer specific differences between the specific S. aureus primer and the 
universal primer for total bacterial DNA.
Table 2b. Mixed effects model scrub versus swab 
coefficient (95% cI) P- value
log total bacterial DnA (fg/ul) 1.23 (0.58-1.88) < 0.001*
log S. aureus DnA (fg/ul) 0.94 (-0.50-2.38) 0.195
shannon-diversity 0.73 (-1.88-0.43) 0.210
The analysis includes 38 samples from 16 individuals. * significant P-value (<0.0167)
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swab and the scrub method (figure 2). The Shannon diversity index indicated that bacte-
rial diversity did not significantly differ between the swab and the scrub samples (table 
2a-b; p=0.210).
Fungi
Fungal DNA was found in four of the 47 collected swabs (8.5%). These four swabs be-
longed to four different individuals. In the scrub samples, fungal DNA was present in 15 
of the 42 samples (35.7%), belonging to 8 individuals. More different unique sequences 
were identified in the scrubs (285) than in the swabs (130). The fungal generum that was 
most abundant in both the swabs and scrubs was Malassezia (table S1).
Figure 1. Relative abundance of 5 most abundant genera in (a) swabs and in (b) scrubs 
a. 
 
b.  
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NOTE: Numbers 1 to 16 refer to the 16 different patients. v1-v4 refer to the 4 different visits, all with one week in 
between. Individual nr. 13 started oral AB during the study.
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DIscussIon
This study compares the use of dry flocked swabs and scrubs to measure the skin mi-
crobiota in patients with AD, adjusting for a time variable and the use of antibacterial 
products (during the study) in a mixed model. A higher absolute amount of both bacte-
rial and fungal DNA was recovered from the scrub samples, compared to the swabs. The 
potential of the scrub method to increase bacterial discovery rates was described earlier 
based on culture methods.29 Secondly, dry swabs and scrubs were found to detect the 
dominant genera equally well at a given time (figure 2). This confirms that dry swabs can 
be used for microbiome analysis of the skin. Finding the same bacterial species using a 
swab and a scrub method, suggests that the deeper level (reached by the scrub) har-
bours no different bacteria from the superficial layer. It also raises the question whether 
the scrub actually reaches much deeper than the swab. What technique should be used 
for microbiome experiments depends on the type of study.
The increased resolution of the scrub makes it the preferred method, especially 
for characterizing fungi, rare microorganisms and for low biomass areas of the skin. 
However, dry flocked swabs are more user-friendly, can be applied on all skin sites and 
identify the dominant sequences of the microbiome equally as well as scrubs. Therefore, 
Figure 2. Venn diagram illustrating the observed overlap of (a) the identified reads (sequences) and (b) the 
identified genera, using 36 swabs and scrubs
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the swabs can be considered for large scale studies and for body sites that are difficult 
to sample with the scrub.
The four most abundant genera that we found on the skin with 16S rRNA sequencing 
were Staphylococcus (Firmicutes), Corynebacteria (Actinobacteria), Streptococcus (Fir-
micutes) and Micrococcus (Actinobacteria), representing common bacterial phyla of the 
normal skin microbiota.30 A clear dominance of staphylococci was found, as expected in 
patients with AD.31 We found a low abundance of fungi, with fungal DNA in only 36% of 
the scrub samples and in less than 10% of the swab samples. This indicates the impor-
tance of using adequate collection methods when sampling the skin for fungi. The skin 
fungal microbiota in healthy controls mainly consists of the genus Malassezia.32 Patients 
with AD are thought to have a higher abundance and diversity of Malassezia species 
compared to controls, suggesting a contribution of fungal species to AD.33 In our AD 
patients, Malassezia was the most abundant genus on the skin. However, we were not 
able to draw any conclusions about the relationships between fungi on the skin and AD.
Limitations of this study include the use of the 515F/806R primer for amplification of 
the V4 variable region, a standard primer at the time we performed our analysis. The 
806R primer is now known for its poor coverage of Propionibacteria. Recent studies 
were published that recommend amplification of the V1-V3 region for the skin or a the 
use of a modified V4 primer.4,5 In our samples Propionibacterium were low abundant. 
However, this could also be inherent to eczema lesions where staphylococci overgrow. 
We do not expect that the choice of sequence region influences our conclusions about 
the swab-scrub comparison. Our study included negative controls (lysis buffer), but 
contamination from other sources e.g. the air or the swab solution (prepared sterile) 
cannot be excluded. We used a cohort of AD patients in this study and the results could 
be specific for this group. The use of antibacterial products during the study could have 
influenced the bacterial composition on the skin. However, this effect is expected to 
be equally present in the swabs as in the scrubs. Finally, the scrub method itself has 
some practical limitations as the collection of scrub samples is restricted to areas of the 
body where the cup can be placed. Despite these limitations, this study provides insight 
into the specific characteristics of different skin microbiota collection methods which is 
important for designing future skin microbiome studies.
In conclusion, scrubs result in increased yields of bacterial and especially fungal DNA. 
This increases the resolution of the measurement and makes the scrub preferable when 
working with fungi or low- biomass skin areas. However, dry flocked swabs identify the 
dominant genera of the bacterial microbiota equally as well as scrubs. Therefore, swabs 
can be considered for large population studies that examine higher-biomass areas of 
the skin.
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suPPleMenTARy MATeRIAl 
Figure s1. Flowchart of the included patients and collected samples
Patients screened
N=21
Patients included 
N=17
Visit 1 
N=17
Visit 2 
N=10
Visit 3 
N=10
Visit 4 
N=10
N=17
N=10
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N=10
N=16*
N=9*
N=8**
N=9*
Total scrubs 
N=42
Total swabs 
N=47
Swab/scrub 
combination 
taken at same 
location
N=39 
(16 patients)
qPCR
   N=38^ 
16s rRNA
sequencing
N=35^^ 
Patients
Samples for analysis 
ScrubsSwabs
* 1 missing (eczema on the volar hand making scrub not feasible)
** 2 missings (eczema on the volar hand + logistic problem)
^ 1 missing samples (failure to collect DNA)
^^ 4 missing samples (bacterial DNA yield to low to generate a PCR 
amplicon)
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Table s1. Presence of fungal genera in the swab and the scrub samples
swab
number of sequences per sample 
(n=4)
Mean (range)
scrub
number of sequences per sample 
(n=15)
Mean (range)
Total fungal DnA 31173 (22780-40086) 37663 (20511-85031)
Malassezia 7554 (2172-13555) 13620 (112-43939)
unclassified 6263 (982-14500) 1365 (0-4519)
unclassified_Malasseziales 5477 (3655-7118) 3623 (118-8994)
candida 4036 (0-10823) 626 (0-4056)
unclassified 2830 (1308-3490) 2566 (150-8160)
cladosporium 821 (43-1825) 1289 (0-4099)
cryptococcus 317 (0-919) 664 (0-3954)
sporobolomyces 127 (31-267) 5305 (0-74381)
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AbsTRAcT 
background
Atopic dermatitis (AD) is associated with a reduced skin microbial diversity and over-
growth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonization 
in the complex pathogenesis remains unclear and studies on the effect of antistaphylo-
coccal therapy in non-infected AD show contradictory results. Long-term anti-S. aureus 
interventions might be needed to restore the microbial balance, but carry the risk of 
bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, 
specifically kills S. aureus leaving other skin commensals unharmed. Bacterial resistance 
towards endolysins has not been reported, nor is it expected, which allows us to study 
its effect as long-term antistaphylococcal treatment in non-infected AD.
Methods
This is a multi-center, placebo controlled, double blinded and randomized superiority 
trial with a parallel group design. A total of 100 participants, aged 18 years or older, diag-
nosed with moderate to severe AD and using a topical corticosteroid in the weeks before 
enrolment are included in the study. The study is executed in the Erasmus MC University 
Medical Centre Rotterdam in collaboration with the Havenziekenhuis Rotterdam. After 
a 2-week run-in period to standardize the corticosteroid use with triamcinolone aceton-
ide 0.1% cream, participants will be randomized to either treatment with Staphefekt in a 
cetomacrogol-based cream or a placebo for 12 weeks, followed by an 8-week follow-up 
period. The primary objective is to assess the difference in the need for corticosteroid 
co-therapy between the Staphefekt and the placebo group, measuring the number of 
days per week of corticosteroid cream (triamcinolone) use. Secondary outcomes include 
the difference in use of corticosteroid cream measured in grams, differences in clinical 
efficacy, quality of life (QoL), microbial composition (including S. aureus) between the 
Staphefekt and the placebo group, and the safety and tolerability.
Discussion
The results of this trial will provide data about the effect of long-term antistaphylococcal 
therapy with Staphefekt on corticosteroid use, clinical symptoms and QoL in patients 
with moderate to severe AD. Additional data about growth characteristics of the skin 
microbiome, including S. aureus, will give insight in the role of the microbiome as a fac-
tor in the pathophysiology of AD. 
Trial registration ClinicalTrials.gov, NCT02840955. Registered on 11 July 2016.
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bAckgRounD
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is associated with 
reduced quality of life (QoL), primarily due to an itchy skin.1-3 The disease is character-
ised by reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus, a 
bacterium that can aggravate skin inflammation via the production of staphylococcal 
enterotoxins that stimulate the release of pro-inflammatory cytokines.4-7 However, the 
importance of S. aureus colonization in the complex pathogenesis, compared to the 
other involved genetic and immunologic factors involved, remains unclear.
Current treatment approaches for AD include topical treatment with emollients and 
anti-inflammatory therapy with (topical) immunosuppressive agents (corticosteroids 
and calcineurin inhibitors), according to the international guidelines.8,9 Antistaphylococ-
cal therapy is only recommended in cases of fever or clinically infected skin.8,9 Clinical 
studies that evaluated the added value of antistaphylococcal therapy in non-infected AD, 
have shown contradictory results. Bath Hextall et al. performed a systematic review of 26 
studies and showed that antistaphylococcal agents reduced the amount of S. aureus on 
the skin in AD. However, the bacteriological reduction did not translate into a decrease in 
clinical symptoms.10 These studies mainly investigated short-term therapies of less than 
one month duration and comprised small and poor-quality studies. As discontinuation 
of therapy after a short treatment period can result in quick regrowth of S. aureus11, the 
results of this systematic review do not necessarily mean that antistaphylococcal agents 
do not work. A more recent review of Brüssow et al. summarizes two intervention trials 
that reported significant improvement of disease severity in non-infected AD after two 
and three months of therapy with antistaphylococcal therapy (bleach baths).12-14 We hy-
pothesize that long-term therapy may be needed to reduce to S. aureus overgrowth and 
maintain a stable and balanced skin microbial composition. Ultimately, this could result 
in disease improvement, prevention of AD flares and less need for (topical) immune sup-
pression. However, long-term use of antibiotics can induce bacterial resistance,15 and 
both the use of antibiotics and dilute bleach baths can cause unnecessary harm to the 
commensal flora, that is hypothesized to have antistaphylococcal properties.16 
In the context of the increasing incidence of bacterial resistance, the interest in bacte-
riophages and their endolysins as antibacterial therapy has been renewed.17 Staphefekt 
SA.100 is an engineered chimeric endolysin that specifically lyses the cell membrane 
of S. aureus via endopeptidase and putative amidase activities.18-20 Long-term applica-
tion of Staphefekt on the skin, targeting only S. aureus and leaving skin commensals 
unharmed, may improve long-term AD outcomes, such as the number of disease flares, 
and may reduce the use of topical corticosteroids. Bacterial resistance to Staphefekt or 
other endolysins has not been observed and could not be induced, which enables us 
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to study the effect of long-term antistaphylococcal treatment in non-infected AD using 
this endolysin-based agent.19,21,22 
The aim of this randomized controlled trial, the MAAS trial, is to evaluate the effect of 
a 3-month antistaphylococcal therapy with Staphefekt on the frequency and quantity 
of topical corticosteroid use, clinical symptoms and QoL in patients with moderate to 
severe AD. In addition, data on the growth characteristics of the skin microbiome, in-
cluding S. aureus, will be collected, which will gain insight in the role of the microbiome 
as a factor in the pathophysiology of AD. 
MeTHoDs/ DesIgn 
Design and setting
The MAAS trial (Microbiome in atopic dermatitis during antistaphylococcal therapy and 
the effect on steroid use), is a multi-centre, randomized, double-blinded, placebo-con-
trolled superiority trial with a parallel group design (figure 1). The study aims to evaluate 
the effect of Staphefekt on the use of corticosteroids, disease severity, QoL and composi-
tion of the microbiome in patients with AD. The study was designed by the Department 
of Dermatology of the Erasmus MC University Medical Centre Rotterdam and will be 
executed in collaboration with the Havenziekenhuis Rotterdam. Enrolment and follow-
up visits take place at these two locations. Participants who comply with the criteria for 
in- and exclusion will start with a 2-week run-in period to standardize the corticosteroid 
use with triamcinolone acetonide 0.1% cream. After completion of the run-in phase, 
participants will be randomized to either treatment with Staphefekt or a placebo for 12 
weeks, followed by an 8-week follow-up period. An Eczema Area Severity Index (EASI) 
over 50 after the run-in phase is a contraindication for further participation. During the 
course of the study, participants visit the outpatient clinic six times (visit 1 through 6) 
and data will be collected on corticosteroid use, disease severity, QoL, skin microbiome 
and adverse events. See table 2 for the SPIRIT diagram of the trial procedures.
ethical considerations
This study follows the Dutch Medical Research Involving Human Subjects Act 1998 
(WMO) and the Helsinki Declaration principles 2008. All study procedures have been 
reviewed and approved by the Medical Ethics Committee of the Erasmus MC University 
Medical Center Rotterdam, the Netherlands (reference 2016-233). Protocol amendments 
will be submitted for review at the Medical Ethics Committee.
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Participants
This study will enrol adults (18 years or older) diagnosed with AD according to the UK 
working party diagnostic criteria for AD.23-25 Participants are eligible for enrolment if 
they have a score between 7.1 and 50.0 on the EASI for disease severity. Topical cortico-
steroids must have been prescribed before enrolment. All patients must be able to read 
and understand the patient information and provide written informed consent. Patients 
are not eligible for enrolment if they used: (1) systemic antibiotics or corticosteroid in 
the two months prior to enrolment, (2) oral immunosuppressive agents or UV therapy 
in the three months before enrolment or (3) local antibiotics or Staphefekt (from com-
mercial sources) one week before enrolment. Other criteria for exclusion are a known 
contact allergy to any of the components of the study drug (e.g. propylene glycol), clini-
cally infected AD or the existence of other skin condition(s) that could interfere with the 
assessment of the AD severity.
Fig 1. Flowchart of the study design
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Recruitment, inclusion and consent
Participants with AD will be recruited from the dermatology outpatient clinic of the 
Erasmus MC and the Havenziekenhuis Rotterdam. Furthermore, Dutch dermatologists 
are informed about the study via the Dutch Trial Network and via scientific conferences. 
Patients with AD are informed via the patient support group and via online media, such 
as DermHome (www.huidhuis.nl). In addition, recruiting advertisements will be placed 
on student forums and in local newspapers. Patients who are interested in participation 
in the trial can contact the researcher directly via email or phone. After a first screen-
ing with regard to the inclusion and exclusion criteria via email or phone, potentially 
eligible participants receive an information letter and will be invited to the dermatology 
outpatient clinic to further assess eligibility. Patients who fulfil the inclusion criteria and 
are willing to participate, will be included in the study after providing written informed 
consent.
sample size
The sample size for this study was calculated based on the primary outcome, namely 
the difference in mean days per week corticosteroid use over 12 weeks between the 
Staphefekt arm and the placebo arm, in patients who are positive for S. aureus on the 
skin at baseline. This is the first study measuring clinical outcomes of Staphefekt in 
patients with AD. We expect to find a mean topical corticosteroid use of 5 days/week 
in the placebo group. This was based on a study of Hon et al. that showed decreased 
use of topical corticosteroids when taking bleach baths, an antistaphylococcal therapy.26 
Based on the results of this study, we anticipate an effect size of 1.25 day/week reduction 
of topical corticosteroid use in the Staphefekt arm. A sample size was calculated using 
an unpaired t-test to compare means in a superiority trial design. With a power of 0.80, 
alpha of 0.05 and SD of 2.0, 40 patients are needed per treatment arm. Assuming 10% 
drop out and 90% of the patients being positive for S. aureus on the skin lesions, 50 
patients will be assigned to each of the two treatment arms.
Randomization and blinding
The participants are randomly assigned, in a 1:1 fashion to either treatment with 
Staphefekt or placebo. Stratified block randomization for AD severity is performed to 
ensure equal distribution of patients with moderate and severe AD over the treatment 
arms (EASI 7.1-21 and EASI 21.1-50). Randomization is done by an independent biostat-
istician of the Erasmus MC, using the statistical software package R version 3.2.2. The 
participants, the researchers and laboratory analyst are blinded for the intervention. The 
pharmacy manages the randomisation list and provides blinded study medication.
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Intervention
After enrolment, all participants start a run-in phase of two weeks in which they receive 
a standardized dosing regimen of topically applied triamcinolone acetonide 0.1% cream 
(table 1). After the run-in period, the patient and the researcher evaluate further partici-
pation, with very severe AD (EASI>50) as a contraindication for continuation. The run-in 
period and randomization is followed by a 12-week treatment period and an 8-week 
follow-up period. During the treatment period, Staphefekt or placebo cream will be 
applied on the total skin surface twice daily to reach optimal reduction of S. aureus, as 
both lesional and non-lesional skin are often colonized.4 The Staphefekt endolysin is 
made available in a cetomacrogol-based cream. The placebo is composed of the same 
cetomacrogol-based cream, without Staphefekt. During the treatment and follow-up 
period triamcinolone will be used according to the corticosteroid dosing regimen (table 
1). Measurements and assessments will be performed at enrolment (start of the run-in 
phase, visit 1), baseline (start treatment with Staphefekt/placebo, visit 2a), 0.5 hours 
after baseline and 2, 6, 12 and 20 weeks after baseline (visit 2b to 6). Table 2 provides an 
overview of the measurements per visit. Unless it is in the best interest of the patients 
(for example in case of an eczema flare), patients are not allowed to use systemic or 
topical immunosuppressive medication (including calcineurin inhibitors), antibiotics or 
antiseptics during the study. Escape medication will be prescribed according to current 
treatment guidelines and its use will be registered. At start of the study, patients receive 
an emollient according to patient’s preference for use during the course of the study. 
The use of this emollient will be registered by weighing the tubes at each visit.
Detailed sample and laboratory procedures
Sampling procedures are based on the ‘Manual of Procedures’ for microbiome sampling 
of the Human Microbiome Project.27 All samples are obtained by one of the researchers 
Table 1. Corticosteroid dosing regimen
week 1 week 2 week 3 week 4 week 5 week 6 week 7 week 8 week 9
saturday X X X X X
sunday X X X X X X X
Monday X X X X X
Tuesday X X X X X
wednesday X X X X X
Thursday X X X X X X X
Friday X X X X X
Start in week 1 or 2 depending on severity of the AD. If the symptoms allow, reduce the use of corticosteroid 
cream weekly according to the scheme. Return to week 1 or 2 in case of an exacerbation. Based on patient’ 
assessment.
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wearing gloves (sterile for the skin scrub). Sterile Copan 490CE.A swabs are used to sample 
the skin, nasal cavity and pharynx. Skin samples are taken from lesional skin, preferably 
located at the antecubital folds or the popliteal fold. The skin surface is swabbed during 
30 seconds. The mucosal surfaces of both the anterior nares are gently rubbed going 
round the area during 10 seconds. The rear of the oropharynx is swabbed for 5 seconds, 
using a tongue depressor. For the skin scrub sample, a ring with an internal diameter 
of 4cm will be placed on the same skin lesion where the swab was collected, but on a 
non-overlapping area. 1 ml of swab solution (0,85% NaCl, 0.1% bacteriological peptone, 
0.1% Tween 80) is pipetted in the ring. After rubbing over the skin with a Copan 480CE 
swab during 1 minute, the swab-solution will be pipetted out the ring into an Eppendorf 
tube. The swabs will be sent to the laboratory at the day of collection using mail. A semi-
quantitative culture technique and MALDI-TOFF for identification of S. aureus will be 
performed. The scrub samples will be stored at -80 degrees Celsius at the Erasmus MC 
Rotterdam until 16S rRNA-sequencing and quantitative S. aureus analysis.
Primary and secondary outcomes
The primary outcome of this study is the days per week of corticosteroid use, compared 
between the Staphefekt and the placebo group over 12 weeks. Patients report their 
triamcinolone use daily in a secured digital platform, ‘DermHome’.* Additionally, the use 
of triamcinolone cream will be measured in grams by weighing the study medication at 
time of issue and return (each visit). Secondary outcomes include clinical efficacy and 
QoL from baseline through week 12 and week 20, change of the microbial composition 
(including S. aureus) and safety. Clinical efficacy is measured using the EASI, the Inves-
tigators Global Assessment (IGA) and registration of the number of flares.28 A flare is 
defined as an exacerbation that requires the need to intensify treatment, from a doctor 
or patient’s perspective. This implies stronger topical therapy or the need for systemic 
treatment. A 50% increase in the EASI score compared to baseline is used as an indica-
tion to intensify treatment. The Pruritus Numerical Rating Scale (Pruritus NRS) and the 
Patient Orientated Eczema Measure (POEM) are included as patient-reported efficacy 
outcomes.29,30 QoL is measured using the Skindex-29.31,32 Changes in the microbiome are 
evaluated by comparing the changes in bacterial composition between the treatment 
groups, determined by 16S rRNA sequencing of the skin scrub samples. Reduction of S. 
aureus is determined by quantitative PCR (and culture for the comparison between visit 
2a and visit 2b). Safety and tolerability is assessed by monitoring the incidence of (seri-
ous) adverse device events through the end of the study, evaluated by medical check-
ups that include evaluation of vital signs. Reportable adverse events will be reported 
within the set timelines to the competent authorities. Table 2 gives a detailed overview 
of the measurements per visit.
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* ‘DermHome’ is a secured digital treatment and research platform, developed in col-
laboration with Patient 1 BV, Almere.33 The platform provides an user-friendly individual 
account that allows patients to report their pruritus score and triamcinolone use daily. 
Thereby the platform provides digital information about the study, including the use of 
Table 2. SPIRIT diagram of study procedures
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   Informed consent X
   baseline questionnaire X
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InTeRVenTIon
AssessMenTs
efficacy
Questionnaire triamcinolone use (primary outcome)
Weight triamcinolone tube at issue and return X X X X X X
EASI28 X X X X X X
IGA X X X X X
Pruritis NRS29
POEM30 X X X X X
Quality of life Skindex-2931,32 X X X X
Microbiome
Swab skin X X X X X X
Scrub skin X X X X
Swab nose X X X X
Swab throat X X X X
safety Medical check-up X X X X X X
other
Photograph (overview + close up sampled lesion) X X X X X
Questionnaire use of emollients and escape medication X X X X X
EASI, eczema area and severity index; IGA, investigators global assessment; Pruritus NRS, pruritus numerical 
rating scale; POEM, patient orientated eczema measure. Visit 1, enrolment in the trial and start of a two weeks 
run-in phase; Visit 2a, start of the intervention (baseline); Visit 2b, 0.5 hours after baseline; Visit 3, 2 weeks after 
baseline; Visit 4, 6 weeks after baseline; Visit 5, 12 weeks after baseline and end of the intervention; Visit 6, follow-
up visit 20 weeks after baseline. All visits take place plus or minus two days from the indicated timeframe.
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the study medication, and an option to contact the researcher and to upload photos in 
case of questions. After every visit the researcher can make notes in the digital file about 
findings, agreements and future appointments.
Data collection, monitoring and data analysis
Data collected during the visits are entered in Open Clinica. This data management 
system allows direct data entry. Data entry is monitored by an independent researcher 
according to a predefined monitoring plan. Triamcinolone use and itch scores filled in 
daily by the patients in ‘Dermhome’ will be extracted in an SPSS format and combined 
with the Open Clinica database. Patients confidentiality will be ensured by using 
identification numbers. Data will be analysed on an intention-to-treat basis. A mixed 
linear regression model will be used to examine if there is a significant difference in 
corticosteroid use over 12 weeks between the intervention and the placebo group.34 
This model accounts for repeated measurements for each patient and is valid in the case 
of missing data. Covariates that could influence the outcome variable will be included 
in the model. Subgroup analysis will be performed to analyse patients that are positive 
for S. aureus on the skin versus patients that are negative for S. aureus before start of 
the intervention. Positive patients are defined as having positive cultures both at visit 1 
and 2a. Negative patients must have two negative cultures. Patients that have one posi-
tive and one negative culture will not be included in the subgroup analysis. Secondary 
outcomes will also be analysed using a mixed model analysis (linear or logistic according 
to the type of data). The findings of this study will be published in national and interna-
tional journals (according CONSORT 2010 Statement) and will be communicated to the 
relevant patient associations.
DIscussIon
The MAAS trial is a randomised, placebo-controlled trial that investigates the effect of 
a 3-month antistaphylococcal therapy with Staphefekt on topical corticosteroid use, 
clinical symptoms and QoL in adults with moderate to severe AD. Additionally, data 
will be collected about the growth characteristics of the skin microbiome, including S. 
aureus. Taking in consideration the current literature on antistaphylococcal therapy, a 
study design using a long-term antistaphylococcal intervention, measuring long term 
outcomes was chosen.
Evidence for the clinical efficacy of Staphefekt, registered as a class 1 medical device 
in Europe, is based on in vitro studies and a case series.18-20 These in vitro studies showed 
that Staphefekt kills different strains of S. aureus (also methicillin-resistant strains), 
without harming the commensal flora or inducing bacterial resistance.19 A case series 
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describes clinical improvement of S. aureus related symptoms, such as folliculitis and 
superinfected dermatitis, and no development of resistance during long-term daily 
treatment with Staphefekt based on the minimal inhibitory concentrations of the cul-
tured S. aureus strains over time.35 The lack of resistance induction can be expected, 
as bacterial killing by an endolysin is independent of the involvement of the bacterial 
metabolism. The co-evolution of bacteriophages and their host bacteria over millions 
of years, ensures that phage endolysins attack essential bonds in the bacterial cell wall 
that cannot be adapted by the host.22 Thereby, the lytic activity of exogenously applied 
endolysins results in lysis of the target cells within seconds, restricting the possibility 
to adapt and develop resistance. Furthermore, attacking several bonds of the bacterial 
wall simultaneously by the use of more than one enzymatically active domain in the 
Staphefekt molecule, makes resistance development even less likely to occur.18 
Because of the proteinaceous nature of endolysins, immunogenicity can be of 
concern. The literature shows the possibility of the formation of non-neutralizing 
antibodies against lysins other than Staphefekt.22 In a study in which the presence of 
anti-Staphefekt IgG was evaluated in serum from 21 Staphefekt-naive healthy human 
donors, pre-existent IgG antibodies recognizing Staphefekt epitopes were detected in 
all the donors (unpublished data). This can be explained, as humans are exposed daily to 
S. aureus and therefore to bacteriophages and their lysins. However, Staphefekt is a large 
size protein molecule (>50kDa), making penetration through the skin and mucosa and 
subsequent antibody reactions unlikely.36 
Calculation of the sample size for this study was hampered as no information was 
available about the effect of Staphefekt on corticosteroid use and clinical efficacy in AD. 
Therefore, the study should be considered as hypothesis generating, giving insight into 
effect sizes and distributions of clinical outcomes. Our expected effect size was based 
on a study of Hon et al. that studies the effect of bleach on corticosteroid use in AD. 
We chose a slightly higher effect size, because we expect the effect of Staphefekt that 
specifically targets S. aureus to be more efficacious than bleach. We consider this effect 
size, a reduction in corticosteroid use of more than one day a week over 12 weeks, as 
clinically relevant because of the (low) risk of side effects and a general reluctance of 
patients to use corticosteroids, resulting in poor compliance and a lack of treatment 
efficacy.37,38
No consensus has been reached yet on a standardized outcome for long-term AD 
control, the primary goal of our study. The Harmonising Outcome Measures for Eczema 
(HOME) initiative reached consensus on the use of EASI and POEM as doctor-based and 
patient-based measures of AD severity, both of which are included as secondary out-
comes in this trial.39 According to the authors of HOME, measures of long-term control 
could include time to flare and the use of rescue medicine.39 Next to corticosteroid use, 
both these study outcomes were included in this study as secondary parameters. 
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In conclusion, this study will evaluate the effects of a 3-month targeted antistaphylo-
coccal therapy with Staphefekt in moderate to severe AD. The lack of resistance induction 
allows long-term treatment with this antistaphylococcal agent. This study will provide 
the first data on the use of antistaphylococcal therapy with Staphefekt in AD and may 
provide new insights in the role of S. aureus in the pathophysiology of AD.
TRIAl sTATus
The first patient was included in the study in July 2016. Patient recruitment is currently 
ongoing and the inclusion is expected to be completed by August 2017.
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MAIn FInDIngs oF THIs THesIs 
The aim of this thesis was to characterize the microbial composition of the skin, nose and 
gut in patients with mild to severe atopic dermatitis (AD) We focused on S. aureus and 
the humoral immune response towards this bacterium, and we designed a clinical study 
to test the effect of a new endolysin-based therapy that specifically targets S. aureus in 
AD. In the following paragraphs we discuss the main findings of this thesis.
The skin and nasal microbiome are associated with AD severity 
In Chapter 2 of this thesis we found an association between the microbial composition 
of both the nose and skin and AD severity (R2 = 2.6%; p=0.017 and R2 =7%; p=0.004). 
The skin microbiome has been associated with AD severity before in children.1 However, 
as far as we know we were the first to evaluate both the skin and nasal microbiome of 
children in a multivariate model, adjusting for covariates including age, use of antibiot-
ics and the location of sample collection on the skin. We found that staphylococci highly 
contribute to the association with AD severity in both the nose and skin. Although we 
could not differentiate between the different staphylococcal species, our results are in 
line with studies that showed higher density of S. aureus in more severe AD (Chapter 4).1,2 
In an additional analysis to characterize S. aureus, we found that children with severe AD 
were positive for S. aureus on lesional skin more often than children with mild AD (58% 
vs 39%). However, this difference was not significant. In the nose, next to staphylococci, 
also Moraxella were positively associated with AD severity. Although the presence of this 
species in the nose has not been associated with AD severity before, different studies 
have found that Moraxella is associated with asthma and asthma development.3,4 We 
retrieved information on the diagnosis of asthma or bronchial hyperactivity (28% of the 
children) from patient records, and the diagnosis did not influence our results when 
adjusting for it. For some species, a decreased abundance contributed to the associa-
tion between the microbiome and AD severity in our study, for example Dolosigranulum 
in the nose and Streptococcus on the skin. High abundance of Dolosigranulum was 
suggested to be beneficial for respiratory health in a study of Biesbroek et al.5 Strep-
tococcus was observed before in lower relative abundance in skin lesions compared to 
nonlesional skin in young patients.6 Although the cross-sectional design of our study 
precludes evaluating cause-event relationships, our results indicate that both the nasal 
and skin microbiome might play a role in the severity of inflammation in pediatric AD. 
Staphylococcal species seem important drivers for the association between both skin 
and nasal microbiome and AD severity. Prospective and controlled cohort studies are 
needed to validate our results and determine which species contribute to (or protect 
for) AD and its severity.
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The skin and nose in AD harbor distinct microbial communities, but 
correlations exist between the two niches.
In Chapter 2 we found that microbial communities in the skin and nose are significantly 
different from each other (R2=26.8, p<0.001). This is in line with studies in healthy sub-
jects showing that each body site is characterized by its own microbial community 
harboring dominant signature taxa.7 Nevertheless, some species such as staphylococci, 
were present in both niches in our patients. However, where most skin samples were 
dominated by staphyloccoci, only a few nasal samples showed dominance of staphy-
lococcal species. Looking at abundance patterns of species in the nose compared with 
(other species) on the skin, we found that many species in the nose and skin showed 
similar patterns of species abundance. Staphylococci on the skin formed an exception 
as they were negatively correlated with many other species in the nose and skin. The 
exact meaning of these relations should be further explored as different biological and/
or immunological mechanisms might underlie our observation. A possible underlying 
mechanism might be cross-transmission of bacteria between the nose and skin.8-10 Pro-
spective large cohort studies should further evaluate the presence of cross-transmission 
between the nasal and skin microbiome, as it might be of relevance for determining 
treatment strategies for AD. Furthermore, it might help to determine if a diagnosis of AD 
influences the persistence of nasal carriage of S. aureus, a risk factor for infections with 
the bacterium.11-13 
The gut microbiome differs between children with AD, with and without a food 
allergy
Severe AD is associated with food allergy.14 Although several studies have shown as-
sociations between the intestinal microbiome and development of atopic diseases, 
the link between intestinal microbiota and food allergy has rarely been studied.15-17 In 
Chapter 3 of this thesis we described the gut microbiome in a group of 82 children with 
mild to severe AD. Of these children, 20 were diagnosed with food allergy mainly for 
peanut and cow’s milk. We aimed to identify gut microbial characteristics associated 
with food allergy, using the gold standard for diagnosing food allergy (double blind 
placebo controlled food challenge), which has rarely been done before. Six bacterial 
species from the gut microbiome were identified that when combined discriminate 
between children with and without food allergy: Bifidobacterium breve, Bifidobacte-
rium pseudocatenulatum, Bifidobacterium adolescentis, Escherichia coli, Faecalibacterium 
prausnitzii and Akkermansia muciniphila (AUC 0.83, sensitivity 0.77, specificity 0.80). Our 
pilot results are based on a small cross-sectional study and should be confirmed in future 
prospective studies and further adjusted for confounders, such as diet and AD severity. 
The exact mechanisms through which the intestinal microbiome influences food allergy 
are not elucidated yet and it is not clear whether a change in microbiome precedes 
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or follows the development of food allergy. A possible mechanism is disruption of the 
gut microbiome that alters the gut epithelial integrity, thereby increasing the risk of 
allergic sensitization through direct uptake of allergens, a hypothesis that is mainly 
based on animal studies.17 Another possible mechanism could be the immune stimula-
tory capacity of gut microbes (via secretion of molecules).18-20 In our study, the children 
with a food allergy were also found to have higher thymus and activation-regulated 
chemokine (TARC) levels, a serum biomarker for AD severity, suggesting increased AD 
severity compared to the non-allergic group.21,22 This raises the possibility that the six 
bacterial species also correlate with AD severity. Furthermore, we cannot exclude that 
elimination diets in the food allergic group have led to changes in the gut microbial 
composition. However, one third of the children in the non-food allergic group also 
reported an elimination diet for a specific food, which makes it unlikely that our findings 
are solely attributed to differences in diets. Our results need to be confirmed in larger 
studies that enable stratification on specific food allergies and adjustment for AD sever-
ity and dietary factors. 
Patients with AD have an increased risk of colonization with S. aureus 
In Chapter 4 we quantified the prevalence of S. aureus in AD patients compared to con-
trols and concluded that patients with AD are significantly more likely to carry S. aureus 
than healthy controls on both the lesional and nonlesional skin. S. aureus was identified 
on lesional skin in 70% of the patients, with a higher prevalence of S. aureus in patients 
with severe AD and in patients under 18 years old. We showed that heterogeneity among 
the included studies was substantial, ranging from 63% to 88% for the pooled outcomes, 
which can be partly explained by the quality of the studies and disease severity of the 
included patients. We also detected publication bias causing an overestimation of the 
pooled outcomes. Although different studies calculated prevalence rates of S. aureus in 
AD, with this meta-analysis we were the first to systematically summarize the data of the 
different studies. Our meta-analysis indicates the importance of S. aureus in AD, not only 
in skin lesions but also in nonlesional skin and the nose. A positive association between 
AD and the presence of S. aureus both on the skin and nose suggest a possible role of 
the bacterium in aggravation of AD inflammation and encourages further research into 
exact mechanisms.
S. aureus evokes an Ige based immune response in a subgroup of patients with 
AD
In Chapter 5 of this thesis we described the first systematic review that summarizes 
data on antibody prevalence against S. aureus in AD. In a pooled analysis we found that 
IgE against SEA and SEB (two staphylococcal superantigens) is present significantly 
more often in patients with AD compared to healthy controls. Pooled analysis of IgE 
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against TSST-1 included only two studies and showed the same trend (not statistically 
significant). Pooled prevalence estimates of antistaphylococcal IgE patients were 33% 
for SEA, 35% for SEB, 14% for SEC, 5% for SED and 16% for TSST-1. Data on other antigens 
were insufficient for a pooled analysis. The observed high heterogeneity in the pooled 
analysis could be partly explained by the variety in IgE detection methods used. We did 
not find a difference in IgE levels between children and adults. Other variables such as 
AD severity and treatment are also likely to contribute to the observed heterogeneity, 
but could not be explored as this information was not available for the included stud-
ies. The increased IgE in patients compared to controls indicates that S. aureus might 
stimulate AD inflammation via IgE mediated mechanisms, such as mast-cell degranula-
tion, suggesting a role of S. aureus as an allergen. It is unclear whether the increased 
IgE is the result of increased skin barrier permeability in AD, predominance of SEB and 
SEA carrying strains in AD skin and/or an inappropriate immune response towards the 
bacterium. It is probably a combination of these factors. Notably, only a subgroup of 
patients show elevated IgE, suggesting that only a part of the AD patients reacts in an 
IgE dependent matter towards S. aureus. On the other hand, only 14% and 24% of the S. 
aureus isolates carry the genes to express SEA and SEB, so a group of AD patients might 
not have encountered the allergen yet.23 Further research is needed to clarify the clinical 
relevance of IgE responses against S. aureus in patients. Our results also indicate a lack of 
studies that evaluate immune responses other than the IgE mediated response against 
staphylococcal superantigens.
children with AD develop an Igg dependent immune response against S. 
aureus and the bacterium might use immune-modulatory antigens to persist 
on the skin in AD 
As outlined in Chapter 5, most research has focused on IgE humoral responses towards a 
limited panel of S. aureus antigens. As IgG is known for its involvement in the neutraliza-
tion and elimination of microbes, we profiled IgG antibodies against 55 S. aureus antigens 
in two cohorts of children with AD (Chapter 6). Our results showed that the children are 
exposed to a wide range of antigens and develop an IgG mediated humoral immune 
response towards them. In one of the cohorts, the IgG response against antigens with 
mainly immune-modulatory functions, (e.g. Leukotoxin (Luk) D and E) was associated 
with the severity of the AD. The exact pathophysiological mechanism that explains this 
finding is unclear, although it can be argued that children with more severe AD might 
have an altered immune response against staphylococcal antigens. The association 
could also be a reflection of the higher S. aureus load on the skin of children with more 
severe AD, that IgG tries to counteract. However, in the latter case one would expect 
increased IgG against all S. aureus antigens rather than a subset. On the other hand, S. 
aureus might express more immune-modulatory antigens, which may lead to a more se-
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vere AD phenotype. By down regulating the immune system locally, S. aureus can more 
easily maintain its colonization on the skin, which can cause chronic inflammation in AD, 
characterized by Th1 cells in the skin. In vitro studies showed that activation of dentritic 
cells by S. aureus lipoteichoic acid and the Th2 cytokine IL-4 (combined) can result in 
enhanced Th1 and Th17 priming.24,25 In acute AD inflammation, where IL-4 is present, 
additional presence of S. aureus on the skin can cause a state of persistent and chronic 
AD. The exact role of S. aureus specific IgG in the inflammatory response in AD should be 
further investigated. A study of Meulenbroek et al. found that the presence of IgG affects 
the binding of food allergen-IgG complexes to B-cells. This mechanism was also seen for 
birch pollen, suggesting a role for IgG also in the allergic response.26 Determination of 
IgG subtypes combined with IgE can help clarify the role of IgG in AD, as different IgG 
subtypes might have different characteristics relating to other AD phenotypes. For ex-
ample in AD, tolerance to cow’s milk was associated with increased IgG4 in combination 
with low specific IgE.27 A control group of children is needed to investigate the normal 
range of IgG antibodies in children without AD. Nevertheless, the results of our study 
shed light onto the IgG mediated immune response to S. aureus in children with AD 
and highlight the relevance of other antigens (adhesins and immune modulators) next 
to the often studied superantigens. Further studies, including IgG subtype responses, 
need to be conducted to validate our results and will help us understand how microbes 
interact with the immune system and possibly induce inflammation.
Techniques for skin microbiome research: scrub results in higher collection of 
bacterial and fungal DnA compared to swab
As mentioned in the introduction of this thesis, investigating the skin microbiome 
imposes some challenges. For example, the low biomass of microbial DNA on the 
skin requires adequate sampling that produces sufficient yield for reliable analysis. In 
Chapter 7 we compared dry nylon-flocked eSwabs versus a scrub method to collect 
skin microbial samples. These eSwabs are thought to enhance bacterial absorption and 
release compared to traditional cotton or rayon swabs, which could be attributed to 
the flocked structure of the swab.28 The scrub sample was collected by placing a sterile 
sampling ring on the skin and adding sterile wash fluid. After scrubbing the skin within 
the ring with a sterile swab, the fluid was collected and analyzed. 29,30 We showed with 
quantitative qPCR that scrubs result in significantly higher amounts of total bacterial 
DNA compared to the swab. However, with 16S rRNA sequencing we showed that both 
methods identify the major genera equally well. The potential of the scrub method to 
increase bacterial discovery rates was described earlier, but based on culture methods.31 
Fungal DNA was found more often in scrub samples compared to swabs (36% versus 
9%). Increased yields of bacterial and fungal DNA make scrubs the preferred method, 
especially for characterizing fungi, rare microorganisms and for low biomass areas of 
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the skin. However, dry eSwabs are more user-friendly and can be applied on all skin 
sites. Also, eSwabs identify the dominant sequences of the microbiome equally well as 
scrubs, at least in the sites sampled in our study (mainly the antecubital folds). Therefore, 
the swabs can be considered for large scale studies and for body sites that are difficult 
to sample with the scrub. A comparison of the eSwab and the scrub with premoistened 
cotton swabs, a method that is commonly used now for microbiome analysis, might 
further help identify the preferred method for microbial analysis. 
PlAce oF THe MIcRobIoMe In THe AToPIc DeRMATITIs DIseAse MoDel 
A recent review on atopic dermatitis describes two main pathophysiological landmarks 
in AD, namely (1) abnormalities of the skin barrier and (2) changes in the immune re-
sponse, with a close interaction between skin barrier biology and immune mechanisms. 
S. aureus is shortly mentioned as a possible contributor to AD exacerbations and chronic 
inflammation.32 We propose a model for AD pathophysiology that includes a third main 
component, namely alterations in the microbiome (figure 1). This model incorporates 
several findings of this thesis that include an association between microbial composi-
tion and AD severity (Chapter 2 and 4) and the interaction of S. aureus with the immune 
system (Chapter 5 and 6).
The model in figure 1 shows three main components: the skin barrier, the immune 
system and the (skin) microbiome. Together they contribute to a balanced ecosystem 
which is important for a healthy skin, influenced by genes and environment (includ-
ing environmental microbes). Bidirectional interactions between the components 
contribute to the mechanical and immunological barrier function of the skin. A healthy 
microbiome strengthens the mechanical skin barrier as commensals occupy space that 
could otherwise be colonized by pathogens. Microbes such as S. epidermidis support the 
local immune system by producing antimicrobial peptides that suppress S. aureus.33,34 
Inflammation in AD is probably the result of a disbalance in this skin ecosystem, result-
ing in an altered barrier, immunological changes and an altered skin microbiome (figure 
1). The alterations in all three components together contribute to AD etiology. The initial 
trigger that causes the disbalanced ecosystem can affect each of the components, which 
might result in a vicious circle where the components constantly aggravate each other, 
leading to a situation of chronic inflammation. It is likely that the contribution of each of 
the three components to the inflammation differs per patient and even within patients 
over time.
The model in figure 1 includes microbiome alterations as a basis for AD pathogenesis, 
and questions the relevance of the debate on whether alterations in the microbiome are 
cause or consequence of AD. It is likely that microbial dysbiosis and S. aureus overgrowth 
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are not the primary events that cause (flares in) AD. A pre-existent barrier defect and 
immunological changes are probably a prerequisite for S. aureus to overgrow. The skin 
barrier defect in AD provides a suitable environment for S. aureus to grow and allows 
contact with immune cells in the skin. Also, presence of Th2 cells is needed for the pro-
duction of IgE against S. aureus antigens.
Once present on the skin, S. aureus can induce inflammation via different mechanisms, 
namely excretion of virulence factors and the activation of both IgG and IgE mediated 
immune pathways. Via these mechanisms S. aureus has the ability to further aggravate 
inflammation or induce flares, even if the microbial dysbiosis and overgrowth is primar-
ily caused by other factors, such as a skin barrier defect. Theoretically, this makes the 
microbiome a possible target for treatment of AD (flares). Although we know that it is 
theoretically possible, evidence that proves that S. aureus is actually aggravating the 
inflammation during a flare is still scarce. Large prospective cohort studies are needed 
that further clarify the role of the microbiome in AD, including S. aureus, with sampling 
specifically around disease flares. The above mentioned ‘cause or consequence’ discus-
sion is also outlined in a letter published by our group in the British Journal of Dermatol-
ogy (Totté et al. 2017).35
clInIcAl IMPlIcATIons oF THe ResulTs PResenTeD In THIs THesIs 
The skin microbiome as a therapeutic target in AD 
Currently, there is no place for antimicrobial therapy in the treatment of AD without signs 
of infection (fever, high staphylococcal load or clinically infected AD (impetiginization of 
the lesions)).36 Based on our model for AD pathogenesis (figure 1), we hypothesize that a 
Figure 1. Disease model of AD including the (skin) microbiome. (Illustration by Marloes van Loon)
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combined treatment strategy targeting all three components, including the alterations 
in the microbiome, could optimize the treatment of AD. To determine the right strategy 
to target the microbiome, we need to know which alterations in the microbiome are 
associated with AD and AD flares. The established association between S. aureus coloni-
zation and AD, makes S. aureus the first target of interest (Chapter 4). In Chapter 2 of this 
thesis we identified other microorganisms that were associated with AD severity. Their 
role as potential treatment targets, next to S. aureus, in AD should be further explored. 
The added value of antistaphylococcal therapy in AD without symptoms of infection 
could not be confirmed before in a published review of clinical studies.37 However, the 
studies that were assessed in this review included approaches that have been tested on 
their ability to treat an exacerbation, in trials with relatively short follow-up periods, not 
showing whether the treatment can provide long-term control of the disease activity. 
We hypothesize that long-term modulation of the microbiome may be needed to main-
tain a stable and balanced skin microbial composition. This can be argued as S. aureus, 
combined with a Th2 cell acute inflammatory environment, can contribute to a state of 
persistent AD.24 Antistaphylococcal treatment could temporarily reduce the ‘pressure’ of 
S. aureus and relieve symptoms, but after stopping the treatment the bacterium is likely 
to regrow quickly. Especially, in the presence of an underlying genetic barrier effect in 
part of the AD patients, which might facilitate colonization with S. aureus.38 Studies did 
describe before that mutations in the gene encoding filaggrin, an important protein for 
skin barrier homeostasis, were associated with the microbial composition in nonlesional 
AD skin.10 Also gram-positive anaerobe cocci were found underrepresented in the mi-
crobiome filaggrin-deficient human skin, which was speculated to favour growth of S. 
aureus.39 
Results of two more recent intervention trials that reported significant improvement 
of disease severity in non-infected AD after two and three months of therapy with anti-
staphylococcal therapy (bleach baths) support the hypothesis that long-term treatment 
is necessary for better disease control.16,40-42 We conclude that long-term studies are 
needed to determine if treatment that aims to restore microbial alterations might have 
a place in the treatment of non-infected AD.
strategies for long term modulation of the skin microbiome 
Currently available treatment strategies to reduce S. aureus, include antibiotics, bleach 
baths and Povidon-iodine (Betadine) scrubs. These agents have a broad-spectrum activ-
ity, indicating that they also affect beneficial microbes on the skin and other body sites.43 
In addition, long-term treatment with antibiotics is undesirable as it can induce S. aureus 
resistance to antibiotics, causing more severe disease, prolonged hospitalization and in-
creased mortality.44-46 New treatment strategies that specifically target only the microbe 
of interest and that allow long-term treatment is therefore urgently needed. New tar-
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geted strategies have been developed, including anti-S. aureus vaccines (unsuccessful in 
clinical testing until now) and topical endolysin-based treatment against S. aureus that 
recently became available for clinical use.38,47 Next to reducing the load of certain target 
species, alterations in the behavior of pathogens changing from virulent to commensal 
have been studied. In an in vitro study, S. aureus was found to change from virulent to 
commensal when exposed to the commensal Corynebacterium striatum.48 A third option 
to reduce the overgrowth of S. aureus includes topical probiotic strategies that involve 
application of species that inhibit growth of S. aureus, for example S. epidermidis and S. 
hominis.33 
Next to therapy directed to S. aureus, treatment with an emollient has also been found 
to reduce AD symptoms with subsequent reduction of Staphylococcus species load.49 
Also, emollient treatment from birth was considered an effective approach for atopic 
dermatitis prevention in a group of high-risk infants.50 These results make treatment 
with an emollient an important first step to optimize the skin microbial composition. 
The precise mechanisms through which emollients have beneficial effects are still poorly 
understood and need further exploration, but they are probably related to improved 
barrier integrity.32 Furthermore, Czarnowicki et al. identified alterations in the expres-
sion of antimicrobial peptides with the application of petrolatum, an over-the-counter 
moisturizer.51
Influence of extra-cutaneous microbial niches
In Chapter 4 we found an increased risk for S. aureus colonization in the nose of AD pa-
tients compared to healthy controls. These results raise the question whether the nose 
should be included when applying topical therapy to modulate the skin microbiome. 
Current American treatment guidelines also recommend combined intranasal mupi-
rocin and bleach baths for infections in AD.52 Studies that evaluate the effect of new 
topical antimicrobials should incorporate measurements of extra-cutaneous microbial 
niches. This will help determine whether a certain extra-cutaneous microbial profile 
influences treatment effects. In general, niches that can be carriage sites are the nares, 
the oropharynx, the axillae, groin, the perineum, and the vagina.53
The microbiome and diagnostics
In current clinical practice, swabs of AD lesions are rarely collected when the lesion does 
not show signs of clinical infection. In this thesis we discussed that S. aureus on the skin 
and in the nose likely plays a role in aggravating inflammation in non-infected AD as 
well, particular in severe AD. This raises the question whether collection of skin and nasal 
swabs to determine S. aureus load in non-infected AD should be considered standard 
practice. Having information about the presence or absence of S. aureus can help deter-
mining whether targeting the microbiome should be considered as part of the treatment 
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strategy, next to skin barrier and anti-inflammatory treatment. Chapter 6 of this thesis 
supports that S. aureus might also contribute to development of chronic AD lesions, also 
previously suggested by Biedermann et al.24 These results should encourage clinicians 
to also consider S. aureus culture in chronic dermatitis where the role of S. aureus seems 
less obvious compared to the more fierce red and oozing acute lesions. Future studies 
should investigate how S. aureus behaves on/in skin with chronic dermatitis compared 
to skin with acute inflammation.
Although the data are very preliminary, the results of Chapter 3 suggest possibilities 
to use the microbial composition as a diagnostic tool. Our pilot data indicated that mi-
crobial patterns in the gut are associated with food allergy in children with AD and that 
it is possible to distinguish non-food allergic children from food allergic children using 
fecal samples. The use of fecal samples would allow for a simple and cheap method to 
distinguish children without a food allergy from children with a food allergy as a first 
step in the diagnostic process, as the current gold standard for diagnosis of food allergy, 
a double blind placebo controlled food challenge, is (time) invasive, costly and can be 
difficult in young children. As discussed in Chapter 3, this was a pilot study and the find-
ings need to be validated in other (clinical) studies, including adjustment for important 
confounders.
Design for an intervention study to target atopic dermatitis - anti-S. aureus 
endolysins 
When the first targeted anti-S. aureus treatment strategy, based on endolysins, became 
available on the market, we decided to study its effect in a clinical setting and were 
the first to report on this.47,54 The endolysin Staphefekt SA.100TM (Staphefekt) is an en-
gineered chimeric endolysin that specifically lyses the cell membrane of S. aureus via 
endopeptidase and putative amidase activities. Incorporated in a cetamacrogol based 
cream, the endolysin is registered as a medical device class 1 in Europe and available 
for topical application. In vitro studies tested the activity of Staphefekt in phosphate 
buffered saline against 28 clinical strains of MSSA, 8 strains of MRSA, and four other 
staphylococcal strains (S. epidermidis, S. hominis, S. haemolyticus and S. lugdunensis).47 
These results indicate that Staphefekt kills different types of S. aureus including methicil-
lin resistant strains (mean reduction in OD of 58%), while causing little harm to the four 
other staphylococci (mean reduction in OD of 4.3%). The effect on other commensal 
species needs further investigation.
We tested Staphefekt in a study of 3 cases with S. aureus-related skin conditions, 
folliculitis and impetiginized dermatitis, and found that Staphefekt led to a reduction 
of clinical symptoms (Totté et al. CR in Dermatology 2017).54 Bacterial resistance to 
Staphefekt was not found in our case study during 4 months of treatment (assessed in 
one of the three patients). We hypothesized that targeting S. aureus with Staphefekt can 
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restore the microbial balance, which might relieve AD inflammation or even prevent 
flares and reduce the use of (topical) steroids. The low risk of resistance should enable 
us to study the effect of long-term microbiome modulation in non-infected AD. Also, 
the targeted mechanism of action enables us to study specifically the role of S. aureus 
in AD pathogenesis. In Chapter 8 we described a protocol to carry-out a randomized 
controlled trial to evaluate the effect of a three months antistaphylococcal therapy with 
Staphefekt. The clinical trial started in 2016 and data collection just finished at the time 
of writing this thesis. 
In the trial design, we incorporated the knowledge gained from the studies in this 
thesis. For example, only patients with moderate to severe AD were included, as they 
have more overgrowth of S. aureus and are therefore more likely to benefit from the 
anti-microbial therapy (Chapter 4). Also, we choose to collect additional scrubs of the 
skin for optimal collection of microbial biomass and resolution for sequencing (Chapter 
7). The decision to test the efficacy of the endolysin directly in patients, has its pros 
and cons. The AD skin is subject to many factors that influence microbial growth due 
to interaction with the skin barrier and host immune system and its direct exposure to 
the environment. This hampers measuring the exact effect of Staphefekt on S. aureus 
growth. An experimental in vitro set up, or a model using the human nares, would en-
able more stable conditions and a better estimation of the direct effect of the endolysin 
on the bacterium. However, the patient-based setting and pragmatic approach in which 
we compared the add-on of the endolysin to standard care with standard care alone, 
gives results that are directly relevant to practice and will help making decision about 
treatment options. The relevance of microbial outcomes is hard to interpret without be-
ing able to relate them to clinical outcomes. For example, we do not know yet whether 
a complete elimination of S. aureus needs to be achieved for clinical improvement, or if 
decreasing the bacterial load will also be sufficient. Based on our case series, where we 
found a clinical improvement while S. aureus could still be cultured from the skin, we 
hypothesize that a reduction of S. aureus can already initiate rebalancing of the micro-
bial dysbiosis. The extent of that reduction is difficult to determine and probably differs 
per patient and disease episode, skin barrier status and host-immune factors. We expect 
that the trial will increase our understanding about how antimicrobial therapies affect 
the microbiome and how this affects diseases states.
MeTHoDologIcAl consIDeRATIons
In part 1 and 2 of this thesis we used two pediatric AD patient cohorts to characterize 
the microbiome, with a focus on staphylococci, and the antibody response against it. To 
investigate how specific the results are for AD inflammation, healthy control groups and 
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patients with other chronic inflammatory skin diseases, such as psoriasis, are needed. 
However, our conclusion focusses on AD severity in well characterized cohorts of chil-
dren with AD. The lack of controls does not influence this particular comparison. Another 
limitation might be the cross-sectional design of our studies which does not allow the 
investigation of cause–effect relationships between the microbiome and AD severity 
and between anti-S. aureus IgG levels and AD severity. Furthermore, we conducted our 
cohort studies in academic centers and our results might not be representative for the 
general AD population. 
In our microbiome studies, we determined the bacterial microbiome by sequencing 
of the 16S rRNA gene. We amplified the V4 variable region of the gene. This region was 
often used in studies characterizing the gut microbiome. In more recent studies it was 
shown that sequencing of this region does not allow classification of staphylococci 
at the species level, which is important when characterizing the skin microbiome. To 
further specify staphylococci in our studies, we performed additional qPCR on S. aureus 
and S. epidermidis. Because we were not able to identify staphylococcal species or even 
strains, we might have missed existing correlations between staphylococcal species and 
AD severity. Additionally, the V4 region in combination with the reverse primer that we 
used (806R) is known for poor coverage of Propionibacteria. Of note, in our samples 
Propionibacterium were indeed low in presence in both the skin and nasal samples, 
while they are described as part of the healthy microbial communities.55 However, the 
low Propionibacteria can still be a true reflection of the AD lesions as staphylococci are 
known to overgrow other species. Thereby, we sampled the antecubital folds which 
are known for a low abundance of Propionibacteria that prefer more sebaceous envi-
ronments.56 Current studies recommend amplification of the V1-V3 region or the use 
of a modified V4 primer for skin microbiome research. This results in better coverage 
of Propionibacterium and better classification of S. epidermidis. Classifying S. aureus 
remains difficult with current 16S rRNA sequencing approaches. 57,58 It should be noted 
that amplification of long regions (such as V1-3) also imposes some challenges with 
regard to generating good quality sequences. New recommendations for sequencing 
will be taken forward for analyzing samples of the clinical trial (Chapter 8).
FuTuRe PeRsPecTIVes 
Aims for future studies
This thesis and previously published literature have shown the complexity of the micro-
bial ecosystem and its interaction with the skin barrier and immune system. It also shows 
the relevance of the microbiome in AD pathogenesis and encourages further research 
on the topic as many aspects still need to be elucidated, such as 1) which microbes are 
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implied in AD pathogenesis, 2) by which mechanisms do they interact with the skin bar-
rier and immune system and cause inflammation and 3) what is the effect of microbial 
modulation on clinical disease.
In this thesis we confirmed the role of S. aureus in AD and we identified other micro-
organisms that might be involved in AD inflammation. Future studies should confirm 
the associations found in this thesis and determine associations on the species level. A 
comparison of microbial communities between patients and healthy controls is crucial 
to generate hypotheses around possible drivers of AD disease. Explorative research to 
identify microorganisms of relevance, should not only focus on bacteria but also on 
other microorganisms including fungi and yeasts. Chapter 3 of this thesis highlights the 
relevance of looking at the effects of groups of bacteria when performing this kind of 
studies, instead of single species. Furthermore, the influence of communities on other 
body sites apart from the skin should be part of the focus. Once species are identified, 
experimental in vitro models and animal challenge models could help to understand by 
which mechanisms bacteria influence inflammation and interact within the skin barrier 
and local immune system. Although there is great interest in new omics techniques, 
culturing of species of interest from humans remains very important to perform these 
experiments. With respect to S. aureus, it would be particularly interesting to study 
which mechanisms or triggers change the behavior of S. aureus into a disease causing 
pathogen, as we know the bacteria can also colonize the skin and mucosa of healthy 
individuals.13 As in vitro and animal models lack generalizability to the complex skin 
ecosystem in vivo, additional patient-based studies are needed to further clarify the role 
of microbial dysbiosis in AD and untangle interactions between the microbiome and 
the host skin barrier and immune system. The still developing AD and immune-system 
makes the pediatric population of interest for studying these interactions. After iden-
tifying mechanisms that are of possible relevance in AD inflammation, well-designed 
clinical trials are needed to determine the added value of new treatment strategies.
Longitudinal studies will allow the investigation of cause-effect relationships between 
AD, the microbiome, and the humoral immune response. Longitudinal population based 
studies from birth to disease development are needed to clarify the role of the microbi-
ome in AD development. Furthermore, it might be important to sample at multiple time 
points during a child’s development. Some studies suggest that the microbiome might 
only influence the development of AD in certain ‘critical’ timeframes during infancy.59-61 
As evidence that proves that S. aureus is truly aggravating the inflammation is still scarce, 
longitudinal sampling around the period of a disease flare is also still needed to identify 
whether changes in the microbiome and increased Staphylococcus levels precede flares. 
This would support a contribution of the microbiome in the onset of flares.
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Techniques and standardization
A complex ecosystem requires complex analysis techniques to enable analysis of 
all species and their interactions with each other and the host. The upcoming omics 
techniques already incorporate a broader perspective of the microbiome. Eventually, 
these new techniques that allow functional analysis next to association analysis, will 
be the key to a better understanding of the relations between microbes and the host 
immune system, the skin barrier and the other microbes and antimicrobial peptides. 
Especially in AD research, where it is crucial to specify staphylococci at the species level, 
metagenomics sequencing has advantages as it provides sufficient resolution to differ-
entiate species and even strains.62 This has been proven difficult with different 16S rRNA 
sequencing approaches, but seems important as studies showed that functional differ-
ences of staphylococcal strains exist and probably contribute to the complexity of AD.2,57 
However, due to the rapid development of the field, methods are not standardized yet. In 
general, differences in study population, sample preparation, sequencing methodology 
and use of bioinformatics tools including reference databases probably cause variation 
in outcomes. Specifically in skin microbiome research, we have to consider the unique 
features of the skin. The low biomass (compared to for example the gut and nose), the 
site specific microenvironments, the distinct local immune system and the high risk of 
contamination require specific approaches. Standardized methods and bioinformatics 
protocols are needed to gain more robust results. Transparency and sharing of sequenc-
ing and bioinformatics methodology in international databases would help standardize 
microbiome research and improvement of methods.
Personalized treatment: identifying phenotypes for atopic dermatitis
The diverse symptoms, different ages of onset, varying natural disease courses and 
comorbidities illustrate the heterogeneity of AD. Due to this heterogeneity, it can be 
expected that patients do not respond equally well to standardized ‘one size fits all’ treat-
ment regimens. Also, systemic treatment and upcoming biologics are costly. Therefore, 
it is important to decide which patient will benefit from which type of treatment. Char-
acterizing patients based on biomarkers of genetic, immunological and microbiological 
origin (the three components of figure 1), will support clinical decision-making and 
lead to a more personalized treatment of AD. By measuring specific biomarkers related 
to these three components, a balanced treatment strategy with more or less focus on 
certain components can be designed. Likely a mix of multiple biomarkers will be needed 
to define subpopulations and predict treatment response (figure 2).63 Some research has 
been done on characterization of barrier and immunological biomarkers. Skin barrier 
integrity can be measured via filaggrin mutation status amongst others.64 In case of a 
genetic defect, focus should be on treatment with emollients to enhance the barrier 
function of the skin. A recent study among patients with moderate to severe AD already 
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identified distinct clusters of patients based on serum biomarker profiles, illustrating 
biological differences between patients, which will help guide the use of biologics.65 
With respect to the microbial component, it is also likely that the role of the microbiome 
in AD pathogenesis differs within subsets of patients. We found that S. aureus was not 
dominating the lesional skin in all children and every child with severe AD had a unique 
skin microbial composition (Chapter 2). Treatment targeting the microbiome might 
therefore not be preferred for all AD patients at all times. Patients with severe AD are 
more likely to benefit from anti- S. aureus treatment, while in mild AD a skin (and nasal) 
swab can be collected to guide decisions.
Next to determining biomarkers to guide AD treatment, it is also important to identify 
biomarkers in young patients that predict the development towards severe disease. 
We know that early treatment of high risk patients has been shown to prevent AD.50 
Currently, family history is often used to identify high risk patients.66 Also the filaggrin 
mutation status can be used as a biomarker, because a mutation in this gene strongly 
predicts a worse prognosis with more severe AD and atopic comorbidities.64,67 
It should be clear that first attempts have been made towards personalizing treatment 
for AD. However, further characterization of patients and development of biomarkers is 
needed. Future cohort studies and trials should incorporate an endotyping approach in 
their design, including assessment of the epidermal, immunological and microbial bio-
Figure 2. possible biomarkers of interest for research on AD treatment personalization. (Illustration by Marloes 
van Loon)
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markers, such as filaggrin mutation status and S. aureus presence, and sufficient power 
to eventually determine which type of patients will benefit from which therapy.63 
FInAl conclusIon
This thesis shows the relevance of the microbiome, in particular S. aureus, in the 
pathogenesis of AD. S. aureus seems to evoke immune responses through different 
mechanisms, as a directly stimulating antigen and as an allergen. We found that next to 
S. aureus, other microbes on the skin and also microbial communities in the nose might 
be involved in AD inflammation. Our results may contribute to the development of treat-
ment strategies that target the microbiome in AD. Further prospective cohort studies 
and experimental research are needed to clarify the role of the microbiome in AD and 
its role in AD treatment. As the role of the microbiome likely differs between patients, 
probably as a result of various genetic and environmental factors, further stratification 
of patients is needed to better guide therapeutic approaches. Eventually this will lead to 
more personalized treatment of AD.
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suMMARy
Atopic dermatitis (AD) is a common chronic inflammatory skin disease affecting up to 
25% of the children and 7% of adults. The disease pathogenesis of AD is complex and 
an impaired skin barrier and altered immune mechanisms are considered the two major 
players in AD inflammation. Also, changes in the skin microbiome are well described 
in AD. The microbiome is the collection of all the microorganisms living in and on 
the human body. Different body sites, such as the gut, nose and skin, harbor distinct 
microbial communities that are essential for maintaining health. For example, the skin 
microbiome is important for the mechanical and the immunological barrier function of 
the skin. It is still poorly understood how the altered microbial composition that is seen 
in patients with AD plays a role in the pathogenesis of the disease. Insight in the role of 
the microbiome in the pathogenesis of AD may help determine the added value of treat-
ment strategies that target the microbiome in AD. It will also guide the development of 
new treatment strategies to modulate the microbiome.
Chapter 1 is the general introduction and provides the main objectives of this thesis. 
We first aimed to characterize the microbial composition of the skin, nose and gut in pe-
diatric patients with mild to severe AD. Our second aim was to estimate the prevalence 
of S. aureus in patients with AD and to study the humoral immune response against 
S. aureus. Additionally, we aimed to design a clinical study to test the effect of a new 
endolysin-based therapy that specifically targets S. aureus in AD.
PART I of this thesis describes the microbiome in patients with AD, including associa-
tions with disease severity and food allergy. In Chapter 2 we characterized the bacte-
rial microbiota of the skin and nose using 16S rRNA sequencing in a cohort of children 
with AD. We concluded that both the skin and nasal microbiome are associated with 
the severity of AD. Results were independent of age, use of medication and location 
of sampling and suggest that both the skin and nasal microbiome influence the sever-
ity of the inflammation in AD. In both the skin and nose an increased abundance of 
the genus Staphylococcus was an important contributor to the association. However, 
increased or decreased abundance of other species was also found to contribute. We 
additionally concluded that the nose and skin harbor distinct bacterial communities, 
but observed that correlations exists between species in the nose and (other) species on 
the skin. The underlying biological mechanisms of these correlations need to be further 
explored. In Chapter 3 we described a proof of concept study in which we characterized 
the gut microbiome in pediatric patients with AD, with and without a food allergy. We 
found that six bacterial species, when combined, discriminate between children with 
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and without food allergy. Our results need to be confirmed in larger studies using well-
defined patient populations.
PART II describes the role of S. aureus in atopic dermatitis and the human immune 
response towards it. In Chapter 4 we presented the results of a systematic review and 
meta-analysis and concluded that patients with AD have a higher risk of having S. aureus 
present on the skin (lesional and non-lesional) and in the nose compared to controls. 
This risk increases with disease severity for lesional skin. Based on the results of this 
study we encourage further evaluation of the role of S. aureus and antistaphylococcal 
therapy in AD. Chapter 5 outlines a systematic review and meta-analysis that shows that 
IgE against staphylococcal enterotoxin (SE) A and SEB in the serum is found more often 
in patients with AD compared to healthy controls. Data on IgG, IgM and IgA as well as 
other antigens were limited. The increased IgE response against S. aureus superantigens 
in certain patients indicates that S. aureus might stimulate AD inflammation via IgE 
mediated mechanisms, such as mast-cell degranulation, in a subgroup of patients. In 
Chapter 6 we profiled IgG antibodies against 55 S. aureus antigens in sera of two pedi-
atric cohorts with mild to severe AD. We found that children develop an IgG mediated 
humoral immune response towards the different antigens, showing that the children are 
exposed to a wide range of antigens. In one of the cohorts, the response against a group 
of mainly secreted proteins with immune-modulatory functions was associated with AD 
severity. The exact pathophysiological mechanism that explains our findings has to be 
further explored. It could be that S. aureus uses immune-modulatory mechanisms to 
maintain its colonization on the skin, which can lead to persistence of AD inflammation.
PART III describes methods to study the effect of a newly developed targeted therapy 
directed against S. aureus in AD. In Chapter 7 we compared a dry flocked swab with 
a scrub to collect skin microbiome samples as a pilot for a clinical trial. We concluded 
that scrubs result in a higher collection of bacterial and especially fungal DNA. However, 
dry flocked swabs identify the dominant sequences of the bacterial microbiota equally 
well as scrubs. The results suggest that scrubs are preferable when working with fungi 
or low- biomass skin areas. Chapter 8 describes the study protocol of a randomized 
controlled trial that studies the effect of local application of a new endolysin-based 
therapy that specifically targets S. aureus on the corticosteroid use and symptoms in AD. 
Methodological considerations and lessons learned from the former chapters, such as 
the choice for a scrub sample method, are outlined in the study design. 
Finally, in Chapter 9, we provided a general overview of the main findings, discussed 
the clinical implications of these findings, considered the limitations of our research 
and suggested directions for future research. This thesis shows the relevance of the 
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microbiome, in particular S. aureus, in the pathogenesis of AD. We proposed a model for 
AD pathogenesis that includes the (skin) microbiome, next to the skin barrier and im-
mune system, as a main component involved in AD etiology. Together, the components 
contribute to a balanced ecosystem important for a healthy skin, influenced by genes 
and environment. A disturbance in one of the components can lead to a disbalance of 
the ecosystem and eventually chronic inflammation. We found that S. aureus, but also 
other microbes on the skin and microbial communities in the nose, might be involved 
in AD inflammation. S. aureus seems to evoke immune responses via different mecha-
nisms, as a directly stimulating antigen and as an allergen. The results of this thesis may 
contribute to the development of treatment strategies that target the microbiome in 
AD. Further prospective cohort studies and experimental research is needed to clarify 
the role of the microbiome in AD and study how the microbiome may be modulated to 
improve AD symptoms. As the role of the microbiome likely differs between patients, it 
is important to define subpopulations of patients, based on epidermal, immunological 
and microbial biomarkers, to predict treatment response and better guide therapeutic 
approaches. Eventually this will lead to more personalized treatment in AD.
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sAMenVATTIng
Constitutioneel eczeem (CE) is de meest voorkomende chronische inflammatoire 
huidaandoening. Tot 25% van de kinderen en 7% van de volwassenen lijdt aan CE. De 
pathogenese van de aandoening is complex, maar de belangrijkste factoren die bijdra-
gen aan de inflammatie bij CE zijn een defect van de huidbarrière en een veranderde 
activiteit van het immuunsysteem. Daarnaast zijn er bij CE ook veranderingen in de sa-
menstelling van het microbioom beschreven, met name van de huid. Het microbioom is 
de verzameling van alle micro-organismen in en op ons lichaam. Micro-organismen be-
vinden zich op verschillende plekken in en op ons lichaam, waaronder de huid, de neus 
en de darmen. In de gezonde situatie vormen de micro-organismen een ecosysteem 
met hun gastheer en vervullen ze belangrijke functies, zoals bijvoorbeeld het versterken 
van de mechanische een immunologische barrière van de huid. Het is nog onduidelijk 
wat de precieze rol is van de veranderingen in het microbioom in de pathogenese van 
CE. Meer inzicht in de rol van het microbioom van de huid, neus en darmen bij CE helpt 
bepalen of therapie gericht op het microbioom van toegevoegde waarde kan zijn en is 
van belang voor het ontwikkelen van nieuwe gerichte behandelstrategieën op dit vlak.
Hoofdstuk 1 is een algemene introductie en beschrijft de belangrijkste doelstellingen 
van dit proefschrift. We stelden ons ten doel om het microbioom van de huid, neus en 
darmen in kaart te brengen bij kinderen met mild tot ernstig CE. Daarna bepaalden we 
de aanwezigheid van S. aureus bij patiënten met CE en de humorale immuunrespons 
tegen S. aureus. Een laatste doel was het opzetten van een klinische trial om het effect 
van een nieuwe behandelstrategie, gebaseerd op endolysinen technologie en specifiek 
gericht tegen S. aureus, te testen bij CE. 
Deel I van dit proefschrift beschrijft de samenstelling van het microbioom in patiënten 
met CE in relatie tot de ernst van de ziekte en het hebben van een voedselallergie. In 
Hoofdstuk 2 karakteriseerden we het bacteriële microbioom van de huid en neus mid-
dels 16S rRNA sequencing in een cohort van kinderen met CE. We concludeerden hieruit 
dat de samenstelling van het microbioom van de huid en neus beiden geassocieerd 
zijn met de ernst van het CE. Deze resultaten bleken onafhankelijk te zijn van de leef-
tijd van het kind, het gebruik van antibiotica en de locatie waar het huidsample was 
afgenomen. De resultaten suggereren dat het microbioom van de huid en neus beiden 
een rol spelen bij de ernst van de inflammatie in CE. Een verhoogde aanwezigheid van 
Staphylococcen leverde een belangrijke bijdrage aan de associatie tussen het huid- en 
neusmicrobioom en de ernst van het CE. Echter, verhoogde of verlaagde aanwezigheid 
van andere bacteriesoorten bleek ook een rol te spelen. Als laatste concludeerden we 
dat het microbioom van de neus en de huid beiden een unieke samenstelling hebben, 
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maar dat er wel correlaties bestaan tussen soorten in de neus en (andere) species op de 
huid. De onderliggende mechanismen voor deze correlaties dienen verder geëvalueerd 
te worden. In Hoofdstuk 3 beschreven we het microbioom van de darm bij kinderen 
met eczeem met en zonder een voedselallergie in een pilotstudie. We vonden dat de 
combinatie van zes bacteriesoorten discrimineert tussen kinderen met voedselallergie 
en CE en kinderen zonder een voedselallergie en CE. Deze resultaten moeten verder 
gevalideerd worden in grotere cohort studies met goed gekarakteriseerde patiëntgroe-
pen.
In deel II van dit proefschrift werd specifieker naar de rol van S. aureus gekeken en 
naar de reactie van het humane immuunsysteem op de bacterie. In Hoofdstuk 4 pre-
senteerden we resultaten van een systematisch literatuur onderzoek en meta-analyse 
waaruit we concluderen dat bij patiënten met CE vaker S. aureus gevonden wordt in 
de neus en op de huid, zowel lesionaal als niet-lesionaal. Ernstiger CE gaat samen op 
met een verhoogde aanwezigheid van S. aureus op de lesionale huid. Deze resultaten 
moedigen aan tot meer onderzoek naar de precieze rol van S. aureus bij eczeem en de 
toegevoegde waarde van therapie gericht tegen deze bacterie. In Hoofdstuk 5 beschre-
ven we een systematisch literatuur onderzoek met meta-analyse welke laat zien dat bij 
patiënten met CE vaker IgE tegen Staphylococcus enterotoxinen A en B wordt gevonden 
in het bloed dan bij gezonde controles. Studies die rapporteerden over IgE tegen andere 
antigenen en over IgG, IgM en IgA, waren zeer schaars. De verhoogde aanwezigheid van 
IgE tegen S. aureus antigenen in bepaalde patiënten suggereert dat S. aureus de inflam-
matie in CE stimuleert via IgE gemedieerde mechanismen, zoals mestcel degranulatie. 
In Hoofdstuk 6 bepaalden we de serum IgG antilichaam respons tegen 55 S. aureus 
antigenen in twee cohorten bestaande uit kinderen met CE. We vonden een IgG geme-
dieerde immuunrespons tegen veel antigenen in beide cohorten wat suggereert dat 
kinderen met CE worden blootgesteld aan een breed scala aan S. aureus antigenen. In 
een van de cohorten vonden we dat de IgG respons tegen vooral immuun-modulerende 
antigenen geassocieerd was met de ernst van het CE. Verklarende mechanismen voor 
deze observatie zouden verder onderzocht moeten worden. Mogelijk kan de S. aureus 
bacterie door middel van het moduleren van het humane immuun systeem zijn positie 
op de huid behouden, wat kan leiden tot chronische inflammatie in CE. 
Deel III van dit proefschrift beschrijft methoden om het effect van een nieuwe interventie 
gericht tegen S. aureus bij CE te testen. In Hoofdstuk 7 vergeleken we een droge ‘flocked’ 
swab met een scrub voor afname van huidmateriaal voor microbioom onderzoek, als een 
pilot voor een klinische studie. De scrubs resulteerden in meer opbrengst van bacterieel 
en schimmel DNA, wat suggereert dat het gebruik van scrubs van toegevoegde waarde 
is, met name wanneer men geïnteresseerd is in schimmels en gisten en in gebieden van 
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de huid die bekend staan om hun lage microbiële biomassa. Echter, de swab methode 
presteerde even goed met betrekking tot het identificeren van de meest voorkomende 
bacteriën. Hoofdstuk 8 beschrijft een studieprotocol voor een gerandomiseerde en 
gecontroleerde klinische trial waarbij gekeken wordt naar het effect van een nieuwe 
interventie, gebaseerd op endolysinen technologie en specifiek gericht tegen S. aureus, 
op het corticosteroïd gebruik en de symptomen bij CE. Leerpunten uit de voorgaande 
hoofdstukken werden meegenomen bij het ontwerpen van de trial, zoals de keuze voor 
de scrub sample methode. 
Ten slotte werd in Hoofdstuk 9 een overzicht gegeven van de belangrijkste bevindingen 
uit dit proefschrift. We benoemden de methodologische beperkingen van de beschre-
ven studies, bediscussieerden de implicaties van de bevindingen voor de kliniek en 
deden aanbevelingen voor toekomstig onderzoek. In deze thesis beschreven we dat 
het microbioom en met name S. aureus, een relevante rol speelt in de pathogenese 
van CE. We stelden een ziekte model voor waarbij we beschreven dat het microbioom 
en belangrijke component vormt, naast de huid barrière en het immuun systeem. De 
drie componenten vormen samen een gebalanceerd ecosysteem, wat interacteert 
met genetische en omgevingsfactoren, en van belang is voor een gezonde huid. Een 
verstoring in een van de componenten kan tot een disbalans in het hele ecosysteem 
leiden, met chronische inflammatie tot gevolg. We vonden dat S. aureus, maar ook 
andere micro-organismen op de huid en in de neus een rol zouden kunnen spelen in 
de inflammatie bij CE. S. aureus lijkt via verschillende mechanismen met het immuun 
systeem te interacteren, enerzijds als antigeen en anderzijds als allergeen. De resultaten 
van dit proefschrift dragen mogelijk bij aan de ontwikkeling van behandelstrategieën 
voor CE die gericht zijn op modulatie van het microbioom. Toekomstige prospectieve 
studies, op cohort- en experimentele basis, zijn nodig om de rol van het microbioom bij 
CE beter te begrijpen en nieuwe behandelstrategieën te onderzoeken. De rol van het 
microbioom in de pathogenese verschilt waarschijnlijk tussen patiënten. Het identifice-
ren van subgroepen van patiënten met CE, op basis van epidermale, immunologische 
en microbiële biomarkers, is belangrijk om gerichtere behandelstrategieën in te kunnen 
zetten. Dit zal uiteindelijk leiden tot meer gepersonaliseerde behandeling van CE.
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